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Abstract 
Generating antibodies against T-independent and T-dependent antigens requires Toll-
Like receptor (TLR) engagement on B cells for efficient responses. However, 
transcriptional regulation of TLR responses in B cells is not well understood. 
Transcription factors of the E26 transformation-specific family (ETS) are critically 
important for regulating hematopoiesis and cellular function. PU.1, Spi-B, and Spi-C are 
highly related ETS transcription factors that can bind nearly identical DNA sequences in 
the genome. PU.1 and Spi-B (encoded by Spi1 and Spib respectively) are important for B 
cell development and function, but the function of Spi-C (encoded by Spic) in B cells is 
not clear. The primary objective of this study was to determine the function of PU.1, Spi-
B, and Spi-C during B cell development, and during TLR-mediated responses. It was 
hypothesized that PU.1 and Spi-B were required for positively regulating components of 
TLR responses, and Spi-C inhibited PU.1 and Spi-B targets. Spi1
+/-
Spib
-/-
 (PUB) B cells 
proliferated poorly in response to TLR ligands compared to WT B cells. The NF-κB 
family member p50 (encoded by Nfkb1) is required for LPS responsiveness in mice, and 
PUB B cells expressed reduced Nfkb1 mRNA transcripts and p50 protein. Forced 
expression of p50 in PUB B cells was capable of restoring TLR-mediated proliferation. It 
was determined that PU.1 and Spi-B directly regulated the Nfkb1 promoter, and were 
required for proper TLR-mediated responses. Next, Spib
-/-
Spic
+/-
 mice were generated to 
determine if Spi-C was functionally redundant with Spi-B. Spib
-/-
Spic
+/- 
mice had restored 
number of B cells in the spleen, and had restored proliferative responses compared to 
Spib
-/-
 mice. Steady-state Nfkb1 levels were elevated in Spib
-/-
Spic
+/- 
B cells compared to 
Spib
-/- 
B cells, and was the potential mechanism of the Spib
-/-
Spic
+/- 
phenotype. It was 
demonstrated that Spi-B directly activated the Nfkb1 gene, while Spi-C directly repressed 
this gene. These results suggest that PU.1 and Spi-B are required for transcriptional 
activation of Nfkb1, and Spi-C has a negative regulatory role in B cell development and 
function. Determining the transcriptional regulation of B cell responses has important 
implications for understanding antibody forming responses, such as those seen in 
vaccinations.  
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Chapter 1  
1 Introduction 
Humans are exposed to millions of potential pathogens on a daily basis. 
Therefore, protection from nearly unlimited pathogens is required over a lifetime. The 
ability of humans to avoid infection upon repeated exposure to pathogens is dependent on 
cellular components of the innate and adaptive immune system. Vaccines have eliminated 
many of the world’s worst diseases such polio and smallpox, but there are currently no 
vaccines for many serious diseases such as HIV, cancers, and malaria. Generating 
vaccine-mediated protection in humans is complex; most current available vaccines have 
been developed with limited understanding of how they activate the immune system  
(Siegrist, 2008). Most effective vaccinations are mediated by antibodies produced by B 
cells. Antibodies function to activate complement, and neutralize or opsonize toxins and 
pathogenic microorganisms to aid in their destruction (Pone et al, 2010). Aside from the 
economic and commercial priorities of the vaccine development industry, the difficulty in 
generating protective vaccines is in maintaining long-lasting protection through the 
correct presentation of antigens (Plotkin, 2009). Therefore, understanding the regulation 
of B cell development, maintenance, and responses to antigens is important for 
determining the cellular mechanism of a vaccine. 
 
1.1 B cell origin, function, and subsets 
B cells are an essential component of the immune system. They can function as 
professional antigen presenting cells, modulate immune responses by cytokine 
production, and are the sole producers of antibodies (Pone et al, 2010). Each B cell 
produces a single unique antibody specificity, which is generated from germline 
recombination of the immunoglobulin (Ig) genes. Identical copies of unique Igs are 
embedded on the surface of a B cell, termed the B cell receptor (BCR), which 
distinguishes B cells from other lymphocytes. The BCR can be further diversified by Ig 
class switch recombination (CSR) and somatic hypermutation events. B cells initially 
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express and produce IgM and IgD isotypes, but can express IgG, IgA, or IgE following 
CSR. BCRs form clusters when bound by an antigen, thereby bringing together signaling 
molecules to contribute to B cell differentiation (Pone et al, 2010). In both mice and 
humans, B cells develop in the bone marrow (BM), and then migrate to the spleen to 
mature.  
1.1.1 B cell development in the bone marrow 
B cell development is a well-studied system in mice, and unlike many other 
somatic tissues, its development continues even in adults. There are many stages of B cell 
development, initiating with a pluripotent hematopoietic stem cell (HSC). HSCs 
differentiate into various progenitor stages, going in the order of a multipotent progenitor 
(MPP), lymphoid-primed multipotent progenitor (LMPP), and common lymphoid 
progenitor (CLP) (Nagasawa, 2006). Each progenitor stage is capable of generating a 
specific cell lineage or progressing to the next stage. CLPs can differentiate into T cells, 
dendritic cells, NK cells, and B cells. In 1991, Hardy et al defined a number of progenitor 
B cell stages in the bone marrow of mice, termed fractions A, B, C, D, E, and F (Hardy et 
al, 1991). The fractions progress in alphabetical order and are characterized based on 
cell-surface phenotype, differences in functionality, and Ig-gene rearrangement (Hardy et 
al, 1991) (Figure 1.1). B cells undergo Ig-gene rearrangement during differentiation, 
which is an important process for generating a repertoire of Ig receptors capable of 
recognizing any antigen.  
Fraction A cells (B220
+
CD43
+
CD24
-
BP-1
-
IgM
-
) are a heterogeneous population 
containing pre-pro B cells, which are the earliest population committed to the B cell 
lineage and require stromal contact for growth (Hardy et al, 1991; Li et al, 1996). 
Fraction A cells differentiate into fraction B (B220
+
CD43
+
CD24
+
BP-1
-
IgM
-
) (pro B) 
cells, where rearrangement of the DJ (diversity and junction) regions of the Ig heavy 
chain begins. In addition, fraction B cells are less dependent on stromal cell contact for 
growth, but require IL-7 for growth (Hardy et al, 1991; Li et al, 1996). At the fraction C 
(B220
+
CD43
+
CD24
+
BP-1
+
IgM
-
) (late-pro B cell) stage, most cells have variable (V)DJ 
Ig heavy chain rearrangements, and a small percentage of DJ rearranged Ig light chain 
can be detected (Ehlich et al, 1993). Rearranged heavy chain expression leads to surface 
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expression of the pre-BCR complex, which provides signaling for further differentiation.  
Within the fraction C population, a subpopulation of cells express higher levels of CD24 
and are termed fraction C’ (large-pre B) cells. Fraction C cells differentiate into fraction 
C’ cells once receiving a signal through the pre-BCR, allowing the cells to enter cell 
cycle (Hardy et al, 1991). IL-7 is also required for growth at the fraction C cell stage, but 
stromal contact is not required (Hardy et al, 1991). B cell development proceeds to 
fraction D (B220
+
CD43
-
CD24
+
BP-1
+
IgM
-
), consisting of small pre-B cells. A large 
portion of fraction D cells will have VJ rearrangement of the Ig light chain occur at this 
stage (Hardy et al, 1991). Cells become fraction E once the Ig light chain has fully 
rearranged VJ regions, and cells begin to express IgM. Fraction E cells are considered 
immature B cells, which migrate to the spleen to differentiate into mature B cells. Mature 
B cells capable of recirculation can be found in the bone marrow and are classified as 
fraction F cells, which express IgD, IgM, and higher levels of B220 compared to fraction 
E cells.   
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Figure 1.1. Defining Hardy Fractions of B cell development in the bone marrow. 
Hardy fractions of B cell development are shown. Differences in cell surface molecules, 
immunoglobulin rearrangement, and growth dependence are indicated. Line presence and 
thickness represents the level of cell surface molecule expression or the dependence of 
growth conditions for the various stages of development. Figure is adapted from Hardy et 
al. (Hardy et al, 1991). 
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1.1.2 Immature B cells 
Transitional B cells are an important link between the BM and periphery during B 
cell development. Immature B cells express BCR on the cell surface, and B cells 
recognizing self-antigens will undergo deletion, receptor editing, or anergy (Chung et al, 
2003). Non-self-reactive, immature B cells leave the bone marrow and progress through 
transient transitional (T1 and T2) B cell stages. Transitional B cells in the spleen are 
identified by CD93 (AA4.1) expression, a marker of immaturity. In addition to CD93, T1 
and T2 B cells are characterized by the surface markers IgM
hi
IgD
-
CD21
-
CD23
- 
and 
IgM
hi
IgD
+
CD21
+
CD23
+
 respectively (Chung et al, 2003).  T1 B cells do not have the 
ability to recirculate and are found in the bone marrow or spleen. T2 B cells, which 
develop from T1 B cells, enter the splenic follicles and have the ability to recirculate 
(Pillai & Cariappa, 2009). The differentiation from T1 to T2 B cells requires basal BCR 
signals, BAFF survival signals, and non-canonical NF-κB signals (Pillai & Cariappa, 
2009). At the T2 B cell stage, cells then develop into mature B cells. The BM of a normal 
6-8 week-old mouse will have ~2x10
7
 immature B cells generated daily, but only ~10% 
will actually reach the periphery (Rolink et al, 1998). 
1.1.3 Mature B cells 
Mature B cells can recirculate through secondary lymphoid organs or join 
enriched static components in the spleen, peritoneal, and pleural cavities (Martin & 
Kearney, 2000). The spleen is the largest secondary lymphoid organ and contains about 
one-fourth of the body’s lymphocytes (Cesta, 2006). Various B cell subsets can be found 
in the spleen including B-1, B-2, and B regulatory cells (Table 1.1).  
1.1.3.1 B regulatory cells 
The smallest populations of B cells in the spleen are B regulatory cells (Bregs), 
which consists of approximately 1-2% of the total B cells in the spleen, and have a 
unique phenotype of CD19
hi
CD1d
hi
CD5
+ 
(Yanaba et al, 2008). Bregs are also known as 
B10 cells since they produce the highest levels of interleukin-10 (IL-10) of all B cell 
subsets (Yanaba et al, 2008). IL-10 has anti-inflammatory and suppressive effects on 
most hematopoietic cells (Bouaziz et al, 2012), thus Bregs are capable of suppressing T 
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cell-mediated inflammation in vivo (Yanaba et al, 2008). Although the current 
developmental origin of Bregs is unknown, it is hypothesized that they are differentiated 
from either T2 marginal zone precursor (MZP) B cells or a separate Breg progenitor 
population (Vitale et al, 2010).  
1.1.3.2 B-1 cells 
B cells in the pleural and peritoneal cavities of adults are primarily B-1 cells, but 
they can also be found in the spleen in low frequencies (Baumgarth, 2011). B-1 cells are 
defined as CD19
hi
CD43
+
CD23
-
IgM
hi
IgD
low
. They can be further subdivided into B-1a or 
B-1b cells according to the presence or absence of CD5 respectively (Baumgarth, 2011). 
B-1 cells generate natural IgM and IgA antibodies, which recognize self-antigens and 
pathogen-expressed molecules without prior antigen exposure (Racine & Winslow, 
2009). Recent studies have also demonstrated that B-1 cells from the liver and peritoneal 
cavity have phagocytic capabilities (Nakashima et al, 2012; Parra et al, 2012), which 
suggests a previously unacknowledged mechanism of pathogen clearance by B cells. 
There has been controversy regarding the development of B-1 cells in relation to B-2 
cells. However, there is increasing evidence suggesting that B-1 cells develop from a 
separate lineage from B-2 cell progenitors (Montecino-Rodriguez & Dorshkind, 2012).  
B-1 progenitor cells have been reported to arise as early as day 9 of gestation in the yolk 
sac of mice (Yoshimoto et al, 2011), but then develop from HSCs during later times 
(Montecino-Rodriguez & Dorshkind, 2012). Fetal liver and neonatal bone marrow HSCs 
are able of differentiating into B-1 or B-2 cells (Kikuchi & Kondo, 2006), but 
commitment to either lineage is already determined by the CLP stage of development 
(Barber et al, 2011).  
1.1.3.3 B-2 cells: marginal zone and follicular B cells 
The spleen is comprised of primarily B-2 cells called marginal zone (MZ) and 
follicular (FO) B cells. MZ B cells account for approximately 15% of the total B cells in 
the spleen, and FO B cells make up more than 70% (Baumgarth, 2011). Both MZ and FO 
B cells express high levels of B220 and CD19, and no longer express CD93. MZ B cells 
are characterized by high levels of surface receptors IgM, CD21, and CD1d, and low 
levels of IgD and CD23 (Pillai et al, 2005). Follicular B cells express lower levels of 
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IgM, CD21, and CD1d, and high levels of IgD and CD23 (Pillai et al, 2005). Aside from 
having different surface phenotypes, MZ and FO B cells also have different functions. 
There are differences in activation between MZ and FO B cells. Activation of B cells 
occurs either through a T-cell independent (TI) or T-cell dependent (TD) manner. TI 
responses occur in the absence of T cell help, and can be further subdivided into TI-type I 
(TI-I) or TI-type 2 (TI-II). MZ B cells reside between the marginal sinus and the red pulp. 
This is an ideal location to meet and respond rapidly to blood-borne pathogens, and thus 
MZ B cells play an important role in TI immune responses (Pillai & Cariappa, 2009; 
Pillai et al, 2005). Examples of TI-I antigens include lipopolysaccharide (LPS), an outer 
membrane component found in all Gram-negative bacteria, which binds to Toll-like 
receptor  (TLR)4. An example of a TI-II antigen is dinitrophenylated ficoll (DNP-ficoll), 
which result in B cell activation through BCR engagement and clustering, independent of 
T cell help (Obukhanych & Nussenzweig, 2006). In contrast, FO B cells have an 
important role in TD immune responses to protein antigens (Pillai & Cariappa, 2009). TD 
antigens involve cross-linking BCRs and processing the antigens onto major 
histocompatibility complex class II (MHCII) molecules, and then are typically followed 
by CD40 co-stimulation by a T-helper cell. FO B cells are not only found in the spleen, 
but can also circulate in the blood. FO B cells are therefore better at generating effective 
antibody responses after interacting with T cells in response to blood-borne pathogens. 
MZ B cells express elevated T cell co-signaling molecules at basal and stimulated levels 
compared to FO B cells (Oliver et al, 1999). In addition, MZ B cells are also more readily 
activated and proliferative than FO B cells after stimulation with LPS, anti-IgM, or anti-
CD40, and can become potent antigen presenting cells for T cells (Oliver et al, 1997; 
Oliver et al, 1999; Snapper et al, 1993; Snapper et al, 1996b). 
A small fraction of MZ or FO B cells which are activated can become plasma 
cells or memory B cells. Plasma cells are terminally differentiated B cells committed to 
antibody secretion. Plasma cells constitutively secrete antibody against an antigen to 
provide protection during a primary response, but are unable to respond to secondary 
infections because of diminished surface Ig expression (Manz et al, 1998). In contrast, 
memory B cells express BCRs for an eliciting antigen and can rapidly secrete high 
amounts of antibody upon secondary exposure. Both memory B cells and plasma cells are  
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Table 1.1. Phenotype, frequency, and function of B cell subsets located in mouse spleens 
 Breg B-1(a/b) MZ FO 
Phenotype B220
+
 
CD19
hi
  
CD5
+
 
CD1d
hi 
 
B220
+
 
CD19
+
 
CD5
(+/-)
 
CD1d
hi
 
 
CD23
-
 
CD43
+
 
IgM
hi
 
IgD
low
 
B220
+
 
CD19
+
 
CD5
-
 
CD1d
hi
 
CD21
hi
 
CD23
low
 
CD43
-
 
IgM
hi
 
IgD
low
 
B220
+
 
CD19
+
 
CD5
-
 
CD1d
low
 
CD21
low
 
CD23
hi
 
CD43
-
 
IgM
low
 
IgD
hi
 
Frequency in 
spleen 
~1% ~2% ~15% >70% 
Major Function 
in spleen 
Anti-
inflammatory 
roles; production 
of IL-10 
Production of 
natural 
antibodies 
Rapid response 
to TI antigens 
Humoral 
response to TD 
antigens 
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important components for long-lasting antibody-mediated immunity as seen in 
vaccinations. 
 
1.2 B cell related diseases 
A fine balance between activation and inhibition of immune function is required. 
Loss of B cell function can make an individual more susceptible to infection, whereas 
gain of function during B cell development or activation can lead to autoimmunity. 
Furthermore, there are instances where either a gain of function or loss of function in B 
cells can result in a cancerous state.  
1.2.1 B cell immunodeficiencies 
Diseases related to loss of B cell function are classified into three major 
categories of B cell immunodeficiencies: 1) defects in early B cell development, 2) CSR 
defects, and 3) common variable immunodeficiency (CVID) (Conley et al, 2009). In all 
cases of B cell immunodeficiencies, there is a reduction in antibody production, which 
results in increased susceptibility to recurrent infections (Conley et al, 2009). Defects in 
early B cell development result in recurrent infections, hypogammaglobulinemia, reduced 
B cells in the periphery, and a block in early B cell differentiation (Conley et al, 2009). 
The most prevalent form of defects in early B cell development is X-linked 
agammagobulinemia (XLA), which accounts for approximately 85% of cases (Conley et 
al, 1998). XLA is caused primarily by mutations in the gene Btk, and is characterized by 
a marked decrease in mature B cells and lack of antibodies of all isotypes (Vetrie et al, 
1993). A smaller proportion of XLA cases have been reported to be caused by mutations 
in genes encoding pre-BCR or BCR signaling components, such as Igα, Igβ, λ5, µ heavy 
chain, and BLNK (Conley et al, 2009; Minegishi et al, 1999a; Minegishi et al, 1998; 
Minegishi et al, 1999b; Yel et al, 1996).  
Defects in CSR result in high levels of serum IgM, but little to no production of 
IgG, IgA, and IgE antibodies (Conley et al, 2009). CSR defects are primarily caused by 
mutations in Cd40lg (Allen et al, 1993). The loss of CD40-CD40L interaction results in 
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impaired T cell, B cell, and monocyte function, which can lead to opportunistic infections 
(Fuleihan, 1998). Mutations in Aicda, which encodes for activation-induced cytidine 
deaminase (AID), have also been attributed with defects in CSR (Revy et al, 2000). AID 
initiates CSR and somatic hypermutation during Ig gene rearrangement by deaminating 
cytosine residues in Ig heavy chain variable regions and switch regions (Muramatsu et al, 
2000; Perlot et al, 2008). 
CVID is characterized by reduced serum immunoglobulins and highly variable 
clinical features (Cunningham-Rundles & Bodian, 1999). In contrast to other B cell 
immunodeficiencies, CVID patients can have normal B cells, but low numbers of 
memory B cells (Wehr et al, 2008). The predisposing genetic factors associated with 
CVID are unknown, but mutations in the genes encoding ICOS, CD19, and TACI have 
been identified to small groups of patients (Grimbacher et al, 2003; van Zelm et al, 2006).  
1.2.2 Autoimmunity 
Several checkpoints occur during B cell development to ensure that B cells do not 
recognize host or self-antigens, collectively called central B cell tolerance. These 
mechanisms include BCR editing (Gay et al, 1993; Tiegs et al, 1993), deletion of self-
reactive B cells (Nemazee & Buerki, 1989), and anergy (Nossal & Pike, 1980). Failure to 
regulate self-tolerance in B cells is associated with autoimmunity. Autoimmunity is 
characterized by immune activation in response to self-antigens leading to tissue 
destruction and organ failure (Alberghini et al, 2015). Some commonly studied 
autoimmune diseases include systemic lupus erythematosus (SLE), rheumatoid arthritis, 
multiple sclerosis, and diabetes (Morel, 2004). B cells can contribute to autoimmune 
diseases through secretion of autoantibodies, presentation of autoantigens to T cells, and 
secretion of proinflammatory cytokines (Chan & Shlomchik, 1998; Harris et al, 2000; 
Wong et al, 2004). Therefore, understanding mechanisms of B cells development and 
function can provide therapeutic targets for preventing B cells from becoming auto-
reactive.  
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1.2.3 B cell leukemia and lymphoma 
If control of activation, proliferation or apoptosis is deregulated in B cells, various 
forms of cancers can arise depending on the initiating cell stage (Figure 1.2). Both 
leukemias and lymphomas have subtypes involving B cells.  Leukemia is a cancer of 
bone marrow origin which results in abnormal growth of leukocytes. Lymphomas are 
characterized by uncontrolled lymphocyte growth which affects lymph nodes. Mutations 
in components of BCR signaling have been attributed to both of these diseases (Buchner 
et al, 2015; Burger & Chiorazzi, 2013; Davis et al, 2010). Chronic activation of BCR 
signaling can lead to proliferation and the activation of pro-survival genes, preventing 
malignant cells from undergoing apoptosis (Davis et al, 2001; Davis et al, 2010; Packham 
et al, 2014). As such, therapeutic strategies for treating leukemia and lymphomas have 
involved using drugs which inhibit BCR signaling kinases, such as Btk and Syk (Davis et 
al, 2010; Woyach et al, 2012). Understanding the regulation of B cell development and 
BCR signaling has provided key insights into how to treat some of these diseases.  
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Figure 1.2. Examples of B cell associated malignancies which can arise from different B 
cell subsets.  
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1.3 Toll-Like Receptors 
Toll-Like receptors (TLR) are evolutionarily conserved, single-spanning 
transmembrane receptors expressed both intracellularly and on the surfaces of many cell 
types. TLRs belong to the Interleukin-1 receptor (IL-1R) family, as the receptors contain 
a C terminal intracellular Toll/IL-1R (TIR) signaling domain (West et al, 2006). TLRs 
function as hetero- or homo-dimers, and recognize conserved structures of viruses, 
bacteria, protozoa, and fungi,
 
collectively called pathogen associated molecular patterns 
(PAMPs) (West et al, 2006). Recognition of ligands by TLRs is dependent on the N-
terminal leucine-rich-repeat (LRR) motif, which contains 24 amino acids forming an α-
helix and β-sheet joined by a loop (Kawai & Akira, 2007). Human TLRs contain 19-25 
LRRs which together form a horseshoe-shaped structure (Bell et al, 2005). TLRs were 
initially identified in Drosophila melanogaster through a cDNA library screen for genes 
that regulated embryonic polarity during development (Hashimoto et al, 1988). TLR 
homologues in vertebrates, specifically TLR4, were discovered in mice and humans for 
being important during LPS-mediated inflammatory responses (Medzhitov et al, 1997; 
Poltorak et al, 1998). To date, thirteen members of TLRs have been identified in mice, 
and eleven in humans (Kawai & Akira, 2007). Each TLR recognizes one or more distinct 
categories of PAMPs. 
LPS is the most widely studied ligand for TLR signaling induction. The 
mechanism for LPS recognition through TLRs is complex. The serum protein LPS-
binding protein (LBP) first binds to LPS and transfers it to the molecule CD14. Delivery 
of LPS by CD14 is then transferred  to TLR4, which forms a complex with MD-2 (Botos 
et al, 2011) . MD-2 is a coreceptor which binds to TLR4 and LPS (Visintin et al, 2006), 
and is essential for LPS recognition (Nagai et al, 2002a). Furthermore, immune cells 
including B cells, DCs, and macrophages express radioprotective 105 (RP105), an 
additional surface molecule which is also capable of LPS recognition (Fugier-Vivier et al, 
1997; Miyake et al, 1995). RP105 interacts with the coreceptor MD-1 for LPS 
recognition and signaling transduction (Nagai et al, 2002b). Interestingly, the functional 
roles of RP105 differ between B cells, DCs, and macrophages. RP105/MD1 enhances 
LPS signaling through TLR4 in B cells (Ogata et al, 2000), but it functions as a negative 
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regulator in macrophages and DCs by directly inhibiting LPS binding to TLR4 
(Divanovic et al, 2005). 
B cells express and respond to ligands of TLR1, TLR2, TLR4, TLR6, TLR7/8, 
and TLR9 (Dasari et al, 2005; Genestier et al, 2007; Gururajan et al, 2007; Hornung et al, 
2002). B cells up-regulate cytokine synthesis, antibody secretion, and cell proliferation 
upon binding of TLR ligands onto their receptors, as a result of activation of the 
transcription factor nuclear factor (NF)-κB (Bekeredjian-Ding & Jego, 2009). The 
signaling events following TLR ligand binding have been well characterized (Figure 1.3). 
Activation of TLRs elicits a signaling response through a MyD88-dependent or TIR-
domain-containing adapter-inducing interferon-β (TRIF)-dependent pathway (Kawai & 
Akira, 2006). Except for TLR3, all TLRs can recruit the MyD88 adaptor protein for TLR 
signaling (Kawai & Akira, 2006; Kawai & Akira, 2007). On the other hand, TLR3 and 
TLR4 are capable of activating NF-κB through the recruitment of the adapter protein 
TRIF (Kawai & Akira, 2006). For the MyD88-dependent pathway, the association of 
TLRs and MyD88 stimulates and recruits members of the interleukin-1 receptor-
associated kinase (IRAK) family, including IRAK-1, IRAK-2, IRAK-4, and IRAK-M 
(Kawai & Akira, 2006; Kawai & Akira, 2007). Once IRAK-4 and IRAK-1 are 
phosphorylated, they dissociate from MyD88 and activate tumor necrosis factor receptor-
associated factor 6 (TRAF-6) (Kawai & Akira, 2006; Kawai & Akira, 2007). A complex 
of proteins is formed with TRAF-6 which in turn activates transforming growth factor-β-
activated protein kinase 1 (TAK1). The TAK1 complex activates the IκB kinase (IKK) 
complex, consisting of IKKα, IKKβ, and IKKγ (Kawai & Akira, 2006; Kawai & Akira, 
2007). The IKK complex phosphorylates IκBs for polyubiquitination and proteasomal 
degradation, which results in NF-κB subunits to be released into the nucleus and bind to 
DNA targets. Additionally, TLR ligands such as LPS are capable of activating 
phosphoinositide 3-kinase (PI3K) within minutes of B cell stimulation (Bone & 
Williams, 2001). TLR signaling can activate the PI3K pathway through the B cell adaptor 
for PI3K (BCAP). Phosphorylated BCAP accumulates at the cell membrane after LPS 
stimulation, and allows its associated PI3K to signal downstream (Ni et al, 2012). It has 
been demonstrated that sustained PI3K signaling and antigen receptor engagement by 
either LPS or BCR crosslinking is necessary for proliferation and survival of activated B 
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cells (Donahue & Fruman, 2003). Furthermore, it has been suggested that promoting 
activation of full TLR signaling requires MHCII interaction with Bruton’s tyrosine kinase 
(Btk) and CD40 (Liu et al, 2011); therefore, TLR signaling is complex and its 
components may have redundant functions.  
Understanding TLR activation in B cells has implications for human health and 
disease. TLR signaling in B cells is required for T-dependent antibody responses (Pasare 
& Medzhitov, 2005). It has been suggested that the production of effective neutralizing 
antibody responses, as seen in vaccinations, involves direct TLR ligand binding on B 
cells (Kasturi et al, 2011). Moreover, TLRs may have roles in B cell malignancies. One 
hypothesis is that chronic infections leading to TLR activation can induce excessive 
somatic hypermutation and CSR events, which can transform normal B cells into 
malignancies such as B cell lymphoma (Isaza-Correa et al, 2014). TLR stimulation can 
also lead to the proliferation of malignant B cells, and induce a cytokine profile which 
creates an immunosuppressive microenvironment (Isaza-Correa et al, 2014). Although 
much is known about TLRs and B cells, transcriptional regulation of genes involved for 
TLR expression on B cells remains unclear.  
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Figure 1.3. MyD88-dependent TLR signaling pathway in B cells.  
A simplified schematic of the TLR signaling pathway is shown. TLR1/2, TLR 2/6, and 
TLR 4 are located at the cell surface, whereas TLR7, TLR8, and TLR9 are located in 
endosomes. Ligand binding results in a cascade of signaling events which eventually 
leads to polyubuitination of Iκ-Bɑ, which allows NF-κB (p65/p50 heterodimer) to 
translocate into the nucleus and upregulate genes involved in survival, proliferation, and 
cytokine and antibody secretion.    
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1.4 Transcriptional Regulation  
Cell fates and cellular function are regulated through complex and precise gene 
expression patterns (Spitz & Furlong, 2012). Regulation of gene expression is controlled 
by transcription factors, which are proteins that bind to cis-acting regulatory DNA 
sequences in order to recruit coactivators and RNA polymerase II (RNA Pol II) to target 
genes. RNA pol II is responsible for the transcription of DNA to mRNA in eukaryotes. 
Transcription factors are essential for the activation or repression of gene expression. Cis-
regulatory DNA sequences include core promoters and promoter-proximal elements 
located near the transcription start site (TSS), and distal enhancers, silencers, and 
insulators (Figure 1.4) (Minegishi et al, 1999b; Spitz & Furlong, 2012). These cis-
regulatory elements contain DNA sequences which transcription factors recognize and 
bind. Transcription factors can bind to promoters within a thousand base pairs of the TSS, 
or further away at distal enhancer, silencer, or insulator elements up to 1 million base 
pairs from the promoter (Maston et al, 2006). Furthermore, each regulatory element can 
contain multiple transcription factor binding sites, which drastically increases the ability 
to generate unique expression patterns. Therefore, understanding how gene expression 
profiles are regulated by regulatory sequences and transcription factors can give insight to 
development and function of cells and tissues. 
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Figure 1.4. Examples of cis-regulatory elements found in transcriptional regulation. 
A simplified schematic of the transcriptional regulatory elements found in eukaryotes. 
Transcription factors can bind to proximal and core promoters, and distal enhancers, 
silencers, and insulators to regulate gene transcription. Figure is adapted from Ong and 
Corces (Ong & Corces, 2011).  
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1.5 Transcription factor NF-κB 
The nuclear factor-κB (NF-κB) family of transcription factors was initially 
discovered in B cells by its ability to bind an enhancer element within the 
immunoglobulin-κ chain (Sen & Baltimore, 1986b). The expression of NF-κB was later 
determined to be inducible, and expressed in other lymphoid and non-lymphoid cell types 
(Sen & Baltimore, 1986a). NF-κB is present in the cytoplasm of most cells in an inactive 
complex with IκB inhibitor proteins (Baeuerle & Baltimore, 1988), which are identified 
by repeat 33 amino acid long ankyrin motifs (Li & Verma, 2002). Activation of NF-κB 
allows for its translocation into the nucleus, where it can bind to promoters or enhancers 
of genes containing the consensus sequence GGGRNYYYCC (R is any purine; Y is any 
pyrimidine; N is any nucleotide) to initiate transcription (Chen et al, 1998). The NF-κB 
family is composed of five subunits: NF-κB1 (p105/p50) , NF-κB2 (p100/p52), RelA 
(p65), RelB, and c-Rel, which all interact with DNA as hetero- or homodimers (Hayden 
& Ghosh, 2008). Both p100 and p105 are precursor proteins for p50 and p52 
respectively, and contain ankyrin repeats which can function as IκB-like proteins (Li & 
Verma, 2002). Only RelA, RelB, and c-Rel contain C-terminal transactivation domains 
which allow transcriptional initiation (Hayden & Ghosh, 2012). All NF-κB family 
members share a Rel homology domain which mediates dimerization, interaction with its 
inhibitor, and DNA binding (Hayden & Ghosh, 2012). Since the initial discovery of NF-
κB, its involvement during development and inflammation induction, response, and 
resolution have been researched in depth. 
1.5.1 Classical and alternative NF-κB signaling 
NF-κB signaling is generally defined as either the classical (canonical) or 
alternative (non-canonical) pathway. In the classical NF-κB pathway, NF-κB can be 
activated in B cells through various mechanisms such as through TLR, BCR, or 
proinflammatory cytokine stimulation (Li & Verma, 2002; Weil & Israel, 2004). A 
signaling cascade leads to phosphorylation of IκB by the IKK complex, which is 
recognized by ubiquitin ligase machinery, polyubiquitinated, and targeted for 
proteasomal degradation like previously described in section 1.3 Toll-Like Receptor. In 
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the alternative pathway, NF-κB is activated through TNF receptor (TNFR) family 
members such as B cell-activating factor (BAFF) receptor (Claudio et al, 2002) and 
CD40 (Homig-Holzel et al, 2008). Activation through TNFR family members leads to the 
activation of NF-κB-inducing kinase (NIK), which leads to the phosphorylation, 
ubiquitination, and processing of p100 to activate RelB/p52 NF-κB complexes (Sun, 
2011). The heterodimerization of NF-κB subunits activated predominantly by each 
pathway allows crosstalk between classical and alternative NF-κB signaling.     
1.5.2 Mouse models of NF-κB and the roles of NF-κB in B cells 
Various NF-κB/Rel complexes are expressed during different developmental 
stages of B cells. In pre-B cells, p50/p65 is the primary inducible complex, p50/Rel is the 
predominant complex in mature B cells, and p52/RelB appears to be the dominant 
complex in plasma cells (Liou et al, 1994). Mice deficient for various NF-κB family 
members have been generated (Table 1.2), and have been used to elucidate the 
developmental and functional roles of each family member in B cells. With the exception 
of Rela, germline deletion of a single NF-κB family member does not result in embryonic 
lethality. Early death in germline Rela null embyros (~E15) is caused by excessive 
apoptosis of hepatocytes (Beg et al, 1995; Doi et al, 1999). Adoptive transfer of Rela
-/-
 
fetal liver cells into lethally irradiated Rag1
-/-
 mice can lead to the generation of 
lymphocytes, but B cell development is significantly impaired as a result of sensitivity to 
TNF-α induced cell death (Prendes et al, 2003). Relb null mice have multiple 
immunological abnormalities, including impaired dendritic cell development, an 
expansion of myeloid cells in the spleen and bone marrow, and multi-organ inflammation 
caused by T cell infiltration (Weih et al, 1995; Weih et al, 1996). Relb
-/- 
mice have 
normal Ig secretion abilities, but have impaired proliferation upon stimulation through 
TLR4, BCR, or CD40 (Snapper et al, 1996a). Rel deletion results in proliferative defects 
in response to LPS, anti-IgM or CD40L stimulation; in addition, there is an impairment in 
both basal and secondary antibody production (Kontgen et al, 1995). In Nfkb1
-/-
 mice, 
there is impaired LPS mediated B cell proliferation and isotype switching (Sha et al, 
1995). Nfkb1, Rela, Relb and Rel, are involved with MZ B cell, but not FO B cell 
development (Cariappa et al, 2000; Weih et al, 2001).  Lastly, Nkfb2 null mice have the 
most profound B cell phenotype. Nfkb2
-/-
 mice have reduced MZ, FO, T1, and T2 B cells 
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in the spleen (Guo et al, 2007). Furthermore, there is a reduction of B cells in the bone 
marrow and lymph nodes, and Nfkb2
-/- 
mice have impaired germinal center formation and 
T-dependent antibody responses (Caamano et al, 1998; Franzoso et al, 1998). 
It is likely that there is functional compensation between NF-κB family members, 
since germline deletion of multiple transcription factors results in a more severe 
phenotype than deleting a single factor. For example, proliferation in response to LPS or 
anti-IgM, antibody production, and germinal center formation is further impaired in 
Nfkb1
-/-
Rel
-/-
mice, and B cells are more apoptotic when stimulated compared to either 
Nfkb1
-/-
 or Rel
-/-
 mice (Pohl et al, 2002). Moreover, B cells fail to progress past the T1 
stage in Nfkb1
-/-
Nfkb2
-/-
 mice (Claudio et al, 2002), whereas differentiation past the T1 
stage is possible in Nfkb1
-/- 
or Nfkb2
-/-
 mice. Overall, activation of NF-κB is an important 
component of B cell development and function.  
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Table 1.2. Phenotype of NF-κB family member null mutations in mice 
Mutated 
gene  
Phenotype in knockout mice References 
Rela - Embryonic lethal (~E15) 
 
- TNF-α induced apoptosis of hepatocytes 
 
- Required for MZ B cell development 
(Beg et al, 
1995) 
 
(Cariappa et al, 
2000) 
 
Relb - Impaired dendritic cell development 
 
- Expansion of myeloid cells in the spleen and bone 
marrow 
 
- Multi-organ inflammation caused by T cell 
infiltration 
 
- Impaired B cell proliferation upon stimulation 
through TLR4, BCR, or CD40 
 
(Weih et al, 
1995; Weih et 
al, 1996) 
 
 
(Snapper et al, 
1996a) 
Rel - B cell proliferative defects following LPS, anti-IgM 
or CD40L stimulation 
 
- Impaired antibody production at the basal level, and 
upon secondary immune response 
 
- Required for MZ B cell development 
 
(Kontgen et al, 
1995) 
 
 
(Cariappa et al, 
2000) 
 
Nfkb1 - Impaired LPS mediated B cell proliferation and 
isotype switching 
 
- Required for MZ B cell development 
(Sha et al, 
1995) 
(Cariappa et al, 
2000) 
 
Nfkb2 - Reduced MZ, FO, T1, T2 B cell numbers in the 
spleen 
 
- Impaired germinal center formation 
 
- Impaired T-dependent antibody responses 
(Guo et al, 
2007) 
(Caamano et al, 
1998; Franzoso 
et al, 1998) 
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1.6 E26 Transformation Specific (ETS) Transcription Factors 
The ETS name is derived from the E26 avian erythroblastosis virus which carried 
the v-ets oncogene (Sharrocks, 2001). Proteins in the ETS family share an evolutionarily 
conserved DNA-binding domain, which forms a winged loop-helix-loop structure to bind 
purine rich consensus motifs containing the core sequence GGAA/T (Ciau-Uitz et al, 
2013; Sharrocks, 2001). Members of the ETS transcription factor family are involved 
with the regulation of a variety of genes involved with growth, activation, and 
development in adults and embryos of many organisms (Sharrocks, 2001; Wasylyk et al, 
1993). Adding to the complexity of transcriptional regulation, ETS proteins can function 
in collaboration with other transcription factors in the activation or repression of target 
genes (Sharrocks, 2001). This thesis focuses on the ETS transcription factors PU.1, Spi-
B, and Spi-C, which belong to the Spi subfamily, and how each is involved with 
transcriptionally regulating genes involved with B cell development and function. Figure 
1.5 demonstrates the structural similarities between PU.1, Spi-B, and Spi-C. All three 
transcription factors contain an N-terminal activation domain rich in acidic amino acids 
(ACID), and have similar amino acid homology within the DNA binding domain (DBD). 
PU.1 contains a Gln-rich (Q) region believed to be necessary for transactivation. The 
proline, glutamic acid, serine, and threonine (PEST) sequence contained within PU.1 and 
Spi-B are known to interact with interferon regulatory factor (IRF) family transcription 
factors, and is suggested to be involved with protein degradation (Brass et al, 1999; 
Rogers et al, 1986). Summarized in Table 1.3 are the phenotypes of mice containing 
germline deletions of PU.1, Spi-B, or Spi-C.  
1.6.1 PU.1 
PU.1 was identified in 1988 as an oncogene from the proviral insertion of the 
Friend spleen focus forming virus into the Spi-1 locus, which induced murine 
erythroleukemia (Moreau-Gachelin et al, 1988). In mice, PU.1 is encoded by the Spi1 
gene and is located on chromosome 2, whereas in humans, PU.1 is encoded by SPI-1 and 
is located on chromosome 11. PU.1 is expressed in most hematopoietic cells, including 
macrophages, granulocytes, dendritic cells (DCs), B cells, and T cells (Carotta et al, 
2010). With over 110 direct target genes identified to date (Turkistany & DeKoter, 2011), 
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PU.1 has been the most well-studied ETS transcription factor. The genes regulated by 
PU.1 include antibodies and their receptors, and cytokines and their receptors involving 
inflammation, leukocyte growth, and development (Turkistany & DeKoter, 2011).  Of all 
the ETS transcription factors, Spi1 defects have the most profound effects on normal 
hematopoiesis (Bartel et al, 2000). Targeted disruption of Spi1 was first generated by 
Scott et al. in 1994 by deleting the PU.1 DNA binding region in exon 5 of the Spi1 gene 
(Scott et al, 1994). Germline knock-out mice for the Spi1 gene (PU.1
-/-
) are unable to 
produce any lymphoid and myeloid cells during fetal hematopoiesis, and are also late-
stage embryonic lethal (Scott et al, 1994). However, erythroid progenitors and 
megakaryocytes are still generated in PU.1
-/-
 fetuses (Scott et al, 1994). Colony forming 
assays using fetal liver cells from embryonic day 14.5 (E14.5) PU.1
-/-
 mice failed to 
generate macrophage, granulocyte, or B cell colonies in vitro (Scott et al, 1997). 
Furthermore, transplantation of fetal liver cells from PU.1
-/-
 mice into lethally irradiated 
C57BL/6 mice failed to reconstitute cells from the lymphoid and myeloid lineages, 
further demonstrating the requirement of PU1 in these cell types (Scott et al, 1997). In 
1996, McKercher et al generated a germline Spi1 null mice using a targeted insertional 
disruption of the PU.1 DNA binding domain (McKercher et al, 1996). One major 
difference in these Spi1 null mice was that they were viable at birth, but died within two 
days as a result of septicemia (McKercher et al, 1996). Mice could survive for up to 17 
days if maintained on antibiotics, and T cell generation was observed 3-5 days after birth, 
suggesting a delay in T cell development (McKercher et al, 1996). Differences observed 
between Spi1 null mice between Scott et al. and McKercher et al. are likely due to 
differences in their deletion strategy of the Spi1 gene. Nonetheless, similar to the findings 
by Scott et al., Spi1 null neonates generated by McKercher et al. produced no mature 
macrophages, neutrophils, B cells, and T cells (McKercher et al, 1996). Therefore, PU.1 
is critical for the development and differentiation of cells of both the innate and adaptive 
immune system. 
The expression level of PU.1 has effects on hematopoietic cell fate decisions. 
High concentrations of PU.1 promote macrophage differentiation, whereas low levels of 
PU.1 favor B cell differentiation (DeKoter & Singh, 2000). High expression of PU.1 
occurs in HSCs and CLPs (Back et al, 2005; Nutt et al, 2005), but PU.1 expression is
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Table 1.3. Phenotypes of mice containing germline deletions for ETS transcription 
factors 
Mutated 
gene  
Phenotype in knockout mice References 
Spi1 (Scott et 
al. 1994) 
- Embryonic lethal (E17.5-18) 
 
- No commitment to B cells, monocytes, dendritic 
cells, neutrophils 
 
(Scott et al, 
1997; Scott et 
al, 1994) 
Spi1 
(McKercher 
et al. 1996) 
- Post-natal viable for 48 h; viable up to 17 days if 
maintained on antibiotics  
 
- Delayed T cell development (when treated with 
antibiotics) 
 
- No mature macrophages, neutrophils, B cells, 
and T cells in neonatal mice 
 
(McKercher et 
al, 1996) 
Spib - Viable, fertile 
 
- Fewer B cells; impaired BCR signaling,  
proliferative defect upon BCR stimulation, 
impaired secondary antibody responses 
 
- Defect in generation of intestinal microfold (M) 
cells; impaired uptake of pathogens 
 
- Impaired plasmacytoid dendritic cell 
development; impaired IFN production through 
TLR7 and TLR9 stimulation 
(Su et al, 1997; 
Su et al, 1996) 
 
 
(Kanaya et al, 
2012; Sato et al, 
2013) 
(Sasaki et al, 
2012) 
 
Spic - Viable  
 
- Defect in development of red pulp macrophages 
(Kohyama et al, 
2009) 
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reduced during commitment to the B cell lineage (Nutt et al, 2005). Although B cells 
express decreased levels of PU.1 upon differentiation, a certain threshold of expression is 
still required for proper B cell development. Mice generated with a hypomorphic allele of 
Spi1 (Spi1
BN/BN
), expressing a 5-fold reduction of PU.1 compared to WT in pro-B cells, 
were unable to generate B cells in the spleen or fetal liver (Houston et al, 2007). 
Furthermore, Spi1
BN/BN
 fetal liver progenitor cells transplanted into sub-lethally irradiated 
Rag2
-/-
Il2rg
-/-
 mice failed to generate B cells in the spleen and bone marrow of recipient 
mice (Houston et al, 2007). Conditional knockout mouse models for PU.1 were generated 
to further investigate the role of PU.1 on B cell development and function (Polli et al, 
2005). PU.1 is essential specifically during the early stages of B cell development, since 
deletion of Spi1 in committed B cell progenitors has no effect on B cell maturation, and 
has minimal effects on T-dependent responses (Polli et al, 2005). Overall, a sufficiently 
high level of PU.1 is required during HSC to pro-B cell differentiation, but PU.1 is not 
essential following B cell commitment.  
1.6.2 Spi-B 
The second Spi subfamily member is Spi-B, which was identified by probing a 
cDNA library generated from Raji Burkitts lymphoma cells with the PU.1 ETS DNA-
binding domain (Ray et al, 1992). Spi-B has been mapped to chromosome 19 in humans 
and to chromosome 7 in mice (Peters et al, 1997; Ray et al, 1992). Spi-B and PU.1 are 
highly conserved in humans, sharing 43% amino acid similarity with overall, and 67% 
similarity in its ETS domain (Ray et al, 1992) (Figure 1.5). Expression of Spi-B was 
initially believed to be exclusive to the B cells and T cells (Su et al, 1996), however, 
more recent studies have demonstrated a role for Spi-B in plasmacytoid dendritic cells 
(pDCs) (Sasaki et al, 2012) and intestinal microfold cells (Kanaya et al, 2012; Sato et al, 
2013). Germline Spi-B knockout mice (Spib
-/-
) are viable and possess mature B and T 
cells, potentially due to its degree of redundancy with PU.1. Although the functionality of  
Spib
-/-
 T cells appears to be normal, Spib
-/-
 B cells have defects in functional and humoral 
responses (Su et al, 1997). Spib
-/-
 B cells which are stimulated in vitro with anti-IgM 
demonstrate poor proliferation with increased rates of apoptosis. Furthermore, Spib
-/- 
mice immunized with dinitrophenol conjugated to keyhole limpet hemocyanin (DNP-
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KLH) produce low levels of IgG1, IgG2a and IgG2b, and are unable to sustain germinal 
centers (Su et al, 1997). Therefore, Spi-B is required for BCR-mediated responses in vitro 
and in vivo.  
Since Spi-B recognizes the same binding sites as PU.1 (Ray et al, 1992) and can 
activate the same reporter gene constructs in vitro (Muller et al, 1996; Ray et al, 1992; Su 
et al, 1996), it strengthened the hypothesis that both Spi-B and PU.1 have partial 
functional redundancy. To determine the function of both PU.1 and Spi-B in B cells, 
mice heterozygous for Spi1 were crossed to Spib
-/- 
to generate Spi1
+/-
Spib
-/-
 (PU.1
+/-
Spib
-/-
; PUB) mice (Garrett-Sinha et al, 1999), since complete PU.1 deletion resulted in 
embryonic lethality (Scott et al, 1994). Many of the deficiencies observed in the Spib
-/-
 
phenotype were further impaired by the additional reduction of PU.1. PUB mice had 
fewer B cells than Spib
-/-
 mice, increased basal levels of apoptotic B cells, further 
impaired anti-IgM and LPS-mediated B cell proliferation, and reduced BCR signaling 
(Garrett-Sinha et al, 1999). Therefore, both PU.1 and Spi-B are required for normal BCR 
signal transduction, and function in a semi-redundant or complementary manner. 
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Figure 1.5. Major domains of the SPI-group ETS transcription factors.  
The percentages indicate the amino acid sequence homology of the ETS DNA binding 
domain (DBD) between the three transcription factors. The acidic transactivation 
domains are denoted ACID. PU.1 and Spi-B has a glutamine (Q) rich and a 
proline/serine/threonine (PST) rich domain following the ACID domain respectively. 
PU.1 and Spi-B also have a proline/glutamic acid/serine/threonine (PEST) domain prior 
to the DBD.  
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1.6.3 Spi-C 
Spi-C is encoded by the Spic gene located on chromosome 10 in mice, and 12 in 
humans, and was initially discovered via a yeast one-hybrid screening of a cDNA library 
made from LPS stimulated splenic B cells (Bemark et al, 1999; Carlsson et al, 2002). A 
second group discovered the same protein and published their findings months later, but 
identified it as PU.1-related factor (Prf) (Hashimoto et al, 1999). Spi-C is expressed in B 
cells, macrophage, and dendritic cell populations in the spleen, bone marrow, and lymph 
nodes according to Northern blot analysis (Bemark et al, 1999). Based on amino acid 
sequence homology in its DNA binding ETS domain, Spi-C is related to Spi-B and PU.1 
(Figure 1.5). Spi-C is also capable of binding to the GGAA/T motif similar to PU.1 and 
Spi-B. However, there is a preference for an A in position -2 (two nucleotides before the 
GGAA core) for Spi-C (Bemark et al, 1999), whereas PU.1 prefers G at the -2 position 
(Ray-Gallet et al, 1995). Similar to PU.1 and Spi-B, Spi-C contains an acidic 
transactivation domain at the N-terminal which is conserved between species  (Carlsson 
et al, 2003).  However, Spi-C differs from PU.1 and Spi-B as it contains a much longer 
C-terminus relative to the ETS binding site (Carlsson et al, 2003). In addition, Spi-C does 
not interact with IRF-4 in vitro, suggesting that Spi-C has functionally distinct roles 
compared to PU.1 and Spi-B (Carlsson et al, 2003). 
In B cells, Spi-C is highly expressed in the mature B cell populations, but is 
absent in the pre-B and plasma cell stages (Bemark et al, 1999). There are few target 
genes known for Spi-C in B cells. Spi-C has been reported to directly transcribe Fcer2a 
(DeKoter et al, 2010), and can cooperate with STAT6 to directly induce transcription of 
IgE (Carlsson et al, 2006). Ectopic expression experiments that overexpressed Spi-C in 
either cultured pro-B cells using a retroviral vector (Schweitzer et al, 2006), or in mice 
using a B cell specific transgene (Zhu et al, 2008), suggested that Spi-C functions as a 
negative regulator of transcription by opposing PU.1 and/or Spi-B activity. However, 
whether this opposition was due to direct competition for binding was not determined. 
Recently a Spic knockout mouse was generated making it possible to determine the effect 
of loss of function of Spi-C (Kohyama et al, 2009). Analysis of Spic
-/- 
mice revealed that 
Spi-C is essential for the generation of red pulp macrophages in the spleen and is 
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inducible by Heme (Haldar et al, 2014). However, the role of Spi-C in B cell 
development and function was not examined closely in these mice.  
 
1.7 Thesis Overview 
This thesis characterizes the transcriptional regulation of BCR and TLR 
expression and signal transduction in B cells by the related ETS transcription factors 
PU.1, Spi-B, and Spi-C. Specifically, the mechanism by which PU.1, Spi-B, and Spi-C 
regulate the transcriptional activity of Nfkb1 in B cells is elucidated. The primary 
objective of this study was to determine the function of PU.1, Spi-B, and Spi-C during B 
cell development, and during TLR-mediated responses. It was hypothesized that PU.1 
and Spi-B were required for positively regulating components of TLR responses, and 
Spi-C inhibited PU.1 and Spi-B targets. 
1.7.1 Chapter 2: Nfkb1 activation by the ETS transcription factors PU.1 
and Spi-B promotes Toll-Like receptor-mediated splenic B cell 
proliferation  
In this study, we found impairment in the ability of PUB B cells to proliferate in 
response to different TLR ligands. The impairment in proliferation was not due to a 
failure of activation or increased rates of apoptosis upon stimulation in PUB B cells. 
Transcript levels of genes associated to the TLR signaling pathway were measured, but 
despite decreased transcript levels of multiple genes of interest in PUB B cells, most were 
not sufficient to explain our phenotype when tested at the protein level. Nevertheless, 
decreased transcript levels of Nfkb1, and lower levels of its encoded protein p50 in PUB 
B cells were detected. P50 is activated upon TLR stimulation, and Nfkb1
-/-
 B cells have a 
proliferative phenotype in response to TLR ligands which is strikingly similar to PUB B 
cells. It was hypothesized that PU.1 and Spi-B were involved with transcriptionally 
regulating the Nfkb1 gene. It was determined that PU.1 and Spi-B directly activated 
Nfkb1 transcription, and were essential for proper TLR-mediated responses. Our results 
demonstrated that PU.1 and Spi-B regulated TLR responses in B cells, which is an 
important auxiliary pathway involved in neutralizing antibody formation.  
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1.7.2 Chapter 3: Identification of a negative regulatory role for Spi-C in the 
murine B cell lineage 
The role of Spi-C in B cell development and function was examined in this study. 
In order to determine whether Spi-C and Spi-B were functionally redundant, a novel 
mouse line was generated that was germline knockout for Spib and heterozygous for Spic 
(Spib
-/-
Spic
+/-
). Spib
-/-
 B cells are defective in BCR signaling, and have reduced FO B 
cells compared to WT mice. Many aspects of the Spib
-/- 
B cell phenotype were rescued in 
Spib
-/-
Spic
+/-
 B cells, including a restoration in FO and T2 B cells, and restored 
proliferation in response to LPS and anti-IgM. The phenotypic rescue in Spib
-/-
Spic
+/-
 
mice was attributed to elevated transcript levels of Nfkb1. It was hypothesized that Spi-C 
was inhibiting Spi-B during transcriptional activation of Nfkb1. It was determined that 
Spi-C directly binds to the Nfkb1 promoter to inhibit Spi-B’s transcriptional activation of 
Nfkb1. Our results demonstrate a novel mechanism for Spi-C in opposing Spi-B in B cell 
development and function. 
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Chapter 2  
2 Nfkb1 activation by the ETS transcription factors PU.1 and 
Spi-B promotes Toll-Like receptor-mediated splenic B cell 
proliferation 
Generation of antibodies against T-independent and T-dependent antigens 
requires Toll-Like receptor (TLR) engagement on B cells for efficient responses. 
However, regulation of TLR expression and responses in B cells is not well understood. 
PU.1 and Spi-B (encoded by Spi1 and Spib respectively) are transcription factors of the 
E26-transformation-specific (ETS) family, and are important for B cell development and 
function. It was found that B cells from mice knockout for Spi-B and heterozygous for 
PU.1 (Spi1
+/-
Spib
-/-
, PUB mice) proliferated poorly in response to TLR ligands compared 
to WT B cells. The NF-κB family member p50 (encoded by Nfkb1) is required for LPS 
responsiveness in mice. PUB B cells expressed reduced Nfkb1 mRNA transcripts and p50 
protein. The Nfkb1 promoter was regulated directly by PU.1 and Spi-B as shown by 
reporter assays and chromatin immunoprecipitation analysis. Occupancy of the Nfkb1 
promoter by PU.1 was reduced in PUB B cells compared to WT B cells. Finally, 
infection of PUB B cells with a retroviral vector encoding p50 substantially restored 
proliferation in response to LPS. We conclude that Nfkb1 transcriptional activation by 
PU.1 and Spi-B promotes TLR-mediated B cell proliferation. 
 
2.1 Introduction 
Toll-Like receptors expressed by B cells recognize conserved microbial products. 
Engagement of TLR-ligands by B cells is required for thymus-independent responses that 
are sufficient to promote CSR, proliferation, and antigen presentation (Browne, 2012; 
Pone et al, 2010). Generation of optimal T-dependent antibody responses also requires 
TLR signaling in B cells (Pasare & Medzhitov, 2005; Ruprecht & Lanzavecchia, 2006). 
For example, efficient antibody responses to protein antigens after immunization with 
synthetic nanoparticles required engagement of TLRs on B cells (Kasturi et al, 2011). 
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Therefore, identifying factors controlling TLR expression and responses in B cells has 
important implications for the generation of neutralizing antibody responses.  
Mature murine B cells express and respond to TLR1, TLR2, TLR4, TLR6, 
TLR7/8, and TLR9 ligands (Genestier et al, 2007; Gururajan et al, 2007; Hornung et al, 
2002), resulting in NF-κB activation through MyD88 or TRIF-dependent pathways 
(Kawai & Akira, 2006). NF-κB activates genes involved in cytokine synthesis, antibody 
secretion, and cell proliferation (Bekeredjian-Ding & Jego, 2009). The NF-κB family 
includes p105 that is processed into p50 (encoded by Nfkb1), p100 that is processed into 
p52 (encoded by Nfkb2), RelA (p65), Rel (c-Rel), and RelB, which all interact with DNA 
as hetero- or homodimers (Hayden & Ghosh, 2008). Optimal TLR signaling in B cells 
may require MHC class II (MHCII) interaction with Bruton’s tyrosine kinase (Btk) and 
CD40 (Liu et al, 2011). However, many aspects of gene regulation involving TLR 
expression and signal transduction in B cells remain unclear.  
PU.1 and Spi-B are E26 transformation-specific (ETS)-family transcription 
factors encoded by Spi1 and Spib respectively, and are important in B cell development 
and function (DeKoter et al, 2010). PU.1 is expressed in most hematopoietic cell types, 
directly regulating many genes involved in cellular communication (Turkistany & 
DeKoter, 2011). Spi-B is expressed in B cells, plasmacytoid dendritic cells, and at lower 
levels in T cells (Su et al, 1996). PU.1 and Spi-B share 67% amino acid homology in 
their DNA binding domain and can bind an identical consensus sequence containing the 
core motif 5'-GGAA-3'
 
(Dahl et al, 2002; Pio et al, 1996; Ray-Gallet et al, 1995). Both 
transcription factors are expressed in B cells, regulate common target genes, and are 
functionally redundant (Sokalski et al, 2011; Xu et al, 2012). Spi1
-/-
 mice die during 
embryogenesis and produce no B cells (Scott et al, 1994). In contrast, viable Spib
-/-
 mice 
have fewer B cells, which are defective in BCR signaling and are unable to generate 
antibody responses to T-dependent antigens (Garrett-Sinha et al, 1999). Spi1
+/- 
Spib
-/-
 
(PUB) mice have greater impairment in B cell numbers and BCR signaling compared to 
Spib
-/- 
or Spi1
+/-
 mice (Garrett-Sinha et al, 1999; Su et al, 1997), and also have reduced 
follicular (FO) and increased marginal zone (MZ) B cell frequencies compared to WT 
mice (DeKoter et al, 2010). Therefore, PU.1 and Spi-B are critically important for B cell 
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development and BCR signaling, but it remains unclear what these transcription factors 
regulate downstream to explain this phenotype. 
In this study, it was determined whether PU.1 and Spi-B regulate innate immune 
responses in B cells. Impairment in TLR-mediated proliferation in PUB B cells was 
observed. Gene and protein expression analysis, luciferase reporter assays, and chromatin 
immunoprecipitation (ChIP) experiments demonstrated that PU.1 and Spi-B directly 
activate Nfkb1 encoding p50. Infection of PUB B cells with a retroviral vector encoding 
p50 significantly increased proliferation in response to LPS. Therefore, decreased P50 
expression is sufficient to explain many aspects of the PUB B cell phenotype. Our results 
suggest that PU.1 and Spi-B are important transcriptional regulators of TLR responses in 
B cells.   
 
2.2  Results 
2.2.1 PUB mice exhibit impaired TLR-mediated B cell proliferation 
PUB B cells were previously reported to have reduced proliferation in response to 
anti-IgM or lipopolysaccharide (LPS) (Garrett-Sinha et al, 1999). To determine if 
impaired proliferation was limited to LPS (TLR4 ligand), splenic B cells were enriched 
by CD43 depletion and cultured with various TLR ligands. Compared to WT B cells, 
PUB B cells proliferated poorly at all tested concentrations of LPS (Fig. 2.1A) or CL097 
(TLR7/8 ligand) (Fig. 2.1B), and proliferated poorly to Pam3CSK4 (TLR2/1), FSL1 
(TLR6/2), ODN1826 (TLR9) (Fig. 2.1C), or anti-IgM (Fig. 2.1D-E) stimulation. Both 
WT and PUB B cells failed to respond to flagellin (TLR5) and Poly(I:C) LMW or HMW 
(TLR3) (Fig. 2.2B), but proliferated nearly equally well in response to anti-CD40 or 
LPS+anti-CD40 stimulation (Fig. 2.2C-D), which indicated no general proliferation 
impairment in PUB B cells. Anti-CD40 stimulation did not restore responsiveness of 
PUB B cells to anti-IgM (Fig. 2.2C-D). Interestingly, although PUB B cells proliferated 
poorly in response to anti-IgM or LPS stimulation alone, LPS+anti-IgM stimulation 
resulted in equivalent WT and PUB proliferation (Fig. 2.1F-G). Similar results were 
obtained using 3-[4, 5-dimethylthiazol-2yl]-2, 5-diphenyl-tetrazolium bromide (MTT) 
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proliferation assays and [
3
H]-thymidine incorporation assays (Fig. 2.2D). Overall, these 
results suggested that proper PU.1 and Spi-B expression was required for TLR-mediated 
B cell proliferation. 
Altered splenic B cell composition could explain proliferative defects in PUB B 
cells. However, PUB mouse spleens have increased ratios of MZ to FO B cell frequencies 
(DeKoter et al, 2010) and MZ B cells were shown to have greater TLR-mediated 
proliferative potential compared to FO B cells (Oliver et al, 1997). Former studies 
reported reduced B cell frequencies in PUB spleens (Garrett-Sinha et al, 1999), which 
was confirmed by our study (Fig. 2.3A-B). PUB spleens contained elevated frequencies 
of CD11b
+
GR1
+
 myeloid cells, but the absolute number of CD11b
+
GR1
+
 splenocytes 
were slightly reduced compared to WT mice (Fig. 2.3C-D). Flow cytometric analysis of 
CD19
hi
CD1d
hi
CD5
+
 B regulatory cells (Yanaba et al, 2008) revealed no significant 
difference in frequency between PUB and WT spleens (Fig. 2.3E). Furthermore, spleens 
from PUB mice contained fewer cells than WT mice (Fig. 2.3F). Elevated B cell 
activating factor (BAFF) is common in B cell lymphopenia (Kreuzaler et al, 2012), and 
conceivably could impede TLR-mediated proliferation. Steady-state levels of serum 
BAFF were found to be elevated in PUB mice compared to WT (Fig. 2.4A). BAFF 
receptor (BAFF-R) expression was reduced on PUB B cells (Fig. 2.4B), consistent with 
what was expected from higher BAFF levels (Kreuzaler et al, 2012). To determine if 
increased BAFF could impair PUB B cell proliferation, splenic B cells were LPS 
stimulated with and without recombinant BAFF. Additional BAFF increased proliferation 
in both untreated or LPS treated groups in WT and PUB B cells (Fig. 2.4C). Therefore, 
impaired TLR-mediated PUB B cell proliferation was not explained by altered B cell 
composition or elevated BAFF levels.  
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Figure 2.1. Impaired TLR-mediated proliferation in PUB (Spi1
+/-
Spib
-/-
) B cells. 
(A and B) B cells from PUB mice responded poorly compared to WT stimulated with 
different concentrations of LPS (A) and CL097 (B). Y-axis indicates OD570, and X-axis 
indicates concentrations of agonists. (C) B cells from PUB mice responded poorly 
compared to WT stimulated with indicated TLR9, TLR6/2, TLR4, and TLR2/1 ligands. 
(D) Impaired PUB B cell proliferation in response to anti-IgM stimulation. (E) 
Quantitation of four independent experiments as done in D. Proliferation indices were 
calculated by normalizing OD570 of treatments to WT untreated. For A-E, B cell 
proliferation was assessed by MTT proliferation assay following 72 h stimulation. Data 
shows the mean ± SD for triplicate wells for A-D and are representative of at least two 
independent experiments. Values in E are shown as mean ±SEM (n=4). *p<0.05; 
**p<0.01; ***p<0.001. 
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Figure 2.2. Proliferation of WT and PUB splenic B cells in response to various stimuli. 
(A) B cells were enriched by magnetic depletion and purity was determined by 
CD19
+
B220
+
 flow cytometry analysis (box). (B) Neither WT nor PUB splenic B cells 
proliferated in response to TLR3, TLR5, and TLR7 ligands.  Proliferation was assessed 
with the presence of different TLR ligands for 72 h in a 96-well plate using a MTT cell 
proliferation assay.  Values are shown as mean ± standard deviation of triplicate wells.  
Data are representative of at least two independent experiments. (C and D) Ex vivo 
stimulation with LPS and anti-IgM, results in impaired B cell proliferation in PUB mice. 
Proliferation was measured in splenic PUB and WT B cells following 72 h stimulation 
with different combinations of LPS (10 μg/mL), anti-CD40 (10 μg/mL), and anti-IgM (50 
μg/mL). Proliferation was assessed using a (C) MTT cell proliferation assay or (D) [3H]-
thymidine incorporation assay.  [
3
H]-thymidine (1 mCi/mL) was added to each well after 
72 h stimulation, followed by scintillation counting 24 h after thymidine treatment.  For 
B-D, values are shown as mean ± standard deviation of triplicate wells, and are 
representative of two independent experiments.  Statistical analysis was performed using 
Student's t-test, * = p<0.05, ** = p<0.01, *** = p<0.001. 
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Figure 2.3. Splenic B and myeloid cell composition in PUB mice. 
(A) Reduced B cell frequencies in the spleen of PUB mice. Flow cytometric analysis was 
performed to determine the frequency of B cells expressing CD19 and B220 in WT and 
PUB mice. Dashed box represents B cells in the spleen. Shown is a representative 
experiment of seven individual experiments. (B) Reduced CD19
+
 and B220
+
 cell 
frequencies and absolute numbers in the spleens of PUB mice. Quantitation of the 
frequency and absolute number of splenic B cells expressing CD19 and B220 (n=7). (C) 
Increased frequency of myeloid cells in the spleens of PUB mice. Flow cytometric 
analysis was performed to determine the frequency of myeloid cells expressing GR-1 and 
CD11b in WT and PUB mice. Shown is a representative experiment of seven 
independent experiments. (D) Increased frequency of myeloid cells, but decreased 
absolute number of myeloid cells in the spleens of PUB mice. Flow cytometric analysis 
was performed to determine the frequency and absolute numbers of splenic myeloid cells 
expressing GR-1 and CD11b for 7 mice. (E) There is no difference between the 
frequency of Breg (B10) cells between PUB and WT mice. Flow cytometric analysis was 
performed to determine the frequency of B10 cells. B10 cells were gated on 
CD19
hi
CD1d
+
CD5
+ 
(bolded quadrant). Shown is a representative experiment of two 
independent experiments. (F) Reduced absolute number of total splenocytes in PUB mice 
compared with C57BL/6 mice. Shown are total splenic cell counts WT and PUB mice 
(n=7). For all panels, *, P<0.05; **, P<0.01; ***. P<0.001. Error bars represent standard 
deviation. 
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Figure 2.4. Proliferation of splenic B cells in response to recombinant BAFF and 
analysis of BAFF-R and BAFF serum levels.  
(A) Elevated BAFF levels were detected in sera from PUB compared to WT mice by 
ELISA. Values are shown as mean ± standard deviation from six individual mice. Data is 
representative of two independently performed experiments. (B) Reduced BAFF-R levels 
on the surface of splenic B cells in PUB mice compared to WT mice. Mean fluorescence 
intensities (MFIs) of BAFF-R was measured by flow cytometry on total CD19
+
 cells, 
gated CD21
hi
CD19
+
 (MZ) B cells, or gated CD21
int
CD19
+
 (FO) B cells from WT and 
PUB spleens. Data is shown as mean ± standard error mean of six independent 
experiments. (C) Addition of recombinant BAFF (100 ng/mL) increased proliferation in 
splenic WT and PUB B cells when treated with LPS, as compared with treatments 
without BAFF. Proliferation was assessed following 72 h stimulation in a 96-well plate 
using a MTT cell proliferation assay. Values are shown as mean ± standard error mean of 
five independent experiments. For all panels, *, P<0.05; **, P<0.01. 
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2.2.2 PUB B cells are activated following stimulation 
We wanted to determine the mechanism of impaired TLR-mediated B cell 
proliferation in PUB mice. To determine whether PUB B cells were capable of activation 
by TLR ligands, MFI of CD25 or CD69 activation markers were measured on total 
B220
+
 cells, or B cells with MZ (CD21
hi
B220
+
), or FO (CD21
int
B220
+
) phenotypes after 
24 h LPS stimulation (Fig. 2.5A). All WT and PUB B cell subsets upregulated CD25 
following LPS stimulation compared to untreated cells (Fig. 2.5B-C). Untreated FO-
phenotype PUB B cells expressed more CD25 than WT (Fig. 2.5C). Next, CD69 
expression was measured 24 h after LPS stimulation (Fig. 2.5D-E). Both WT and PUB B 
cells increased CD69 expression following LPS stimulation for all subsets (Fig. 2E). 
CD69 was also measured 72 h post stimulation in total B220
+
 cells. PUB B cells failed to 
upregulate CD69 to WT levels following 72 h LPS stimulation (Fig. 2.5F-G). In contrast, 
PUB B cells expressed higher levels of CD69 following anti-IgM stimulation, and LPS + 
anti-IgM stimulation resulted in equivalent expression between WT and PUB B cells 
(Fig. 2.5F-G). In summary, PUB B cells were activated following LPS stimulation, but 
CD69 upregulation was reduced compared to WT when measured at 72 h.   
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Figure 2.5. Splenic PUB B cells are activated following LPS stimulation.  
(A) Flow cytometry gating strategy on total B220
+
, MZ (CD21
hi
B220
+
), or FO 
(CD21
int
B220
+
) B cells. (B) Histograms show increased CD25 expression following 24 h 
LPS stimulation in WT and PUB B cells. (C) Quantitation of data shown in B. (D) 
Histograms show increased CD69 expression following 24 h LPS stimulation in WT and 
PUB mice. (E) Quantitation of data shown in D. (F) CD69 expression is lower in PUB 
total B cells than WT total B cells at 72 h post stimulation with LPS. CD69 expression is 
also shown for anti-IgM and LPS+anti-IgM conditions. (G) Quantitation of data shown in 
F. Values in C, E, and G show the normalized CD25 or CD69 MFI ±SEM for five 
independent experiments. Normalized MFI was calculated by dividing MFI values by 
WT untreated MFI for each given subset. *p<0.05; **p<0.01. 
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2.2.3 Apoptosis in PUB splenic B cells is not increased following LPS 
stimulation 
PUB B cells were previously reported to exhibit increased steady-state levels of 
apoptosis (Garrett-Sinha et al, 1999). Therefore, impaired TLR-mediated PUB B cell 
proliferation could be due to increased apoptotic cell death. To test this hypothesis, we 
stained B cells for Annexin V and PI after 72 h incubation with or without LPS and/or 
anti-IgM (Fig. 2.6A). Under the culture conditions used, a mean of 36% of WT B cells 
were low/negative for Annexin V staining after anti-IgM stimulation, while a mean of 6% 
of PUB B cells were low/negative for Annexin V staining after anti-IgM stimulation (Fig. 
2.6A, 2.6C). Therefore few PUB B cells survived anti-IgM stimulation, in accord with 
proliferation results shown in Fig. 2.1E. Frequencies of apoptotic (Annexin V
hi
PI
-
) PUB 
B cells untreated or anti-IgM stimulated were significantly higher than WT controls; and 
frequencies of live (Annexin V
-
PI
-
) PUB B cells untreated or anti-IgM stimulated were 
significantly decreased compared to WT controls. However, frequencies of apoptotic 
cells between LPS or LPS+anti-IgM treated WT and PUB B cells were similar (Fig. 
2.6B). No significant difference was observed between live WT and PUB B cells 
stimulated with LPS or LPS+anti-IgM. (Fig. 2.6C). Therefore, these results suggest that 
reduced proliferation of PUB B cells in response to LPS was not primarily due to 
increased apoptosis. 
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Figure 2.6. Apoptosis in PUB B cells is not elevated following LPS stimulation. 
 (A) Apoptosis was analyzed by flow cytometry using Annexin V and PI staining in 
enriched B cells that were untreated or treated with indicated stimuli. (B) Quantitation of 
apoptotic (Annexin V
hi 
PI
-
) cells. (C) Quantitation of live (Annexin V
- 
PI
-
) cells. Data in 
B and C show the mean ± SEM of four independent experiments. *p<0.05; **p<0.01; 
***p<0.001. 
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2.2.4 PUB mice have altered transcript and protein levels of genes involved 
in TLR signaling 
MZ B cells are more readily activated and proliferative than FO B cells after LPS 
stimulation (Oliver et al, 1997; Snapper et al, 1993). Despite increased MZ B cells in 
PUB mice (DeKoter et al, 2010), impaired proliferation occurred in splenic PUB B cells 
for all MyD88 dependent TLR ligands compared to WT (Fig. 2.1B-C). Therefore, 
components of the MyD88-dependent signaling pathway might be regulated by PU.1 and 
Spi-B. To test this hypothesis, RNA was prepared from sorted MZ B cells from WT and 
PUB mice. Steady-state levels of mRNA transcripts encoding components of the MyD88-
dependent signaling were measured by RT-qPCR analysis. We examined transcript levels 
of downstream signaling components (Fig. 2.7A), TLRs and related receptors (Fig. 2.7B), 
and NF-κB/Rel subunits (Fig. 2.7C). Significant reductions in Myd88, Cd14, Tlr8, Tlr7 
and Nfkb1 transcripts were measured in PUB MZ B cells (Fig. 2.7A-C). Next, we 
stimulated enriched total B cells with LPS for 16 h and assessed gene expression profiles 
by RT-qPCR. Transcript levels of downstream TLR signaling genes were not 
significantly different in PUB B cells compared to WT (Fig. 2.7D). Although steady-state 
transcript levels of TLR and related receptors were reduced in PUB MZ B cells, 
transcript levels of Tlr2, Cd14, and Tlr8 were higher in total LPS stimulated PUB B cells 
(Fig. 2.7E). Lastly, LPS stimulated PUB B cells expressed lower transcript levels of Rel 
and Nfkb1 (Fig. 2.7F).  
MyD88 is the adapter protein utilized by all TLRs to which B cells responded in 
our hands (Fig. 2.1). However, immunoblotting analysis showed MyD88 levels were 
unchanged between PUB and WT enriched B cells (Fig. 2.8A). Despite elevated Cd14 
transcripts in LPS stimulated PUB B cells, surface CD14 expression was equal to WT 72 
h post LPS or anti-IgM stimulation, and was elevated when LPS+anti-IgM stimulated 
(Fig. 2.8B). Therefore, our results suggest that altered levels of MyD88 and CD14 did not 
account for defective TLR responses in PUB B cells. 
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Figure 2.7. Measurement of steady-state and LPS stimulated transcript levels of TLR 
signaling genes. 
(A-C) Steady-state transcript levels of genes related to downstream TLR signaling (A), 
TLRs and related receptors (B), and NF-B subunits (C) were measured in MZ B cells of 
PUB and WT mice. (D-F) Transcript levels in total B cells following 16 h LPS 
stimulation of genes related to downstream (D) TLR signaling, (E) TLRs and related 
receptors, and (F) NF-B subunits. Analysis was performed on RNA prepared from MZ 
B cells enriched by cell sorting, or total enriched B cells. RT-qPCR was used to 
determine relative mRNA transcript levels in PUB B cells compared to WT B cells, after 
normalizing to Gapdh or B2m. Y-axis indicates mean fold change ±SEM relative to WT 
levels for three individual mice. Values of 1 (dashed line) indicate no difference in 
transcript levels between PUB and WT B cells. *p<0.05; **p<0.01; ***p<0.001. 
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Next, surface expression of TLRs and related receptors were examined by flow 
cytometry. Reduced TLR2 and TLR1 was measured on freshly isolated MZ, FO, and 
total B cells of PUB mice (Fig. 2.8C). LPS can also activate B cells through binding 
RP105 (Nagai et al, 2012), but levels between WT and PUB B cells were equal (Fig. 
2.8D). TLR signaling in B cells has been reported to involve MHCII, CD40, and Btk 
interaction
 
(Liu et al, 2011), and PU.1 activates the Btk promoter (Himmelmann et al, 
1996). PU.1 also directly regulates the transcriptional coactivator CIITA, which regulates 
MHCII genes
 
(Yoon & Boss, 2010). Since PU.1 transcriptionally regulates genes 
involved with TLR signaling, TLR-mediated B cell proliferation might be regulated by 
PU.1 and/or Spi-B through these auxiliary pathways and interactions. Decreased gene 
transcription in PUB mice could result in decreased protein, and consequently fewer 
protein interactions required for TLR signaling. To test this hypothesis, we measured 
protein levels of MHCII, CD40, and Btk. PUB B cells failed to upregulate surface 
MHCII (Fig. 2.8E) or CD40 (Fig. 2.8F) following 72 h LPS or anti-IgM stimulation. 
Immunoblotting analysis showed equal Btk protein expression between PUB and WT B 
cells (Fig. 2.8G). Overall, decreased TLR responsiveness in PUB B cells was 
accompanied by reduced TLR1 and TLR2 expression, and a failure to upregulate MHCII 
or CD40. However, these observations were not sufficient to explain the PUB phenotype. 
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Figure 2.8. PUB B cells have decreased basal surface expression of TLR1 and TLR2 and 
cannot upregulate MHCII and CD40 expression following stimulation.  
(A) Immunoblotting for MyD88 and -actin was performed using total spleen cells (top 
panel) or enriched B cell lysates (lower panel) from WT and PUB mice. (B) CD14 
expression is increased in PUB B cells following LPS+anti-IgM stimulation, but not 
increased when stimulated with LPS or anti-IgM. (C) PUB B cells have decreased TLR1 
and TLR2 expression. TLR1 and TLR2 MFI was measured for gated MZ (CD21
hi
B220
+
), 
FO (CD21
int
B220
hi
), and total B220
+
 B cells using flow cytometry. Data shows the mean 
±SEM (n=5). (D) RP105 surface levels are equivalent between WT and PUB B cells. 
RP105 MFI was measured for MZ, FO, and total B220
+
 cells using flow cytometry. Data 
shows the mean ±SEM (n=3). PUB B cells fail to upregulate (E) MHCII expression or 
(F) CD40 expression following LPS, anti-IgM, or LPS+anti-IgM stimulation. (G) 
Immunoblotting for Btk, and -actin was performed using enriched B cell lysates from 
WT and PUB mice. Immunoblotting experiments are shown as a representative of two 
individual mice. For B, E, and F, enriched B cells were stimulated for 72 h before 
analysis of CD14, MHCII, and CD40 expression by flow cytometry. Values represent 
MFIs of total B cells expressing the indicated markers, normalized to untreated WT B 
cells. Normalized MFIs were calculated by dividing MFI values by the WT untreated 
MFI. Data shows the mean ±SEM of four independent experiments. *p<0.05; **p<0.01.  
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2.2.5 Direct Nfkb1 promoter activation by PU.1 and Spi-B 
Steady-state levels of Rel and Nfkb1 mRNA transcripts were expressed at reduced 
levels in PUB B cells stimulated with LPS compared to WT B cells (Fig. 2.7F). It was 
previously shown that Rel is regulated by PU.1 and/or Spi-B in B cells (Hu et al, 2001). 
Nfkb1 encodes for p50 and is required for murine B cell proliferation in response to LPS 
or anti-IgM (Sha et al, 1995). Reduced p50 expression could sufficiently explain many 
aspects of the PUB phenotype. Immunoblotting analysis confirmed lower p50 levels in 
splenic PUB B cells (Fig. 2.9A). We therefore investigated the role of reduced Nfkb1 in 
PUB B cell proliferation.  
PU.1 and Spi-B can interchangeably bind sites of target genes (Ray-Gallet et al, 
1995). To determine locations of binding similarity between PU.1 and Spi-B, genome-
wide ChIP-sequencing (ChIP-seq) was performed using anti-FLAG Ab on WEHI-279 B 
cell lymphoma cells overexpressing either 3X-FLAG tagged PU.1 or Spi-B. Both PU.1 
and Spi-B were enriched at the Nfkb1 promoter (Fig. 2.9B). To determine whether PU.1 
and Spi-B regulate Nfkb1 directly, we aligned the murine Nfkb1 promoter sequence from 
multiple species, using a published transcription start site (TSS) for reference (Cogswell 
et al, 1993). At the promoter, a 213 bp region was found to be 87% conserved between 
multiple species, with exception to the 67% conservation of the Tasmanian Devil 
sequence (Fig. 2.9C). Potential PU.1/Spi-B transcription factor binding sites were 
predicted using MatInspector software. Three conserved binding sites with a matrix 
similarity score >0.9 were predicted among all species, and a lower scoring fourth site 
was identified near the TSS (Fig. 2.9C). Next, luciferase assays were used to determine 
PU.1 and Spi-B’s contribution to Nfkb1 transcriptional activation. The conserved Nfkb1 
mouse promoter region was cloned and tested by transient transfection in WEHI-279 
cells. Site directed mutagenesis was performed on the predicted PU.1/Spi-B binding sites 
of the two closest sites of the TSS of the promoter, by substituting GGAA (TTCC on 
complement strand) binding site to GGAC (GTCC) (Fig. 2.9D), which was previously 
reported to abolish PU.1 binding (DeKoter et al, 2010; Xu et al, 2012). Transcriptional 
activation was detected at the Nfkb1 promoter, and mutation of PU.1/Spi-B sites 
significantly reduced transcriptional activation (Fig. 2.9E). To determine if PU.1 interacts 
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directly with the Nfkb1 promoter, ChIP analysis was performed. Reanalysis of published 
ChIP-seq data (Heinz et al, 2010), and with our own ChIP-seq results (Fig. 2.9B), 
revealed PU.1 interacting at the Nfkb1 promoter. Chromatin was prepared from freshly 
isolated untreated and LPS stimulated B cells, and immunoprecipitated with anti-PU.1 or 
control Abs. WT and PUB B cells were LPS stimulated for 16 h, as this time-point 
provided increased p50 expression upon LPS exposure (Souvannavong et al, 2007). 
Relative amounts of immunoprecipitated DNA was determined by qPCR from the Nfkb1 
promoter region, the positive control Mef2c gene enhancer (DeKoter et al, 2010), and the 
negative control Hprt. ChIP analysis confirmed less PU.1 occupancy at the Nfkb1 
promoter of both freshly isolated untreated and LPS treated PUB B cells, whereas no 
significant difference occurred at Hprt (Fig. 2.9F-G). Together, these data indicate that 
both PU.1 and Spi-B directly activate Nfkb1 transcription in mice, suggesting that 
reduced p50 expression in PUB B cells is the result of reduced PU.1 and Spi-B. 
Enrichment of PU.1 and Spi-B binding did not occur most highly at the promoter 
of Nkfb1. Several intronic regions of Nfkb1 contained even larger PU.1 and Spi-B 
enrichment sites, suggesting that PU.1 or Spi-B may have higher affinity at enhancer 
regulatory elements within the gene body which could act as enhancers (Fig. 2.10A). 
Using the mouse intron as a template, an alignment was performed across multiple 
species on the intron outlined in Fig. 2.10A. It was found that there was a high degree of 
sequence similarity and a conserved ETS binding site within the intronic region (Fig. 
2.10B). The conserved region containing the ETS binding site was cloned into a pGL3-
SV40 vector, which contained the SV40 promoter upstream of the luciferase gene. When 
luciferase activity was measured in the pGL3-SV40 vector with the Nfkb1 intron inserted, 
there was no increase in luciferase activity (Figure 2.10C). Therefore, the PU.1/Spi-B 
binding region in intron 6-7 of Nfkb1 did not increase activation of the SV40 promoter.  
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Figure 2.9. Nfkb1 is directly activated by PU.1 and Spi-B.  
(A) PUB B cells express decreased p50 protein levels. Immunoblotting for p50 and -
actin was performed using enriched B cell lysates from WT and PUB mice. (B) 
Chromatin immunoprecipitation-sequencing (ChIP-seq) analysis of PU.1 and Spi-B 
interaction with the Nfkb1 gene. Murine WEHI-279 B cell lymphoma cells expressing 
3XFLAG-tagged PU.1 (top) or Spi-B (bottom) were analyzed using anti-FLAG ChIP-
seq. Peaks located within and near the Nfkb1 gene are shown, and the dashed box 
represents PU.1 and Spi-B binding at the Nfkb1 promoter. (C) Schematic showing 
alignment of the annotated Nfkb1 promoter between multiple species. Grey text 
represents conserved nucleotides, and boxes indicate predicted PU.1 binding sites with 
similarity score and strand location (+/-) listed. Circled nucleotide represents known TSS 
in the human Nfkb1 promoter. Dots represent TSS upstream or downstream of the 
annotated sequence. (D) Luciferase reporter vector schematic with an arrow representing 
the murine Nfkb1 TSS. The Nfkb1 promoter sequence was cloned by PCR and ligated 
into pGL3-basic. Predicted ETS binding sites (wt) were mutated (mut) using site-directed 
mutagenesis. (E) Mutated ETS binding sites reduced promoter activity in WEHI-279 B 
cells. Cells were transfected with plasmids indicated on the x-axis. The y-axis indicates 
fold-induction of luciferase activity relative to pGL3-basic. Luciferase activity was 
normalized by transfection with Renilla luciferase expression vector. Data shows the 
mean ±SEM (n=5). (F) Interaction of PU.1 with the Nfkb1 promoter is reduced in PUB B 
cells. ChIP data shows % enrichment relative to input for PU.1 interaction with Nfkb1 
and Hprt promoters, and is representative of three independent experiments. (G) Mean 
fold enrichment of PU.1 binding in PUB B cells normalized to WT B cells for indicated 
genes. Values of 1 (dashed line) indicate no difference in PU.1 binding between PUB and 
WT B cells as compared to IgG. ChIP was performed on chromatin prepared from 
untreated or LPS stimulated (16 h) freshly isolated splenic WT and PUB B cells using 
anti-PU.1 and control IgG Abs. qPCR was used to measure the amount of 
immunoprecipitated DNA after purification. Primers were designed to recognize 
promoters of Nfkb1, Hprt, and Mef2c enhancer. Data shows the mean ±SEM of three 
independent experiments. *p<0.05. 
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Figure 2.10. Analysis of PU.1/Spi-B binding in the Nfkb1 intron. 
(A) PU.1 and Spi-B bind to the intron of Nfkb1. ChIP-seq analysis was performed in 
WEHI-279 3XFLAG-PU.1 and WEHI-279 3XFLAG-Spi-B cells, and 
immunoprecipitated with anti-FLAG antibody. The dashed box indicates the intron 
region of Nfkb1 where PU.1 and Spi-B bind. (B) Alignment of the Nfkb1 intron across 
multiple species where PU.1 and Spi-B bind. The region has a high degree of similarity 
shown by the grey highlighted nucleotides. The sequence in the box is the ETS binding 
site predicted by MatInspector. (C) The conserved intron sequence (400 bp) was cloned 
into the pGL3-SV40 vector, and luciferase activity was measured in transfected WEHI-
279 cells.  
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2.2.6 Forced expression of p50 or c-Rel in PUB B cells increases TLR-
mediated proliferation 
PU.1 and Spi-B have been previously reported to directly regulate Rel 
transcription (Hu et al, 2001). The Rel gene encodes for the NF-κB family member c-Rel, 
which is required for survival and proliferation of B cells (Hu et al, 2001; Kontgen et al, 
1995). Lower transcript levels of both Rel and Nfkb1 were detected in LPS stimulated 
PUB B cells (Fig. 2.7F). Therefore it is conceivable that forced expression of c-Rel or 
p50 could increase TLR-mediated proliferation in PUB B cells.   
To assess whether PU.1 and Spi-B could directly bind near promoters of other 
NF-κB family member, re-analysis of ChIP-seq data in WEHI-279 3XFLAG-PU.1 and 
WEHI-279 3XFLAG-Spi-B cell was performed. It was confirmed that PU.1 and Spi-B 
can bind proximal to the TSS of Nfkb2, Rela, Relb, and Rel (Figure 2.11). Therefore, 
PU.1 and Spi-B may be involved with the transcriptional regulation of genes for all NF-
κB family members in B cells.  
To determine if the PUB phenotype could be complemented by forced p50 or c-
Rel expression, a retroviral vector was constructed encoding FLAG-tagged p50 (MIG-
P50) (Fig. 2.12A). A previously described retroviral vector containing c-Rel in the 
MIGR1 vector was used to generate MIG-cRel virus (Sanjabi et al, 2005). FLAG-tagged 
p50 protein was confirmed to be expressed in retroviral packaging cells transfected with 
MIG-P50 using immunoblot (Fig. 2.12B). WT and PUB splenic B cells were enriched by 
magnetic separation and stimulated with LPS and BAFF for 24 h to improve B cell 
survival, followed by infection with MIG-P50 or MIGR1 virus as a control. Green 
fluorescence, indicating B cell infection, was determined by flow cytometry (Fig. 2.12C). 
Next, proliferation in response to LPS was assessed 24 hours post infection using MTT 
assay (Fig. 2.12D). Despite low infection frequencies, both WT and PUB splenic B cells 
infected with MIG-P50 virus had significantly increased proliferation compared to 
MIGR1 infected cells (Fig. 2.12E). These data therefore suggest that forced p50 
expression restores proliferation in PUB B cells. 
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Figure 2.11. PU.1 and Spi-B bind near TSS of all NF-κB family members in WEHI-279 
B cells. 
FLAG-tagged PU.1 and Spi-B enrichment at all NF-κB family members is demonstrated 
by enriched sequence tags. ChIP-seq was performed using anti-FLAG antibody on 
WEHI-279 3XFLAG-PU.1 and WEHI-279 3XFLAG-Spi-B cells.  
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For efficient retroviral integration, B cells needed to be in a state of division. 
Since PUB B cells proliferated poorly in response to LPS alone (Fig. 2.6A, C), WT or 
PUB B cells were stimulated with LPS, IL-2, IL-4, and IL-5 (IL-2+4+5), conditions 
previously reported to improve survival (Grumont et al, 1998). LPS+IL-2+4+5 had 
minimal effects on proliferation/survival in unstimulated or LPS stimulated WT B cells 
measured using the MTT assay (Fig. 2.13A). However, the addition of IL-2+4+5 
increased the frequency of PUB B cells that proliferated/survived compared to LPS alone 
(Fig. 2.13A). To differentiate between a proliferation or survival effect of IL-2+4+5 on 
PUB B cells, cells were stained with the proliferation dye eFluor® 450 prior to 
stimulation, and the dilution of eFluor® 450 was assessed 72 h later by flow cytometry. 
WT and PUB B cells responded minimally to IL-2+4+5 alone, based on the dilution of 
eFluor® 450 (Fig. 2.13B). In WT B cells, addition of IL-2+4+5 did not affect LPS-
stimulated dilution of eFluor® 450 dye. In contrast, the frequency of cells that diluted 
eFluor® 450 dye was dramatically increased in PUB B cells stimulated with LPS and IL-
2+4+5 compared to LPS alone (Fig. 2.13B). These results suggested that IL-2+4+5 
increased survival in LPS stimulated PUB B cells.   
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Figure 2.12. Forced expression of p50 significantly restores proliferation in PUB B cells.  
(A) Schematic of the retroviral vector encoding FLAG-tagged Nfkb1 and GFP. (B) P50 
expression in transfected Plat-E cells. Immunoblot analysis was performed using anti-
FLAG and anti--actin antibodies. Cell lysates were generated from Plat-E lysates 
transfected with MIGR1 and MIG-P50 at high (44%) and low (18%) transfection 
efficiencies. (C) Infection frequencies as determined by flow cytometry of green 
fluorescence. WT splenic B cells were infected with MIGR1 (solid line, 18%) and MIG-
P50 (dashed line, 5%) virus. PUB splenic B cells were infected with MIGR1 (solid line, 
16%) and MIG-P50 (dashed line, 4%) virus. Filled histograms indicated uninfected cells. 
(D) Proliferation of WT and PUB B cells 24 h post-infection with MIGR1 and MIG-P50 
virus. Cells were stimulated 24 h with LPS + BAFF prior to infection. Proliferation was 
assessed via a MTT proliferation assay. Data shows the mean ±SD of duplicate 
measurements, and is representative of 5 individual experiments. (E) Quantitation of five 
individual experiments as performed in D. Data shows the mean ±SEM. Proliferation 
index was calculated by normalizing OD570 of MIG-P50 infected cells to MIGR1 infected 
cells in WT and PUB. *p<0.05. 
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 Next, to determine whether increased expression of p50 or c-Rel could increase 
proliferation in infected WT or PUB cells, B cells were stimulated with LPS and IL-
2+4+5 for 24 h, then infected with MIGR1 (control), MIG-P50, or MIG-cRel retrovirus. 
GFP expression was used as a marker for p50 or c-Rel infection, and a GFP
+ 
population 
was gated for proliferation analysis (Fig. 2.13C). WT and PUB B cells were infected with 
MIGR1, MIG-P50, and MIG-cRel retroviruses with similar frequencies (Fig. 2.13D). 
Next, proliferation was assessed for gated GFP
+
 p50-infected cells using eFluor® 450 
staining and flow cytometry 48 h post infection. All cells that expressed GFP had also 
diluted eFluor® 450, compared to GFP negative cells, which was expected since 
retroviral infection requires cell division (Fig. 2.13E). For both WT and PUB GFP
+
 B 
cells infected with MIG-P50, there was an increase in the frequency of cells that had 
diluted eFluor® 450 compared to cells infected with MIGR1, suggesting one or more 
extra rounds of cell division (Fig. 2.13E). This result was statistically significant based on 
five independent experiments, and expressed either as a decrease in the eFluor® 450 
mean fluorescence intensity (MFI) gated on GFP
+
 cells (Fig. 2.13F), or as the relative 
frequency of cells diluting eFluor® 450 dye past the gate shown in Fig. 7G (Fig. 2.13G). 
Finally, proliferation was assessed on MIG-c-Rel infected B cells (gated GFP
+
 cells) by 
eFluor® 450 staining using flow cytometry 48 h post infection (Fig. 2.13H). Similar to 
MIG-P50 infection, MIG-cRel infection in WT and PUB B cells resulted in a greater 
degree of proliferation compared to MIGR1 infected cells (Fig. 2.13I). In addition, a 
greater frequency of B cells proliferated when infected with MIG-cRel, compared to 
MIGR1 infection (Fig. 2.13J). Overall, these results demonstrated that infection with 
retroviral vectors encoding p50 or c-Rel expression was capable of increasing TLR-
mediated proliferation in WT and PUB B cells.  
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Figure 2.13. Forced expression of p50 or c-Rel increases proliferation in PUB B cells. 
(A) Proliferation of WT and PUB B cells in response to LPS and IL-2+4+5. Proliferation was 
assessed 72 h post stimulation using an MTT proliferation assay. Data shows the mean ±SD 
of triplicate measurements, and was representative of 2 individual experiments. (B) PUB B 
cells have enhanced survival when stimulated with IL-2+4+5 in combination with LPS (grey 
line), compared to LPS (dashed line) or IL-2+4+5 (dotted line) alone. Shaded histogram 
represents untreated B cells. Proliferation was assessed by the dilution of the proliferation 
dye eFluor® 450 using flow cytometry 72 h post stimulation. Data shown are representative 
of three independent experiments. (C) MIGR1, MIG-P50, and MIG-cRel infected B cells 
were identified by GFP expression (dashed gate) using flow cytometry. B cells were labeled 
with proliferation dye eFluor® 450 and stimulated with LPS and IL-2+4+5 for 24 h prior to 
infection with virus. (D) Similar infection frequencies between MIGR1, MIG-P50, and MIG-
cRel infected WT and PUB B cells based on gated population in C. (E) GFP+ B cells were 
gated and assessed for dilution of eFluor® 450 to compare proliferation between MIG-P50 
(dashed line) and MIGR1 (solid line) infected B cells. Shaded histogram represents 
unstimulated control B cells. (F) WT and PUB B cells infected with MIG-P50 proliferate and 
have increased dilution of eFluor® 450 compared to MIGR1-infected cells. Results are 
expressed as the mean fluorescence intensity (MFI) of gated GFP+ cells. (G) Increased 
frequency of proliferating cells observed in MIG-P50 infected cells compared to MIGR1 
infected cells. Results are expressed as the mean frequency of cells that diluted eFluor® 450 
past the gate shown in panel E. (H) GFP+ B cells were gated and assessed for dilution of 
eFluor® 450 to compare proliferation between MIG-c-Rel (dashed line) and MIGR1 (solid 
line) infected B cells. Shaded histogram represents unstimulated control B cells. (I) WT and 
PUB B cells infected with MIG-c-Rel proliferate more than MIGR1 infected cells, based on 
dilution of eFluor® 450. (J) Increased frequency of proliferating cells observed in MIG-c-Rel 
infected cells compared to MIGR1 infected cells. Results are expressed as the mean 
frequency of cells that diluted eFluor® 450 past the gate shown in panel J. For F-G and I-J, 
data is a quantitation of five individual experiments as performed in E and J respectively. 
Data shows the mean ±SD. Normalized MFIs in F and I were calculated by dividing MFI 
values of MIG-P50/MIG-cRel infected cells to MFI values of MIGR1 infected cells. 
*p<0.05, **p<0.01, ***p<0.001. 
75 
 
 
76 
 
2.3  Discussion 
The goal of this study was to understand how TLR-initiated signaling in B cells is 
regulated. B cells from PUB mice proliferated poorly in response to TLR ligands. LPS 
stimulated PUB B cells were activated and did not have increased apoptosis relative to 
WT cells. The mechanism for the PUB phenotype revealed reduction in steady-state and 
LPS stimulated levels of Nfkb1 transcripts, and accordingly lower p50 protein levels. 
Mutation of two of the three ETS binding sites within the cloned Nfkb1 promoter reduced 
its activation, suggesting that PU.1 and Spi-B regulate its transcription. PU.1 and Spi-B 
interacted with the Nfkb1 promoter as shown by ChIP analysis, and PU.1 occupancy at 
the Nfkb1 promoter was decreased in PUB B cells. Proliferation of PUB B cells was 
increased upon retroviral complementation with p50. In summary, these results suggest 
that activation of Nfkb1 by PU.1 and/or Spi-B promotes TLR-mediated splenic B cell 
proliferation. 
PU.1 and Spi-B are thought to be able to bind identical DNA binding sites (Ray-
Gallet et al, 1995). This idea was supported by our ChIP-seq results showing that PU.1 
and Spi-B directly bind to the Nfkb1 promoter. Multiple TLR signaling genes have been 
characterized as direct PU.1 targets, including Tlr4, Tlr9, Btk, and Rel (Hu et al, 2001; 
Muller et al, 1996; Roger et al, 2005; Schroder et al, 2007). It is likely that altered protein 
levels of these genes may contribute to the PUB B cell phenotype in addition to reduced 
p50. Notably, transcript levels of Rel were reduced in PUB B cells stimulated with LPS. 
The Rel gene encodes the NF-κB family member c-Rel, which is important for survival 
and proliferation in B cells (Hu et al, 2001; Kontgen et al, 1995). Reduced c-Rel 
expression impairs B cell proliferation, as Rel
+/-
 and Rel
-/-
 B cells proliferate poorly in 
response to LPS or anti-IgM (Kontgen et al, 1995). Therefore, it is likely that impaired 
proliferation of PUB B cells in response to LPS or anti-IgM is explained by reduced p50 
and c-Rel (Hu et al, 2001). Proliferation in Rel
-/-
 B cells is reported to be more impaired 
than Nfkb1
-/-
 B cells in response to either LPS or anti-IgM (Grumont et al, 1998; Kontgen 
et al, 1995; Pohl et al, 2002). In addition, Rel
+/-
 B cells have reduced proliferation in 
response to LPS or anti-IgM compared to WT B cells, but there is no difference in levels 
of proliferation between Nfkb1
+/-
 and WT B cells for those same mitogens (Sha et al, 
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1995; Snapper et al, 1996b). LPS stimulated Nfkb1
-/-
 B cells fail to proliferate, anti-IgM 
stimulation results in only a small reduction in proliferation, and anti-CD40/CD40L 
stimulation results in normal proliferation (Garrett-Sinha et al, 1999; Sha et al, 1995; 
Snapper et al, 1993). Deletion of both NF-κB1 and c-Rel (Nfkb1-/-Rel-/-) in B cells results 
in a further impaired response to LPS or anti-IgM compared to Nfkb1
-/-
 or Rel
-/-
 B cells. 
Future studies will need to be done to determine whether restoration of both p50 and c-
Rel together can further improve proliferation responses in PUB B cells.  
PUB B cells were unable to increase MHCII or CD40 expression upon LPS or 
anti-IgM stimulation. The impairment of MHCII and CD40 upregulation upon anti-IgM 
expression could be explained by increased apoptosis in PUB B cells. CD40 was 
functional in PUB B cells since anti-CD40 stimulation appeared normal despite 
decreased levels of CD40 on PUB B cells, furthermore, LPS+anti-CD40 stimulation was 
able to rescue defective LPS-mediated proliferation. Failure to upregulate MHCII and 
CD40 upon stimulation could result in decreased protein interaction necessary for TLR 
activation, which could be a consequence of reduced p50 signaling. PUB B cells were 
activated by LPS as measured by CD25 and CD69, but CD69 was not upregulated as 
high as WT B cells. The Cd69 gene promoter has multiple PU.1 binding sites, and is 
transcriptionally regulated by NF-κB complexes (Castellanos et al, 1997; Lopez-Cabrera 
et al, 1995). Therefore, reduced MHCII, CD40, and CD69 upregulation upon LPS 
stimulation may be a consequence of reduced p50 expression.   
Although proliferation in PUB B cells was impaired upon TLR or IgM 
stimulation alone, the combination of LPS+anti-IgM synergistically restored proliferation 
and activation to WT levels in PUB B cells. The molecular basis of this observation is 
unclear, but a comparable finding was made using Nfkb1
-/-
, Rel
-/-
, or Nfkb1
-/-
Rel
-/-
 B cells, 
where LPS synergized with anti-IgM when inducing proliferation (Pohl et al, 2002). 
Furthermore, LPS and IL-2+4+5 were used to maximize cell survival to allow B cells 
into early-log phase growth for viral infection. The combination of IL-2+4+5 was 
previously reported to not induce proliferation on its own, but synergized with 
proliferative responses to mitogens in WT, Rel
-/-
, and Nfkb1
-/-
 B cells (Grumont et al, 
1998). Similarly, PUB B cells did not proliferate highly in response to IL-2+4+5 alone, 
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but the proliferation response was increased in response to LPS and IL-2+4+5. This 
synergistic proliferation observed in PUB B cells is likely due to multiple or alternate 
signaling pathways becoming activated, that are not regulated by PU.1 and Spi-B. For 
example, LPS can also activate PI3K (Bone & Williams, 2001) or mitogen-activated 
protein kinase (MAPK) pathways (Gerondakis et al, 2007). Therefore, there are likely 
alternative pathways that can compensate in the event of having loss of PU.1 and Spi-B 
function. Further analysis of PU.1 and Spi-B involvement on the activation of these 
pathways through TLR ligands is required.  
PUB mice have reduced frequencies of B cells with an increased ratio of MZ to 
FO B cells, indicating  PU.1 and Spi-B may regulate peripheral B cell differentiation 
(DeKoter et al, 2010). FO and MZ B cell differentiation both require canonical NF-κB 
signaling. Weak BCR signaling promotes MZ B cell development, whereas strong BCR 
signaling drives FO B cell development (Pillai & Cariappa, 2009). Nfkb1
-/-
 mice have MZ 
B cells, although in decreased numbers (Cariappa et al, 2000), and MZ B cells 
accumulate over time in spleens of these mice (Ferguson & Corley, 2005). Therefore, 
increased MZ B cell and decreased FO B cell frequencies in PUB spleens might be 
caused by a combination of altered NF-κB signaling, weakened BCR signaling, and 
increased apoptosis upon BCR stimulation. 
In summary, our experiments establish the importance of PU.1 and Spi-B for 
innate immune responses in B cells. Decreased p50 and reduced Nfkb1 gene activation in 
PUB mice is associated with poor TLR-mediated B cell proliferation. Understanding 
TLR regulation in B cells has implications for generation of antibody responses, since 
effective thymus-independent responses and production of antibodies in vaccinations are 
dependent on direct TLR triggering on B cells (Kasturi et al, 2011). Further analysis of 
mice lacking Spi-B and reduced PU.1 is expected to provide additional insight into other 
genes involved in TLR signaling and antibody forming responses. 
 
79 
 
2.4 Materials and Methods 
2.4.1 Generation and breeding of mice 
Mice were housed at Western University’s Health Sciences animal facility (London, 
Ontario, Canada) and monitored under an approved animal use subcommittee protocol in 
accord with Western University Council on Animal Care. C57BL/6 (WT) mice were 
purchased from Charles River Laboratories (Pointe-Claire, Quebec, Canada). PUB mice 
were generated by mating male and female PUB mice, and genotyping was performed by 
PCR as previously described (Garrett-Sinha et al, 1999; Su et al, 1997). Experiments 
were performed on mice aged 6-16 wks.  
2.4.2 B cell enrichment and proliferation analysis 
RBCs were removed from spleen cell suspensions by hypotonic lysis with ammonium 
chloride solution. B cells were enriched by negative selection using biotin-conjugated 
anti-CD43 (S7) Ab, streptavidin (SA) microbeads, LD depletion columns, and a 
VarioMACS™ separation unit (Miltenyi Biotec, Germany). Enrichment of B cells 
provided a >95% pure B cell population as determined by flow cytometry. B cells 
(2x10
5
/well) were plated in 96-well flat bottom plates and stimulated with LPS (10 
μg/mL, List Biological Laboratories), anti-IgM Ab (50 μg/mL, affinity pure F(ab’)2 
fragment, goat anti-mouse IgM, μ chain specific; Jackson ImmunoResearch 
Laboratories), Pam3CSK4 (1 μg/mL), HKLM (108 cells/mL), Poly(I:C) LMW or HMW 
(10 μg/mL), ST-FLA (10 μg/mL). FSL1 (1 μg/mL), ODN1826 (5 uM, InvivoGen), BAFF 
(100 ng/mL, Peprotech, New Jersey, USA), or LEAF
TM
 purified anti-mouse CD40 (10 
μg/mL; IC10, BioLegend) in complete DMEM. Proliferation was assessed after 72 h 
incubation at 37°C with a TACS
®
 MTT Cell Proliferation assay (Trevigen) used 
according to the manufacturer’s instructions. For [3H]-thymidine incorporation assays, 
[
3
H]-thymidine (1 mCi/mL/well) was added after 72 h stimulation, followed by 
scintillation counting 18 h later.    
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2.4.3 Flow cytometry  
Antibodies purchased from eBioscience (San Diego, CA) or BioLegend (San Diego, CA) 
included allophycocyanin (APC)-conjugated anti-B220 (RA3-6B2), anti-MHCII [I-A/I-E 
(M5.144.15.2)], anti-CD40 (3/23), BAFF-R (eBio7H22-E16), phycoerythrin (PE)-
conjugated anti-CD19 (1D3), IgG Isotype Control (eBio299Arm), anti-CD69 (H1.2F3), 
anti-CD281/TLR1 (eBioTR23), anti-CD282/TLR2 (T2.5), IgG2a κ Isotype Control 
(eBM2a), anti-CD14 (Sa14-2), anti-CD180/RP105 (RP/14), fluorescein isothiocyanate 
(FITC)-conjugated anti-CD21/CD35 (eBio8D9), Alexa Fluor®488-conjugated anti-CD1d 
(1B1), Biotin-conjugated anti-CD25 (7D4), anti-CD5 (53-7.3), or SA conjugated-PE. For 
proliferation analyses, cells were stained with the proliferation dye eFluor® 450 
(eBioscience). Antibody-stained cell analysis and sorting was performed using a 
FACSCalibur and FACSAriaIII system respectively (BD Biosciences, San Jose, CA). 
Sorted cells were determined to be >98% purity. Data analysis was performed using 
FlowJo software (FlowJo LLC, Ashland, OR).  
2.4.4 Reverse transcription-quantitative PCR 
RNA was isolated using Trizol® reagent (Life Technologies Inc. Burlington ON). cDNA 
was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Mississauga, Ontario, 
Canada), and qPCR was performed with a Rotor-Gene 6000 instrument (Corbett Life 
Sciences, Valencia, CA). Relative mRNA transcript levels were normalized to GAPDH 
or β2m and compared between samples using the comparative threshold cycle method. 
Calculations were performed using REST© 2009 software (Pfaffl et al, 2002). Primer 
sequences are listed in Table 2.1.  
2.4.5 Immunoblot analysis 
Lysates were prepared using the Laemelli method and applied to 8%-10% SDS 
polyacrylamide gels for electrophoresis. Proteins were transferred to nitrocellulose 
membranes using a Trans-Blot Semi-Dry system (Bio-Rad), and membranes were 
blocked for 1 h in 5% milk in TBST. Membranes were probed with polyclonal anti-
MyD88 (eBioscience), anti-Btk (B3H5, Cell Signaling Technology, Whitby ON), anti-
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Nfkb1 (Poly6197, BioLegend), or anti-β-Actin (I-19, Santa Cruz Biotechnology) Ab, and 
diluted to concentrations recommended by their manufacturers in 1% milk/TBST 
overnight at 4°C. A secondary horseradish peroxidase-conjugated anti-goat or anti-mouse 
Ab was incubated in 1% milk/TBST. Membranes were washed and visualized with 
SuperSignal West Pico reagent (Thermo-Fisher Scientific, Waltham MA). 
2.4.6 Bioinformatic analysis 
A TSS was previously described for the human NFKB1 promoter (Cogswell et al, 1993). 
DNA sequences from human, mouse, rat, macaque, dog, cow, and Tasmanian devil were 
obtained from the Ensembl database and aligned using MacVector (Accelrys, San Diego, 
CA). Predicted transcription factor binding sites were analyzed using MatInspector 
(Genomatix, Ann Arbor, MI), with scores >0.9 selected for further analysis.   
2.4.7 Plasmids and cloning 
The Nfkb1 promoter was amplified from C57BL/6 genomic DNA by PCR using LA-
TAQ (TaKaRa Clontech Laboratories Inc, Mountain View, CA), purified, and cloned 
into pSC-A vector using a PCR cloning kit (Agilent Technologies, La Jolla, CA). A 
468bp Nfkb1 promoter fragment was PCR amplified using a forward primer containing a 
HindIII site and subcloned. The promoter was HindIII digested from pSC-A and ligated 
into the HindIII site of the pGL3-basic (Promega) luciferase reporter vector. Predicted 
ETS binding sites were mutated using the QuickChange lightning site-directed 
mutagenesis kit according to the manufacturer’s instructions (Agilent Technologies). The 
murine stem cell virus-internal ribosomal entry site-green fluorescent protein (MSCV-
IRES-EGFP; MIGR1) retroviral vector has been described (Pear et al, 1998). MSCV-
P50-IRES-EGFP (MIG-P50) was generated by cloning p50-FLAG from the p50 cFlag 
pcDNA3 vector purchased from Addgene (Plasmid 20018; Cambridge, MA) by XhoI and 
EcoRI digestion. P50-FLAG was cloned into the psC-A vector, excised with EcoRI, and 
ligated into the MIGR1 vector. MIG-cRel (Plasmid 26984) was obtained from Addgene 
(Cambridge, MA) (Sanjabi et al, 2005). All constructs were verified by DNA sequencing. 
Transfection-quality plasmid DNA was prepared by growth in DH5α bacteria and 
purified with plasmid maxi prep kit (Qiagen). All restriction enzymes were purchased 
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from New England Biolabs (Ipswich, MA). Primer sequences used for cloning are listed 
in Table 2.1.  
2.4.8 Generation of retrovirus 
MIG-P50, MIG-cRel, and MIGR1 retroviral vectors were generated by transient 
transfection using PEIpro
TM
 (Polyplus-transfection, Illkirch, France) into Platinum-E 
(Plat-E) packaging cells (Morita et al, 2000). Plat-E cells were maintained in complete 
DMEM (1.5 g/mL glucose) with blasticidin (10 μg/mL) and puromycin (1 μg/mL). Cells 
were passaged in antibiotic free media 72 h prior to transfection, then plated at 3x10
6
 
cells per 100mm culture dish. A 2:1 PEI/DNA (20 µL PEIpro
TM
 and 10 µg plasmid 
DNA) ratio was used for transfections, with a final working concentration for PEI at 0.5 
µg/mL. Transfections were performed using DMEM without FBS or antibiotics for 4 h at 
37°C. Cells were washed with fresh complete DMEM following transfection and 
incubated for 48h at 37°C. Virus-containing supernatants were collected following 48 h, 
and virus production was confirmed by green fluorescence and FLAG-tagged protein 
using flow cytometry and immunoblot respectively. 
2.4.9 Retroviral infection of primary B cells and proliferation analysis 
To assess proliferation in total B cells, B cells were isolated from spleens by 
magnetic enrichment as mentioned in 2.4.2 and stimulated for 24 h with BAFF (100 
ng/mL) and LPS (10 μg/mL). Next, cells were infected by spinoculation with virus by 
centrifugation at 800 x g for 2 h at 30°C in the presence of polybrene at a final 
concentration of 4 μg/mL. After centrifugation, cells were cultured for another 24 h. 
Infection frequencies were detected by flow cytometric analysis for green fluorescence 
expression. Proliferation of total cells was assessed by MTT proliferation assay. 
To assess proliferation specifically in infected B cells, B cells were isolated from 
spleens by magnetic enrichment as mentioned in 2.4.2 and stained with the cell 
proliferation dye eFluor® 450 (10 µM; eBioscience). B cells were stimulated for 24 h 
with LPS, IL-2 (10 ng/mL), IL-4 (10 ng/mL), and IL-5 (10 ng/mL). Next, cells were 
infected by spinoculation with virus by centrifugation at 800 x g for 2 h at 30°C in 
  
83 
 
Table 2.1. Forward and reverse primers used for RT-qPCR analysis, cloning, and site 
directed mutagenesis.  
Primer Name DNA Sequence (5’ -> 3’) Product size 
B2m fwd 5’-TGG CTC ACA CTG AAT TCA CCC CCA-3’ 100 bp 
rev 5’-TCT CGA TCC CAG TAG ACG GTC TTG-3’ 
Cd14 fwd 5’-CCC AAG CAC ACT CGC TCA ACT TT-3’ 106 bp 
rev 5’-ATC AGT CCT CTC TCG CCC AAT-3’ 
Rel fwd 5’-ACC CAA TTT ATG ACA ACC GTG CCC-3’ 170 bp 
rev 5’-ACC TCT GGC TTC CCA GTC ATT CAA-3’ 
Gapdh fwd 5’-GAA CAT CAT CCC TGC ATC CA-3’ 78 bp 
rev 5’-CCA GTG AGC TTC CCG TTC A-3’ 
Hprt ChIP fwd  5’-GGC CCA CCT AGT CAG ATA AGA GT-3’ 193 bp 
rev 5’-GAA AGC AGT GAG GTA AGC CCA AC-3’ 
Myd88 fwd 5’-TAA GTT GTG TGT GTC CGA CCG TGA-3’ 192 bp 
rev 5’-ATC AGT CGC TTC TGT TGG ACA CCT-3’ 
Traf6 fwd 5’-TTT ACG GGA AGC AGT GCA AAC ACC-3’ 181 bp 
rev 5’-ATT TGG GCA CTT TAC CGT CAG GGA-3’  
Irak3 fwd 5’-AGA GCT GGC TGC ATA TTT CAC GGA-3’ 107 bp 
rev 5’-GGG TTG TGC CAT TTG TGC ACT GTA-3’ 
Irak4 fwd 5’-ACG GGC TTC GGC AAG GCT A-3’ 192 bp 
rev 5’-ATC CAG CAG TAG TTG AGG TTC ACG-3’ 
Mef2c ChIP fwd 5’-GAA GGA AGC ACC TTT ACA CC-3’ 125 bp 
rev 5’-TTC AGC AAA TCC CTC CTA GT-3’ 
Md2 fwd 5’-TAG AGT TGC CGA AGC GTA AGG AAG-3’ 116 bp 
rev 5’-TCC CTC GAA AGA GAA TGG TAT TGA-3’ 
Nfkb1 fwd 5’-GCT GAG TCC TGC TCC TTC TAA A-3’ 104 bp 
rev 5’-CCT CTG TGT AGC CCA TCT GTT GC-3’ 
Nfkb1 ChIP fwd 5’-TCC GTC TGT CTG CTC TCT-3’ 123 bp 
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Rev 5’-GGT GGC GAA ACC TCC TC-3’ 
Nfkb2 fwd 5’-CGG TGG AGA CGA AGT TTA TTT GCT C-3’ 169 bp 
rev 5’-ATC TTG TGA TAG GGC GGT GT-3’ 
Rela fwd 5’-CGG GAT GGC TAC TAT GAG GCT GAC-3’ 134 bp 
rev 5’-GGG TTA TTG TTG GTC TGG ATT CGC-3’ 
Relb fwd 5’-ACA CCC ACA TAG CCT CGT-3’ 126 bp 
rev 5’-ATT TCC TTC TTC CTA ACA CAC TGGA-3’ 
Tlr1 fwd 5’-ACA GTC AGC CTC AAG CAT TTG GAC-3’ 117 bp 
rev 5’-TAC CCG AGA ACC GCT CAA CC-3’ 
Tlr2 fwd 5’-ATG CTT CGT TGT TCC CTG TGT TGC-3’ 125 bp 
rev 5’-AAA GTG GTT GTC GCC TGC TTC CA-3’ 
Tlr4 fwd 5’-ACT GTT CTT CTC CTG CCT GA-3’ 102 bp 
rev 5’-GGG ACT TTG CTG AGT TTC TGA TCC-3’ 
Tlr7 fwd 5’-GTG ATG CTG TGT GGT TTG TCT GGT-3’ 108 bp 
rev 5’-CAC TTT GAC CTT TGT GTG CTC CTG-3’ 
Tlr8 fwd 5’-TGG TTA TGT TGG CTG CTC TGG TTC-3’ 110 bp 
rev 5’-TTG GGA TGT GGA TGA AGT CCT GTA GC-3’ 
Tlr9 fwd 5’-TGG ACG GGA ACT GCT ACT ACA AGA AC-3’ 101 bp 
rev 5’-CTT CAG AGA CAG ATG GGT GAG ATT GC-3’ 
Tollip fwd 5’-GGT CGC CTC AGC ATC ACT-3’ 104 bp 
rev 5’-TCA TAA ACA GCA TAG CCC AGA CGCA-3’ 
Nfkb1 Promoter fwd 5’-CCC AAA GAA TAA AGA CGC TCA AAT GC-3’ 1745 bp 
rev 5’-TCA GAA GAC CGA AGG AAG CCT ACA-3’  
Nfkb1 Sublone w/ HindIII 
fwd 
5’-CAA GCT TAC CTC CCG CCC CC-3’ 468 bp 
Rev 5’-CCT GGA GAT GCG GCG CGG-3’  
pGL3-Nfkb1 Mutation 5’-TCT CGA CGT CAG TGG GAA TGT CCA GC-3’ N/A 
pGL3-Nfkb1 Mutation anti 5’-TCG CTC ACT CTC TCA CGT CCT GGC TGG-3’  
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the presence of polybrene at a final concentration of 4 μg/mL. Infection frequencies were 
detected by flow cytometric analysis for green fluorescence expression. Proliferation of 
infected cells was assessed by the dilution of eFluor® 450 using flow cytometry 48h post 
infection.  
2.4.10  Transient transfection by electroporation 
WEHI-279 cells in mid to early log phase growth were washed three times with serum-
free DMEM (4.5g/L, Lonza). Cells were incubated for 10 min at room temperature with 
10 μg of each luciferase reporter plasmid and 1 μg of pRL-TK (Promega). Cell-DNA 
mixtures were electroporated at 220 V and 950 mF using 4-mm gap cuvettes and a 
GenePulser II with Capacitance Extender (Bio-Rad), incubated at room temperature for 
10 min, then transferred to 6-well culture plates in complete DMEM and incubated at 
37°C for 24 h. A Dual-Luciferase Reporter Assay System (Promega) was performed on 
cell lysates. Light production was measured using a Lumat LB 9507 tube luminometer 
(Berthold Technologies, Oak Ridge, TN). 
2.4.11 ChIP-Seq Analysis 
ChIP-seq experiments were performed using mouse WEHI-279 cells. Cells were spin-
infected with a MIGR1 vector for expression of 3XFLAG-PU.1 or 3XFLAG-Spi-B. 
Immunoprecipitation was performed using anti-FLAG microbeads (M2, Sigma-Aldrich, 
St. Louis, MO).  Purified chromatin was sequenced using an Illumina HiSeq instrument. 
Peak finding and data analysis was performed using Galaxy Suite (Blankenberg et al, 
2010; Giardine et al, 2005; Goecks et al, 2010). Reads were aligned to the reference 
genome (NCBI37/mm9), using BOWTIE (Langmead et al, 2009). Peaks were called 
using MACS version 1.0.1 (Zhang et al, 2008) with default parameters, a P-value cutoff 
for peak detection of 1e-05 and an effective genome size of 2.7e+9 bp. Functional 
analysis of cis-regulatory regions bound by PU.1 and Spi-B were identified using 
GREAT V.2.0.2 (McLean et al, 2010). Data are available from the Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo) under accession number GSE58128. 
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2.4.12 ChIP experiments  
Chromatin was prepared from enriched B cells as previously described (DeKoter et al, 
2010). In brief, cells were cross-linked and lysed followed by sonication. Sonicated 
chromatin was incubated overnight at 4°C with anti-PU.1 or control mouse anti-IgG Ab 
(Santa Cruz Biotechnology) conjugated to protein G DynaBeads (Invitrogen, Burlington, 
Ontario, Canada). Magnetic bead complexes were enriched using a MagneSphere® 
Technology Magnetic Separation Stand (Promega) and washed. Immunocomplexes were 
eluted and cross-linked chromatin was reversed overnight at 65°C. DNA was purified 
using a QIAquick PCR purification kit (Qiagen). Enrichment was measured using qPCR 
of immunoprecipitated DNA using primers indicated in supplemental Table 2.1.  
2.4.13 ELISA analysis 
Serum was collected and quantified using a Quantikine ELISA Mouse 
BAFF/BLyS/TNFSF13B Immunoassay kit (R&D Systems, Minneapolis, MN) according 
to the manufacturer’s instructions. Plates were analyzed using an EON Microplate 
Spectrophotometer with Gen5 software (BioTek, Winooski, VT). 
2.4.14 Statistical analysis 
Statistical significance was determined using Student’s t test unless otherwise indicated. 
P values ≤0.05 were considered significant. For all figures, *P ≤0.05, **P ≤0.01, and 
***≤P 0.001. Statistical analysis was performed using Prism 5.0 (Graph-Pad Software). 
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Chapter 3  
3 Identification of a negative regulatory role for Spi-C in the 
murine B cell lineage 
Spi-C is an E26 transformation-specific family (ETS) transcription factor that is 
most highly related to PU.1 and Spi-B. Spi-C (encoded by Spic) is expressed in 
developing B cells, but its function in B cell development and function is not well 
characterized. To determine if Spi-C functions as a negative regulator of Spi-B (encoded 
by Spib), mice were generated that were germline knockout for Spib and heterozygous for 
Spic (Spib
-/-
Spic
+/-
). Interestingly, loss of one allele of Spic substantially rescued B cell 
frequencies and absolute numbers in the spleens of Spib
-/-
 mice. Spib
-/-
Spic
+/-
 mice had 
restored proliferation compared to Spib
-/-
 mice in response to anti-IgM or LPS 
stimulation. Spib
-/-
 B cells had reduced expression of genes required for B cell receptor 
signalling including Nfkb1 encoding P50, and Nfkb1 transcript levels were restored by 
loss of one allele of Spic. Finally, Spi-B was shown to directly activate the Nfkb1 gene 
while Spi-C was shown to repress this gene. These results indicate a novel role for Spi-C 
as a negative regulator of B cell development and function. 
 
3.1 Introduction 
B cell development occurs in the bone marrow of mammals, where committed 
progenitor B (pro-B) cells are generated from lymphoid progenitor cells. Pro-B cells 
develop into mature B cells through a series of defined stages marked by rearrangement 
of immunoglobulin heavy chain (IgH) and immunoglobulin light chain genes. Immature 
B cells leaving the bone marrow are termed transitional-1 (T1) B cells, which migrate to 
the spleen and differentiate into T2 B cells (Pillai & Cariappa, 2009). T2 B cells can 
mature into either follicular (FO) or marginal zone (MZ) B cells that go on to participate 
in antibody formation and immune regulation (Pillai & Cariappa, 2009).  
Transcription factors function as either activators or repressors of gene expression 
to govern B cell development. E26-transformation-specific (ETS) transcription factors 
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PU.1 (encoded by Spi1) and Spi-B (encoded by Spib) function as transcriptional 
activators during B cell development. PU.1 is required to generate B cell progenitors, as 
Spi1
-/-
 mice have a profound block in B cell development (Houston et al, 2007; Scott et 
al, 1994). Spib
-/-
 mice have reduced numbers of B cells that are defective in BCR 
signalling and are unable to sustain antibody responses to T-dependent antigens (Garrett-
Sinha et al, 1999; Su et al, 1997). PU.1 and Spi-B activate transcription by interacting 
with the consensus core motif 5’-GGAA-3’ at specific sites within the genome (Ray-
Gallet et al, 1995). Due to the similarities in DNA binding specificities and overlapping 
expression patterns, many gene targets are functionally redundant between PU.1 and Spi-
B, although there are also exclusive roles for each (DeKoter et al, 2010; Sokalski et al, 
2011; Su et al, 1997).  
Transcriptional networks that control B cell differentiation include both 
transcriptional activators and repressors (Rothenberg, 2014). Interestingly, few published 
examples of negative regulators of ETS transcription factor function exist. Spi-C is an 
ETS transcription factor that is a potential negative regulator. Spi-C was originally 
described as a PU.1-related protein containing an N-terminal acid activation domain 
(Bemark et al, 1999; Carlsson et al, 2003; Carlsson et al, 2006). Ectopic overexpression 
of Spi-C in either cultured pro-B cells using a retroviral vector (Schweitzer et al, 2006) or 
in mice using a B cell specific transgene (Eμ-Spi-C) (Zhu et al, 2008) has suggested that 
Spi-C functions as a negative regulator by opposing PU.1 activity. Transgenic Spi-C 
expression under the control of the B cell-specific IgH intronic enhancer resulted in 
reduced absolute numbers of T1, T2, MZ, and FO B cells in Eμ-Spi-C mice compared to 
WT mice (Zhu et al, 2008). Recently a Spic knockout mouse was generated, allowing for 
Spi-C loss-of-function analysis (Kohyama et al, 2009). Spi-C was revealed to be essential 
for generating red pulp macrophages in the spleen and is inducible by Heme (Haldar et al, 
2014). Spi-C is upregulated in B cells lacking the transcriptional repressors Bach1/Bach2, 
and results in altered gene expression patterns in B cells (Itoh-Nakadai et al, 2014). 
Therefore, Spi-C may have a regulatory role in B cells for development and function.  
The goal of this study was to determine if Spi-C plays a negative regulatory role 
in B cell development and function. A loss-of-function approach was used by crossing a 
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Spic null allele onto a Spib knockout background (Spib
-/-
Spic
+/- 
mice). The effect of Spic 
heterozygosity in Spib
-/-
 mice might 1) have no effect on the phenotype, 2) further impair 
B cell development, or 3) rescue the Spib
-/-
 phenotype. It was observed that Spic 
heterozygosity substantially rescued both development and function of B cells in Spib
-/-
 
mice. Taken together, our results identify a negative regulatory role for Spi-C in B cells.  
 
3.2 Results 
3.2.1 Restored splenic B cells numbers in Spib-/-Spic+/- mice compared to 
Spib
-/-
 Spic
+/+
 mice 
To determine roles of Spi-C in B cell development, mice homozygous for 
germline null alleles of Spib (Su et al, 1997) and heterozygous Spic (Kohyama et al, 
2009) were mated. Spib
-/-
Spic
+/-
 mice were generated near Mendelian ratios (Table 3.1) 
and were healthy and fertile. However, few Spib
-/-
Spic
-/- 
mice were generated (Table 3.1). 
Therefore, these studies focussed on analysis of Spib
-/-
Spic
+/+
 and Spib
-/-
Spic
+/-
 mice.  
To determine that the haploid state of Spi-C is insufficient in Spib
-/-
Spic
+/-
 mice, 
immunoblot analysis was performed on WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 spleen lysates to 
detect protein levels of Spi-C. A reduction in Spi-C was measured in Spib
-/-
Spic
+/-
 spleen 
lysates compared to WT or Spib
-/- 
(Fig. 3.1A). As previously noted, Spib
-/- 
mice had 
reduced total numbers of splenocytes compared to WT (Fig. 3.1B). However, total 
numbers of splenocytes were substantially rescued in Spib
-/-
Spic
+/-
 mice compared to 
Spib
-/- 
mice (Fig. 1B). In order to assess the population of mature B cells, frequencies of 
B220
+
CD93
-
 cells were determined using flow cytometry (Fig. 3.1C). Spib
-/-
 spleens 
contained decreased frequencies of mature B cells and decreased absolute numbers of 
mature B cells. In contrast, Spib
-/-
Spic
+/- 
spleens had substantially rescued frequencies and 
absolute numbers of mature B cells compared to Spib
-/-
 spleens (Fig. 3.1D). Overall, these 
results showed that knocking out one allele of Spic on a Spib
-/-
 background rescued 
absolute number of mature B cells in Spib
-/-
 spleens. These results suggest that Spi-C 
levels are involved in regulating B cell differentiation. 
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Table 3.1. Expected and actual frequencies of mouse genotypes from offspring generated 
by mating male and female Spib
-/-
Spic
+/-
. 
Genotype Number of mice 
produced 
Expected 
Frequencya (%) 
Actual Frequencyb 
(%) 
Spib
-/-
Spic
+/+
 101 25 36.5 
Spib
-/-
Spic
+/-
 174 50 62.8 
Spib
-/-
Spic
-/-
 2 25 0.7 
aExpected frequencies are based on Mendelian ratios. 
bActual frequencies are based on the genotyping of 277 pups. 
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3.2.2 Rescued absolute number of FO B cells in Spib-/-Spic+/- spleens 
compared to Spib
-/-
 spleens 
 Spib
-/- 
mice were reported to have reduced frequencies of FO B cells (DeKoter et 
al, 2010). To determine whether mature MZ and FO B cell populations were restored in 
Spib
-/-
Spic
+/-
 spleens, flow cytometry was performed on splenocytes from WT, Spib
-/-
 and 
Spib
-/-
Spic
+/-
 mice. Mature B cells were gated on B220
+
CD93
-
, followed by analysis of 
CD21 and IgM surface expression to identify FO (CD21
low
IgM
int
) and MZ (CD21
hi
IgM
hi
) 
B cells (Fig. 3.1E). Absolute numbers of MZ B cells were unaffected by either reduced 
Spi-B or Spi-C expression. However, FO B cells were decreased in both frequency and 
absolute number in Spib
-/- 
spleens compared to WT (Fig. 3.1F). Spib
-/- 
Spic
+/-
 spleens 
contained restored absolute numbers of FO B cells compared to Spib
-/-
 spleens (Fig. 
3.1F). Next, MZ and FO B cell populations were quantified by CD23 and IgM surface 
expression (Fig. 3.1G). Absolute numbers of MZ B cells (IgM
hi
CD23
-/low
) were 
unchanged between WT, Spib
-/-
 and Spib
-/-
Spic
+/-
 spleens. However, frequencies of FO B 
cells (IgM
int
CD23
+
) were reduced in Spib
-/-
 spleens, and this reduction was rescued in 
Spib
-/-
Spic
+/-
 spleens (Fig. 3.1H). Taken together, these results suggest that the rescue in 
absolute numbers of mature B cells in Spib
-/- 
Spic
+/-
 spleens was primarily a result of 
increased FO B cells.  
 It has been previously reported that there is differential Spi-C transcript 
expression between B-1a, B-1b, and splenic B2 cells (Kretschmer et al, 2003). To assess 
if there were any differences in B-1 cell populations in the peritoneal cavity of Spib
-/-
Spic
+/-
, peritoneal fluid isolated from WT, Spib
-/-
 and Spib
-/-
Spic
+/-
 mice were analyzed by 
flow cytometry (Figure 3.2A). No differences in CD19
+
CD5
+
 (B-1a) cell frequency were 
detected between WT, Spib
-/-
 and Spib
-/-
Spic
+/-
 mice (Figure 3.2B). Spib
-/-
Spic
+/-
 B-1a 
cells from the peritoneal cavity expressed elevated CD19 levels compared to WT mice 
(Figure 3.2C). Therefore, loss of Spi-C expression in Spib
-/-
Spic
+/-
 mice altered CD19 
expression in B-1a cells.  
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Figure 3.1. Spi-C heterozygosity rescues absolute numbers of B cells in the spleens of 
Spib
-/-
 mice. 
(A) Spi-C protein expression measured in WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 spleen lysates. 
Immunoblot was performed using anti-Spi-C antibody and anti-β-Actin as a loading 
control. Data shown is a representative of 3 individual experiments. (B) Cell counts based 
on total cells isolated from the spleens of WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. (C) Mature 
B cells were quantified by flow cytometry based on B220 and CD93. The dashed box 
represents the mature B cell population. (D) Quantitation of the frequency and absolute 
number of B220
+
CD93
-
 splenocytes identified in WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. (E) 
Mature FO and MZ B cell populations were quantified based on CD21 and IgM surface 
expression. (F) Quantitation of the frequency and absolute number of MZ (CD21
hi
IgM
hi
) 
and FO (CD21
low
IgM
int
) mature B cells (B220
+
CD93
-
) in the spleen. (G) Mature FO and 
MZ B cell populations were quantified based on CD23 and IgM surface expression. Cells 
were isolated from WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 spleens and analyzed by flow cytometry. 
(H) Quantitation of the frequency and absolute number of MZ (CD23
low
IgM
hi
) and FO 
(CD23
hi
IgM
int
) mature B cells (B220
+
CD93
-
) in the spleen. For B, and D, data is shown 
as mean and SD of 14 individual mice. For F and H, data is shown as mean and SD of 9 
individual mice. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 3.2. B-1a cells from the peritoneal cavity of Spib
-/-
Spic
+/- 
mice express elevated 
CD19 levels.  
(A) Comparison of the frequency of CD19
+
CD5
+
 cells in the peritoneal cavity of WT, 
Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. Dashed box represents the B-1a population. Data is a 
representative of three independent experiments. (B) Quantitation of A showing the mean 
frequency of B-1a cells as a percentage of total CD19
+
 cells. (C) Levels of CD19 
determined by the mean fluorescence intensity (MFI). For B and C, data shows mean and 
SD of three individual mice.  
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3.2.3 Increased transitional B cells in Spib-/-Spic+/- spleens compared to 
Spib
-/- 
spleens 
Since Spib
-/- 
Spic
+/- 
spleens had increased numbers of FO B cells compared to 
Spib
-/-
, it was hypothesized that there were increased immature B cells developing in the 
bone marrow of these mice. To test this, flow cytometry analysis was performed using 
the “Hardy” staining scheme for bone marrow cells (Hardy et al, 1991) (Fig. 3.3A). 
Although Spib
-/-
 mice had increased fraction D and reduced fraction F populations 
compared to WT B cells, no significant differences in frequencies of fractions A through 
F were observed between Spib
-/-
 and Spib
-/- 
Spic
+/-
 mice (Fig. 3.3B-C). These results 
suggested that restored FO B cell numbers were not due to an increase in frequency of B 
cell progenitors derived from the bone marrow. 
To assess whether rates of apoptosis were altered in Spib
-/- 
Spic
+/-
 B cells, flow 
cytometry was performed on WT, Spib
-/-
 and Spib
-/- 
Spic
+/-
 splenocytes. Cells were gated 
into T1, T2, MZ, and FO B cell populations based on B220, CD93, IgM, and CD23 
staining, and apoptotic cells were gated for Annexin V
+
7-AAD
- 
(Fig. 3.4A). No 
differences were detected in apoptotic frequency in either total B cells (Fig. 3.4B) or 
gated T1, T2, MZ, or FO B cells (Fig. 3.3C) between WT, Spib
-/-
 and Spib
-/- 
Spic
+/-
 mice. 
These results suggest that reduced Spi-C expression does not significantly alter steady-
state levels of apoptosis in Spib
-/- 
mice. 
 To determine the source of rescued numbers of FO B cells in Spib
-/-
Spic
+/-
 spleens 
compared to Spib
-/-
, immature transitional B cell populations were examined. Immature B 
cells were gated on expression of both B220 and CD93 (Fig. 3.5A). There were increased 
frequencies of B220
+
CD93
+
 immature B cells in both Spib
-/-
 and Spib
-/-
Spic
+/- 
spleens 
compared to WT, but no significant difference in frequency of these cells between Spib
-/-
 
and Spib
-/-
Spic
+/-
 spleens. In contrast, absolute numbers of immature B cells were nearly 
doubled in Spib
-/-
Spic
+/-
 spleens compared to WT or Spib
-/-
 spleens
 
(Fig. 3.5B). To 
determine which immature B cell subset was accountable for overall increased numbers, 
analysis of transitional T1, T2, and T3 B cell populations was performed by gating 
immature B220
+
CD93
+
 B cells for differential expression of IgM and CD23 (Fig. 3.5C).  
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Figure 3.3. No differences in B cell composition between Spib
-/-
, and Spib
-/-
Spic
+/-
 mice 
in the bone marrow. 
(A) Bone marrow analysis was performed on WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. Cells 
were analyzed by flow cytometry and gated using the Hardy scheme for quantifying B 
cell populations during development. Data shown is a representative of 8 individual mice. 
(B) Quantitation of individual fractions A-F located in the bone marrow calculated as a 
percentage of total B220
+
 cells in the bone marrow. (C) Quantitation of individual 
fractions A-F located in the bone marrow calculated as a percentage of total cells in the 
bone marrow. Fractions were gated using the Hardy scheme. For B-C, data is shown as 
mean and SD of 8 individual mice. **p<0.01; ***p<0.001. 
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Figure 3.4. No differences in the frequency of apoptosis between WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 B cells. 
(A) Rates of apoptosis were analyzed by flow cytometry using Annexin V and 7-AAD 
staining on WT, Spib
-/-,
 and Spib
-/-
Spic
+/-
 splenocytes. Prior to Ab staining, spleens were 
enriched for B cells by magnetic CD43
+ 
cell depletion. Cells were stained for B220, 
CD93, IgM, CD23, Annexin V, and 7-AAD to allow for gating on transitional T1, T2, 
and mature FO and MZ B cell populations. Apoptotic frequencies (Annexin V
+
 7-AAD
-
;
 
red box) were assessed for each gated subset. (B) Quantitation of the frequency of 
apoptosis in total B cells. (C) Quantitation of apoptotic transitional T1, T2, FO and MZ B 
cells. For B-C, data is shown as mean and SD of 4 individual mice.  
 
100 
 
 
101 
 
No differences in T3 B cells were observed between WT, Spib
-/-
 and Spib
-/- 
Spic
+/-
 
spleens. In contrast, Spib
-/-
 and Spib
-/- 
Spic
+/- 
spleens contained elevated frequencies and 
absolute numbers of T1 B cells compared to WT spleens, although there was no 
quantitative difference in the T1 population between Spib
-/-
 and Spib
-/- 
Spic
+/- 
mice. For 
T2 populations, Spib
-/- 
spleens contained fewer cells than WT, and both frequency and 
absolute numbers of T2 cells were increased in Spib
-/- 
Spic
+/-
 spleens (Fig. 3.5D). To 
confirm that T2 B cell numbers were increased in Spib
-/- 
Spic
+/- 
spleens compared to Spib
-
/-
, splenic B cells were examined using an alternative staining scheme based on CD21 and 
IgM expression (Fig. 3.6A). Absolute numbers of T2 B cells were significantly reduced 
in Spib
-/-
 spleens compared to WT, and were rescued in Spib
-/- 
Spic
+/- 
spleens using the 
alternative staining scheme (Fig. 3.6B). In summary, these results showed that reduced 
Spi-C in Spib
-/-
Spic
+/- 
mice resulted in a substantial rescue of the frequency of T2 cells in 
the spleen of Spib
-/- 
mice. 
3.2.4 LPS and anti-IgM mediated proliferation is rescued in Spib-/-Spic+/- B 
cells compared to Spib
-/- 
B cells 
B cells lacking Spi-B have been previously reported to have impaired 
proliferative responses to either LPS or anti-IgM (Garrett-Sinha et al, 1999; Su et al, 
1997). To determine whether Spic heterozygosity could rescue functional defects of Spib 
knockout B cells, proliferation of Spib
-/-
 and Spib
-/-
Spic
+/-
 splenic B cells in response to 
LPS or anti-IgM was assessed using a MTT proliferation assay. Compared to WT B cells, 
Spib
-/-
 B cells proliferated poorly in response to LPS or anti-IgM (Fig. 3.7A). In contrast, 
Spib
-/-
Spic
+/-
 B cells were substantially rescued for LPS or anti-IgM-mediated 
proliferation compared to Spib
-/-
 B cells (Fig. 3.7A-B). To confirm the proliferation 
rescue, LPS-mediated proliferation was measured by flow cytometry following staining 
B cells with carboxyfluorescein succinimidyl ester (CFSE) (Fig. 3.7C). Fewer cells 
underwent cell division in Spib
-/-
 B cells stimulated with LPS compared to WT B cells. 
However, more proliferating cells were detected in Spib
-/-
Spic
+/-
 B cells compared to 
Spib
-/-
 B cells (Fig. 3.7D). Therefore, these results suggested that B cell proliferation in 
response to LPS or anti-IgM is positively regulated by Spi-B, but negatively regulated by 
Spi-C.  
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 Figure 3.5. Spib
-/-
Spic
+/-
 mice have elevated transitional B cells and restored transitional-
2 B cells compared to Spib
-/-
 mice.  
(A) Total transitional B cell populations were quantified in WT, Spib-/-, and Spib-/-Spic+/- 
mice. Splenocytes were stained with CD93 and B220 and analyzed by flow cytometry. 
The dashed-box represents total transitional B cells. (B) Increased frequencies and 
absolute number of total transitional B cells in spleens of Spib-/- and Spib-/-Spic+/- mice. (C) 
Transitional B cell subsets T1 (Top left box, IgMhiCD23-), T2 (Top right box, 
IgMhiCD23+), and T3 (Bottom right box, IgMlowCD23+) were quantified in WT, Spib-/-, and 
Spib-/-Spic+/- mice. Cells were gated on B220 and CD93 and analyzed for IgM and CD23 
staining by flow cytometry. (D) Increased T2 subset in Spib-/-Spic+/- compared to Spib-/- 
mice. Quantitation of results shown in (C). Data is shown as mean frequency and 
absolute numbers of gated B220+CD93+ splenocytes. For B and D, data is shown as the 
mean and SD of 9 individual mice. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 3.6. Spib
-/-
Spic
+/-
 mice have restored transitional-2 B cells compared to Spib
-/-
 
mice. 
(A) T2 B cells (IgM
+
CD21
int
; dashed box) were quantified in WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. Cells were gated on B220 and CD93 and analyzed for IgM and CD21 
staining by flow cytometry. (B) Restored T2 subset in Spib
-/-
Spic
+/-
 compared to Spib
-/-
 
mice. Quantitation of results shown in (A). Data is shown as mean and SD for frequency 
and absolute numbers of gated B220
+
CD93
+
 splenocytes from 7 individual mice. 
*p<0.05. 
105 
 
 
106 
 
 To determine if the Spib
-/-
Spic
+/-
 B cell phenotype could be reversed by ectopic 
expression of Spi-C, Spib
-/-
Spic
+/-
 mice were crossed to Eμ-Spi-C transgenic mice (Zhu et 
al, 2008). Spleens from Eμ-Spi-C Spib-/-Spic+/- mice contained fewer cells than Spib-/-
Spic
+/-
 spleens (Fig. 3.7E). Flow cytometry analysis was performed on Eμ-Spi-C Spib-/-
Spic
+/- 
spleens to assess for differences in B cell populations. Frequencies of MZ and FO 
B cells in Eμ-Spi-C Spib-/-Spic+/- spleens were unchanged compared to Spib-/-Spic+/- 
spleens, however, there was a significant reduction in the absolute number of MZ and FO 
B cells in Eμ-Spi-C Spib-/-Spic+/- mice (Fig. 3.7F). Proliferation of Eμ-Spi-C Spib-/-Spic+/- 
B cells following LPS stimulation was assessed by CFSE staining. Compared to Spib
-/-
Spic
+/-
 B cells, frequencies of proliferating Eμ-Spi-C Spib-/-Spic+/- B cells decreased (Fig. 
3.7G). This data suggests that reintroducing Spi-C using a lymphocyte-specific transgene 
reverses the Spib
-/-
Spic
+/-
 B cell proliferation phenotype.  
 Since anti-IgM mediated proliferation was restored in Spib
-/-
Spic
+/-
 B cells 
compared to Spib
-/-
, it was possible that Spib
-/-
Spic
+/-
 B cells could have restored BCR 
signaling. To test for this, phosphorylated levels of Syk were measured in B cells using 
flow cytometry (Fig. 3.7H). There was a detectable increase in phospho-Syk levels 
following anti-IgM stimulation; however, there was no difference in the increase between 
WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 B cells (Fig. 3.7I). Next, total Syk was measured in B cells 
using immunoblot analysis. There was a noticeable increase in total Syk protein in Spib
-/-
, 
and Spib
-/-
Spic
+/-
 B cells compared to WT B cells (Fig. 3.7J). Therefore, the restoration in 
BCR signaling in Spib
-/-
Spic
+/-
 B cells is likely independent of Syk. 
 It was previously reported that Spib
-/- 
mice had normal basal levels of all Ig 
isotypes (Su et al, 1997). To determine whether reduced Spi-C had an effect on isotype 
switching in Spib
-/-
Spic
+/-
 mice, basal serum levels of different immunoglobulin were 
measured by ELISA. No significant differences in basal levels of IgM (Fig. 3.8A) or 
IgG2b (Fig. 3.8B) were measured between WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice. Therefore, 
the data suggests that Spi-C does not alter basal levels of Ig isotypes in Spib
-/-
Spic
+/-
 
mice. 
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Figure 3.7. B cell proliferation is rescued in Spib
-/-
Spic
+/-
 mice compared to Spib
-/-
 mice. 
(A) Spib
-/-
Spic
+/-
 B cells have significantly increased proliferation compared to Spib
-/-
 B 
cells. Proliferation was measured using an MTT proliferation assay. Data shown is the 
mean and SD of triplicate wells and is a representative of 5 experiments. (B) Quantitation 
of 5 experiments from (A) showing proliferation index, which is calculated by 
normalizing corrected OD
570 
values to the untreated WT control. Data is shown as mean 
and SEM. (C) Proliferation assessed by flow cytometry following CFSE staining on WT, 
Spib
-/-
, and Spib
-/-
Spic
+/-
 B cells. Gate shown represents the frequency of proliferating 
cells. Data shown is a representative of 4 individual experiments (D) Quantitation of 
CFSE experiments as performed in (C) showing frequency of cells that underwent cell 
division. (E) Cell counts based on total cells isolated from the spleens of Spib
-/-
Spic
+/-
 and 
Eµ-Spi-C Spib
-/-
Spic
+/- 
mice. (F) Quantitation of the frequency and absolute number of 
MZ and FO mature B cells (B220
+
CD93
-
) in the spleens of Spib
-/-
Spic
+/-
 and Eµ-Spi-C 
Spib
-/-
Spic
+/- 
mice. FO and MZ B cell populations were quantified based on CD23 and 
IgM surface expression measured by flow cytometry. For E and F, data is shown as mean 
and SD of 5 individual mice. (G) Proliferation assessed by flow cytometry following 
CFSE staining on Spib
-/-
Spic
+/-
 and Eµ-Spi-C Spib
-/-
Spic
+/-
 B cells. Data is shown as mean 
and SD for 4 individual experiments. (H) Phospho-Syk levels were assessed in WT,  
Spib
-/-
, and Spib
-/-
Spic
+/-
 B cells using flow cytometry. Splenocytes were stained with 
B220, stimulated with anti-IgM for 2 minutes or untreated, and then stained with 
phospho-Syk prior to analysis. (I) Quantitation of phospho-Syk levels in B220
+
 
splenocytes following anti-IgM stimulation. Phospho-Syk levels are shown as normalized 
phospho-Syk MFI of anti-IgM to untreated. Data is shown as the mean and SD of 5 
individual experiments. (J)  Syk protein expression measured in WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 B cell lysates. Immunoblot was performed using anti-Syk antibody and anti-β-
Actin as a loading control. Data shown is a representative of 3 individual experiments. 
For A-D and G, total B cells were enriched by magnetic separation and stimulated with 
LPS or anti-IgM for 72 hours. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 3.8. Equivalent basal serum antibody levels between WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 
mice.  
(A) IgM and (B) IgG2b serum levels measured by ELISA. Data shows mean and 
standard deviation (n=6). 
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3.2.5 Spi-C represses Nfkb1 promoter activation by Spi-B 
Finally, a potential mechanism for Spi-C’s regulation of B cell proliferation was 
investigated. Stimulation of B cells with LPS or anti-IgM results in NF-κB transcription 
factor activation (Pone et al, 2010). P50 (encoded by Nfkb1) is required for murine B cell 
proliferation in response to LPS or anti-IgM (Sha et al, 1995). We recently showed that 
PU.1 and Spi-B are required for Nfkb1 transcription in B cells, and retroviral transduction 
with p50 substantially rescues LPS-induced proliferation of Spi1
+/-
Spib
-/-
 B cells (Li et al, 
2015). Therefore, it was determined whether restored proliferation in Spib
-/-
Spic
+/-
 B cells 
was associated with increased mRNA transcript levels of Nfkb1 compared to Spib
-/-
 B 
cells. RT-qPCR was performed on cDNA synthesized from MZ and FO B cells sorted 
from Spib
-/-
 and Spib
-/-
Spic
+/- 
spleens. Steady-state Nfkb1 mRNA transcript levels were 
increased in MZ and FO B cells of Spib
-/-
Spic
+/- 
mice compared to Spib
-/-
 mice (Fig. 
3.9A), suggesting that Spi-C may negatively regulate Nfkb1 in B cells.  
To assess whether Spi-B and Spi-C regulate Nfkb1 directly, the murine Nfkb1 
promoter sequence was aligned with multiple species using a published transcription start 
site (TSS) for reference (Cogswell et al, 1993). The Nfkb1 5’ UTR contained two highly 
conserved ETS binding sites predicted among all species near the TSS using 
MatInspector software (Fig. 3.9B). Next, the mouse Nfkb1 proximal promoter was cloned 
as described in Materials & Methods and ligated into the pGL3-basic luciferase reporter 
vector. Site directed mutagenesis was performed to mutate two predicted ETS binding 
sites closest to the transcriptional start site by substituting GGAA (TTCC on complement 
strand) with GGAC (GTCC), which has been previously reported to abolish Spi-B 
binding (DeKoter et al, 2010; Xu et al, 2012) (Fig. 3.9C). To determine whether Spi-B 
and Spi-C regulate Nfkb1 transcription in opposing fashion, luciferase assays were 
performed using transient transfection of WEHI-279 B lymphoma cells that ectopically 
express 3XFLAG tagged Spi-B or Spi-C (DeKoter et al, 2010; Xu et al, 2012). WEHI-
279 cells infected with an empty MIGR1 virus were used as a control (WEHI-279 
MIGR1). Expression of 3XFLAG Spi-B and Spi-C protein was confirmed by anti-FLAG 
immunoblot analysis in infected cell lines (Fig. 3.9D). The Nfkb1 promoter was active in 
WEHI-279 MIGR1 cells, and mutation of the ETS sites impaired its activation (Fig. 
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3.9E). WEHI-279 Spi-B cells displayed a higher level of activation compared to WEHI-
279 MIGR1 cells, whereas mutation of the ETS sites reduced Nfkb1 activation. 
Interestingly, the activity of the Nfkb1 promoter in WEHI-279 Spi-C cells was lower than 
both WEHI-279 MIGR1 and WEHI-279 Spi-B cells, and mutation of the ETS site 
resulted in no change of activity (Fig. 3.9E). To confirm that Spi-C expression decreased 
Nfkb1 transcriptional activation, luciferase activity was measured following co-
transfection of a Spi-C expression vector (pcDNA3 Spi-C) and the pGL3-Nfkb1 vector 
into WEHI-279 Spi-B cells. Co-transfection with pcDNA3 Spi-C resulted in decreased 
Nfkb1 activation compared to co-transfection with the vector control (pcDNA3) (Fig. 
3.9F). These results suggest that Spi-B transcriptionally activates Nfkb1, and Spi-C 
inhibits Nfkb1 transcription. 
We recently showed that PU.1 and Spi-B directly interact with the Nfkb1 
promoter to activate its transcription (Li et al, 2015). To determine if Spi-C directly 
interacts with the Nfkb1 promoter, ChIP analysis was performed using anti-Spi-C and 
anti-FLAG Ab on chromatin isolated from WEHI-279 Spi-C and WEHI-279 MIGR1 
cells. Relative amounts of immunoprecipitated DNA were determined by qPCR from the 
Nfkb1 promoter region, and the Gapdh promoter as a negative control. ChIP analysis 
confirmed that Spi-C was significantly enriched at the Nfkb1 promoter compared to the 
Gapdh promoter in WEHI-279 Spi-C cells, but not WEHI-279 MIGR1 cells (Fig. 3.9G). 
Together, these data indicate that Spi-C directly interacts with the Nfkb1 promoter, 
suggesting that it opposes Spi-B-mediated activation of Nfkb1 transcription in B cells. 
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Figure 3.9. Spi-C inhibits activation of the Nfkb1 promoter by Spi-B. 
(A) Measurement of transcript levels of Nfkb1 in Spib
-/-
Spic
+/- 
compared to Spib
-/-
 B cells. 
RT-qPCR analysis was performed on RNA prepared from unstimulated sorted FO and 
MZ B cells. mRNA transcript levels of genes indicated on the X-axis were quantified 
after normalizing to β2 microglobulin (B2m). Data is shown as mean and SD, and is a 
representative of 3 individual mice. (B) Alignment of the annotated Nfkb1 promoter 
between multiple species, showing nucleotides 105-130 of the conserved 213 bp region. 
Grey text represents conserved nucleotides, and boxes indicate predicted PU.1/Spi-B 
binding sites with similarity score and strand location (+/-) listed. Circled nucleotide 
represents known TSS in the human Nfkb1 promoter. Dots represent TSS upstream or 
downstream of the annotated sequence. (C) Schematic of luciferase reporter vector. The 
Nfkb1 promoter was cloned by PCR and ligated into pGL3-basic. ETS binding sites (wt) 
were mutated (mut) using site-directed mutagenesis. (D) WEHI-279 B cell lymphoma 
cell lines were generated that overexpress 3XFLAG-Spi-B or Spi-C. Immunoblot 
analysis demonstrates the overexpression levels of Spi-B or Spi-C in these cell lines. (E) 
Overexpression of Spi-C inhibits activation of the Nfkb1 promoter. Mutation of the 
predicted ETS binding sites reduces promoter activity in WEHI-279 MIGR1 and WEHI-
279 Spi-B cells. (F) Spi-C expression in WEHI-279 Spi-B cells decreases Nfkb1 
activation. WEHI-279 Spi-B cells were co-transfected with a Spi-C expression vector 
(pcDNA3 Spi-C) along with the luciferase vectors. In E and F, cells were transfected with 
the plasmids indicated on the x-axis. The y-axis indicates fold-induction of luciferase 
activity relative to pGL3-basic. Luciferase activity was normalized by transfection with 
Renilla luciferase expression vector. Data shown is the mean and SEM of three 
independent experiments. (G) Spi-C directly binds to the Nfkb1 promoter. ChIP analysis 
was performed on WEHI-279 MIGR1 and WEHI-279 Spi-C cells immunoprecipitated 
with anti-FLAG or anti-Spi-C Ab. Data shows percent enrichment relative to input for 
Spi-C interaction with Nfkb1 and Gapdh promoters. Statistics was performed using a 
paired Student’s t-test. Error bars represent SEM from 6 independent experiments. 
**p<0.01; *p<0.05.  
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3.3 Discussion 
The purpose of these experiments was to understand how Spi-C contributes to B 
cell development and function. Spi-C heterozygosity restored many aspects of the Spib
-/- 
phenotype. Spib
-/-
Spic
+/- 
mice had restored numbers of FO and T2 B cells in their spleens 
relative to Spib
-/- 
mice. Furthermore, proliferation in response to LPS and anti-IgM-
mediated stimulation was restored in Spib
-/-
Spic
+/-
 B cells compared to Spib
-/- 
B cells. 
Investigation of a potential mechanism for the Spib
-/-
Spic
+/- 
phenotypic rescue revealed 
that steady-state levels of Nfkb1 were elevated in sorted FO and MZ B cells from Spib
-/-
Spic
+/- 
spleens compared to Spib
-/- 
spleens. Ectopic expression of Spi-B in B cells resulted 
in increased Nfkb1 promoter activity, which was dependent on the ETS binding site. 
Conversely, overexpression of Spi-C inhibited Nfkb1 activation by Spi-B. ChIP and 
ChIP-seq analysis demonstrated that both Spi-B and Spi-C are capable of directly binding 
to the Nfkb1 promoter. In summary, these results suggest that Spi-C opposes Spi-B in B 
cell transcriptional regulation.  
Intercrosses of Spib
-/-
Spic
+/- 
mice generated Spib
-/-
Spic
-/-
 mice at a frequency less 
than 1% of live births. Similar findings were reported where intercrosses of Spic
+/- 
mice 
generated only 9% Spic
-/- 
(Kohyama et al, 2009). Previous studies have demonstrated that 
embryos injected with Spic-siRNA resulted in reduced rate of blastocyst development 
(Kageyama et al, 2006). It is possible that Spi-B and Spi-C may have overlapping roles in 
prenatal development, and therefore embryonic death may be occurring at the blastocyst 
stage in Spib
-/-
Spic
-/-
 mice. Therefore, low birth frequency of Spib
-/-
Spic
-/-
 mice is likely 
due to reduced embryonic or fetal viability.  
Few target genes for Spi-C have been identified in B cells, and Spi-C was 
reported to function either as an activator or as a repressor of gene transcription. It is 
possible that altered expression of other unidentified target genes may contribute to the 
Spib
-/-
Spic
+/-
 B cell phenotype. Spi-C ectopically expressed in pro-B cells can directly 
bind and oppose transcription of the Fcgr2b gene mediated by PU.1 (Schweitzer et al, 
2006). In contrast, transcription of the gene Fcer2a, encoding CD23, was reported to be 
directly activated by Spi-C in WEHI-279 Spi-C cells (DeKoter et al, 2010). Earlier 
116 
 
reports showed that Spi-C cooperated with STAT6 to directly induce transcription of IgE 
under the control of IL-4 (Carlsson et al, 2006). In macrophages, Spi-C was reported to 
directly activate Vcam1 transcription (Kohyama et al, 2009). Our data demonstrated that 
Spi-C directly opposes transcriptional activation of Nfkb1 by preventing Spi-B and 
possibly PU.1 from binding to the Nfkb1 promoter in B cells. In summary, Spi-C is 
capable of both activation and repression of its target genes, and can also transcriptionally 
regulate target genes by preventing other transcription factors from binding.  
Previous studies have demonstrated that the transcription factors PU.1 and Spi-B 
are required to maintain proper levels of Nfkb1 in B cells (Li et al, 2015). Spi-B directly 
binds to the Nfkb1 promoter and activates transcription. In contrast, Spi-C directly binds 
to the Nfkb1 promoter, but does not activate transcription. Therefore, decreased Spi-C 
expression may reduce its occupancy of the Nkfb1 promoter in Spib
-/-
Spic
+/- 
B cells, 
permitting increased activation of Nfkb1 by PU.1. Elevated Nfkb1 transcript levels in 
Spib
-/-
Spic
+/- 
B cells compared to Spib
-/- 
B cells suggest that Spi-C and Spi-B oppose each 
other to regulate appropriate Nfkb1 levels. Spib
-/- 
and Nfkb1
-/-
 B cells proliferate similarly 
to LPS and anti-IgM. LPS stimulated Nfkb1
-/-
 B cells fail to proliferate, and anti-IgM 
stimulation results in reduced proliferation (Sha et al, 1995). Overall, elevated Nfkb1 
expression in Spib
-/-
Spic
+/-
 B cells compared to Spib
-/- 
B cells may sufficiently explain the 
rescue in proliferation. 
Spib
-/-
Spic
+/- 
mice have restored FO and T2 B cell numbers compared to Spib
-/- 
mice, indicating that Spi-B and Spi-C regulate peripheral B cell differentiation. FO and 
T2 cell differentiation both require NF-κB signaling and BCR signaling. Transitioning 
from a T1 to T2 B cell requires non-canonical NF-κB signals and basal BCR signals, and 
maturation of a T2 to a FO B cell requires canonical NF-κB signals and strong BCR 
signaling (Pillai & Cariappa, 2009). Nfkb1
-/-
Nfkb2
-/-
 mice have a developmental block at 
the T2 stage and fail to generate any mature B cells (Claudio et al, 2002). Therefore, 
elevated Nfkb1 expression in developing Spib
-/-
Spic
+/- 
could be sufficient to explain the 
restored FO B cell population. It is also conceivable that Spi-C may also be a negative 
regulator of c-Rel expression, as PU.1 and Spi-B have been previously reported to 
directly activate Rel transcription (Hu et al, 2001). Alternatively, it is possible that FO 
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and T2 B cells in Spib
-/-
Spic
+/-
 have a longer life-span than Spib
-/-
 B cells, which could 
contribute to its restoration.   Spib
-/- 
B cells have impaired BCR signaling and thus 
proliferate poorly in response to anti-IgM stimulation (Garrett-Sinha et al, 1999; Su et al, 
1997). Transgenic Spi-C expression in B cells results in reduced transcript levels of the 
BCR signaling genes Btk and Blnk in FO B cells (Zhu et al, 2008). Restored proliferative 
response to anti-IgM in Spib
-/-
Spic
+/- 
B cells compared to Spib
-/- 
B cells suggests that BCR 
signaling is possibly restored due to reduced Spi-C expression. Since WT, Spib
-/-
, and 
Spib
-/-
Spic
+/- 
B cells are capable of phosphorylating Syk at equivalent levels following 
anti-IgM stimulation, the rescue in BCR signaling is likely downstream of Syk. 
 
 
Therefore, rescued FO and T2 B cells in Spib
-/-
Spic
+/- 
spleens might be caused by a 
combination of restored NF-κB and BCR signalling. 
It is possible that aspects of the B cell phenotype of Spib
-/-
Spic
+/-
 mice are not 
cell-intrinsic. However, evidence was provided for a cell-intrinsic effect of Spi-C on B 
cell proliferation using the Eµ-Spi-C transgenic mouse. In this mouse model the Spi-C 
transgene is under the control of a lymphocyte-specific Eµ intronic enhancer. We found 
that crossing this transgenic mouse to Spib
-/-
Spic
+/- 
mice (Eμ-Spi-C Spib-/-Spic+/-) resulted 
in a reduction in proliferation from isolated B cells, suggesting Spi-C has a cell-intrinsic 
effect on B cell function. Furthermore, overexpression of Spi-C in Eμ-Spi-C Spib-/-Spic+/- 
mice reduced the number of FO and MZ B cells, suggesting a cell-intrinsic role for Spi-C 
in B cell development. 
In summary, our results demonstrate a novel mechanism for Spi-C as a negative 
regulator of B cell development and function. Understanding transcriptional regulation in 
B cells has human health implications, since dysfunctional B cell development can lead 
to leukemia of the B cell lineage (Sokalski et al, 2011; Xu et al, 2012). Furthermore, 
antibody formation in B cells is transcriptionally regulated, so understanding potential 
activators and repressors of this process can improve interventions for vaccine 
development. Further analysis on mice lacking Spi-B and reduced Spi-C can provide 
additional insight into other genes involved in B cell development, function, and disease. 
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3.4 Materials and Methods 
3.4.1 Generation and breeding of mice 
Mice were housed at Western University’s Health Sciences animal facility (London, 
Ontario, Canada) and monitored under an approved animal use subcommittee protocol in 
accord with Western University Council on Animal Care. C57BL/6 (WT) mice were 
purchased from Charles River Laboratories (Pointe-Claire, Quebec, Canada). Spib
+/-
Spic
+/-
 mice were backcrossed to C57BL/6 mice for 5 generations prior to the generation 
of Spib
-/-
Spic
+/- 
mice. Spib
-/-
Spic
+/-
 mice were generated by mating male and female Spib
-/-
Spic
+/-
 mice. E-Spi-C Spib-/-Spic+/- mice were generated by mating E-Spi-C+ male 
mice to Spib
-/-
Spic
+/-
 females. Genotyping was performed by PCR as previously 
described (DeKoter et al, 2010; Kohyama et al, 2009). All experiments were performed 
on mice aged 6-12 wks.  
3.4.2 B cell enrichment and proliferation analysis 
RBCs were removed from spleen cell suspensions by hypotonic lysis with ammonium 
chloride solution. B cells were enriched by negative selection using biotin-conjugated 
anti-CD43 (S7) Ab, streptavidin (SA) microbeads, LD depletion columns, and a 
QuadroMACS™ separation unit (Miltenyi Biotec, Germany). B cells (2x105/well) were 
plated in 96-well flat bottom plates and stimulated with LPS (10 μg/mL, List Biological 
Laboratories), anti-IgM Ab (50 μg/mL, affinity pure F(ab’)2 fragment, or goat anti-
mouse IgM, μ chain specific; Jackson ImmunoResearch Laboratories), in complete 
IMDM. Proliferation was assessed after 72 h incubation at 37°C with a TACS
®
 MTT Cell 
Proliferation assay (Trevigen, Gaithersburg, MD) used according to the manufacturer’s 
instructions. For CFSE analysis, 10x10
6
 B cells were stained with 5 μM of CFSE 
(Biolegend, San Diego, CA) for 5 min at room temperature prior to plating. Frequency of 
stained cells was assessed after 72 h incubation at 37°C by flow cytometry.  
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3.4.3 Flow cytometry  
Antibodies and reagents purchased from eBioscience (San Diego, CA), BD Bioscience 
(Franklin Lakes, NJ), or BioLegend included 7-AAD, CFSE, brilliant violet 421 
conjugated anti-CD45R/B220 (Ra3-6B2), allophycocyanin (APC)-conjugated IgM 
(II/41), APC-conjugated Annexin V, biotin-conjugated anti-CD43 (S7), phycoerythrin 
(PE) conjugated CD93 (AA4.1), PE conjugated anti-BP-1 (BP-1), PE-conjugated anti-
CD19 (1D3), PE-conjugated phospho-Syk (moch1ct), fluorescein isothiocynate (FITC)-
conjugated CD24 (30-F1), FITC-conjugated anti-CD21/CD35 (eBio8D9), FITC-
conjugated anti-CD23 (B3B4), and PE-Cy5-conjugated streptavidin. Cells were blocked 
with purified anti-CD16/CD32 (Mouse BD Fc Block
TM
). Intracellular staining was 
performed using a two-step protocol and intracellular fixation and permeabilization 
buffer set obtained from eBioscience. Antibody-stained cell analysis was performed 
using FACSCalibur and LSRII systems, and sorting was performed using a FACSAriaIII 
system (BD Biosciences). Sorted cells were determined to be >98% purity. Data analysis 
was performed using FlowJo software (TreeStar Inc., Ashland, OR).  
3.4.4 Reverse transcription-quantitative PCR 
RNA was isolated with Trizol reagent (Invitrogen, Burlington, Ontario, Canada). cDNA 
was synthesized using an iScript cDNA Synthesis Kit (Bio-Rad, Mississauga, Ontario, 
Canada), and qPCR was performed with a Rotor-Gene 6000 instrument (Corbett Life 
Sciences, Valencia, CA). Relative mRNA transcript levels were normalized to β2m and 
compared between samples using the comparative threshold cycle method. Calculations 
were performed using REST© 2009 software (Pfaffl et al, 2002). Primer sequences are 
listed in Table 3.2.  
3.4.5 Immunoblot analysis 
Lysates were prepared using Laemelli buffer and applied to 8%-10% SDS 
polyacrylamide gels for electrophoresis. Proteins were transferred to nitrocellulose 
membranes using a Trans-Blot Semi-Dry system (Bio-Rad), and membranes were 
blocked for 1 hour in 5% milk in TBST. Membranes were probed with anti-Spi-C (Aviva 
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Systems Biology, San Diego, CA), anti-Flag (M2, Sigma Aldrich, St. Louis, MO), anti-
Syk (C-20, Santa Cruz Biotechnology, Dallas, Texas), or anti-β-Actin (I-19, Santa Cruz 
Biotechnology) Ab, and diluted to manufacturer recommended concentrations in 1% 
milk/TBST overnight at 4°C. A secondary horseradish peroxidase-conjugated anti-goat 
Ab was incubated in 1% milk/TBST. Membranes were washed and visualized with 
SuperSignal West Pico reagent (Thermo-Fisher Scientific). 
3.4.6 ELISAs 
Serum was collected and quantified for IgG2b and IgM.  ELISA kits were purchased 
from eBioscience and performed according to the manufacturer’s instructions. ELISA 
plates were analyzed using an Epoch microplate spectrophotometer with Gen5 software 
(BioTek, Winooski, VT). 
3.4.7 Plasmids and cloning 
Spi-C cDNA was cloned into the hemagglutinin (HA) tag-containing pcDNA3 vector as 
previously described (Schweitzer et al, 2006). The Nfkb1 promoter was amplified from 
C57BL/6 genomic DNA by PCR using LA-TAQ (TaKaRa; Clontech Laboratories Inc, 
Mountain View, CA), purified, and cloned into the pSC-A vector using a PCR cloning kit 
(Agilent Technologies, La Jolla, CA). A 468bp Nfkb1 promoter was PCR amplified using 
a forward primer containing a HindIII site and subcloned. The promoter was HindIII 
digested from pSC-A and ligated into the HindIII site of the pGL3-basic 
(Promega, Madison, WI) luciferase reporter vector. ETS binding sites were mutated using 
the QuickChange lightning site-directed mutagenesis kit according to the manufacturer’s 
instructions (Agilent Technologies). Constructs were verified by DNA sequencing. 
Transfection-quality plasmid DNA was prepared by growth in DH5α bacteria and 
purified with plasmid maxi prep kit (Geneaid, New Taipei City, Taiwan). All restriction 
enzymes were purchased from New England Biolabs (Ipswich, MA). Primer sequences 
used for cloning are listed in Table 3.2.  
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Table 3.2. Forward and reverse primers used for RT-qPCR analysis, cloning, and site 
directed mutagenesis.   
Primer Name DNA Sequence (5’ -> 3’) 
B2m fwd 5’-TGG CTC ACA CTG AAT TCA CCC CCA-3’ 
rev 5’-TCT CGA TCC CAG TAG ACG GTC TTG-3’ 
Gapdh promoter ChIP fwd 5’-GTCTGTTATATGGGCGTCCTGTCA-3’ 
rev 5’-CGTTCACACCGACCTTCACCATTT-3’ 
Nfkb1 fwd 5’-GCT GAG TCC TGC TCC TTC TAA A-3’ 
rev 5’-CCT CTG TGT AGC CCA TCT GTT GC-3’ 
Nfkb1 promoter ChIP fwd 5’-TCC GTC TGT CTG CTC TCT-3’ 
rev 5’-GAA AGC AGT GAG GTA AGC CCA AC-3’ 
Nfkb1 Promoter fwd 5’-CCC AAA GAA TAA AGA CGC TCA AAT GC-3’ 
rev 5’-TCA GAA GAC CGA AGG AAG CCT ACA-3’ 
Nfkb1 Sublone w/ HindIII fwd 5’-CAA GCT TAC CTC CCG CCC CC-3’ 
Rev 5’-CCT GGA GAT GCG GCG CGG-3’ 
pGL3-Nfkb1 Mutation 5’-TCT CGA CGT CAG TGG GAA TGT CCA GC-3’ 
pGL3-Nfkb1 Mutation anti 5’-TCG CTC ACT CTC TCA CGT CCT GGC TGG-3’ 
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3.4.8 Transient transfection  
WEHI-279 MIGR1, MIG-3XFLAG-Spi-B, and MIG-3XFLAG-Spi-C cells were 
generated as previously described (DeKoter et al, 2010; Xu et al, 2012). Cells in mid to 
early log phase growth were washed three times with serum-free DMEM (4.5g/L, Wisent 
Inc, St-Bruno, Quebec) and incubated for 10 minutes at room temperature with 10 μg of 
each luciferase reporter plasmid and 1 μg of pRL-TK (Promega). Cell-DNA mixtures 
were electroporated at 220 V and 950 mF using 4-mm gap cuvettes with a GenePulser II 
with Capacitance Extender (Bio-Rad), incubated at room temperature for 10 min, then 
transferred to 6-well culture plates in complete DMEM and incubated at 37°C for 24 
hours. A Dual-Luciferase Reporter Assay System (Promega) was performed on cell 
lysates. Light production was measured using a Lumat LB 9507 tube luminometer 
(Berthold Technologies, Oak Ridge, TN). 
3.4.9 ChIP experiments  
Chromatin was prepared from enriched B cells as previously described (Sokalski et al, 
2011; Xu et al, 2012). In brief, cells were cross-linked and lysed followed by sonication. 
Sonicated chromatin was incubated overnight at 4°C with anti-Spi-C (generated by 
Fulkerson lab) and anti-FLAG (M2, Sigma-Aldrich) conjugated to protein G DynaBeads 
(Invitrogen). Magnetic bead complexes were enriched using a MagneSphere® 
Technology Magnetic Separation Stand (Promega) and washed. Immunocomplexes were 
eluted and cross-linked chromatin was reversed overnight at 65°C. DNA was purified 
using a QIAquick PCR purification kit (Qiagen, Limburg, Netherlands). Enrichment was 
measured using qPCR of immunoprecipitated DNA using primers indicated in Table EI.  
 
3.4.10 ChIP-Seq Analysis 
ChIP-seq experiments were performed using mouse WEHI-279 cells. Cells were spin-
infected with a MIGR1 vector for expression of 3XFLAG-PU.1 or 3XFLAG-Spi-B. 
Immunoprecipitation was performed using anti-FLAG microbeads (M2, Sigma-Aldrich).  
Purified chromatin was sequenced on an Ilimuna HiSeq at the BC cancer research 
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agency. Peak finding and data analysis was performed using Galaxy Suite (Blankenberg 
et al, 2010; Giardine et al, 2005; Goecks et al, 2010). Reads were aligned to the reference 
genome (NCBI37/mm9), using BOWTIE (Langmead et al, 2009). Peaks were called 
using MACS version 1.0.1 (Zhang et al, 2008) with default parameters, a P-value cutoff 
for peak detection of 1e-05 and an effective genome size of 2.7e+9 bp. The ChIP-seq data 
from this publication have been submitted to the Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo) and assigned the identifier GSE48891 and GSE58128. 
3.4.11 Statistical analysis 
Statistical significance was determined using one-way or two-way ANOVA analysis with 
a Bonferroni post-test unless otherwise indicated. P values ≤0.05 were considered 
significant. For all figures, *P ≤0.05, **P ≤0.01, and ***≤P 0.001. Statistical analysis 
was performed using Prism 5.0 (Graph-Pad Software). 
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Chapter 4  
4 Overall discussion and future directions 
This thesis describes the ability of the transcription factors PU.1, Spi-B, and Spi-
C to control B cell development and proliferative function. The hypothesis that PU.1 and 
Spi-B were required for positively regulating components of TLR responses was tested. 
In chapter 2, B cells from PUB (Spi1
+/-
Spib
-/-
) mice were shown to be impaired for TLR-
mediated proliferation responses. The impairment in PUB B cells was attributed to 
reduced levels of p50 protein, which is encoded by the Nfkb1 gene. It was demonstrated 
that both PU.1 and Spi-B are capable of directly binding to the Nfkb1 promoter, and the 
ETS binding sites within the promoter were required for efficient transcription of the 
gene. Impaired TLR-mediated proliferation was restored upon retroviral reinsertion of 
p50 into PUB B cells. These results suggest that Nfkb1 activation by PU.1 and Spi-B is 
important for TLR-initiated B cell responses. 
Chapter 3 characterized the role of Spi-C in B cells. The hypothesis that Spi-C 
inhibited target genes of PU.1 and Spi-B was tested. By generating the novel mouse 
model Spib
-/-
Spic
+/- 
and comparing it to Spib
-/-
 mice, it was determined that Spi-C has a 
functionally distinct role compared to Spi-B. Spi-C heterozygosity restored many aspects 
of the Spib
-/- 
phenotype, including a restoration in FO and T2 B cell numbers in the 
spleen, and restored LPS and anti-IgM-mediated B cell proliferation. Nfkb1 was 
hypothesized to participate in the mechanism for the Spib
-/-
Spic
+/-
 phenotype. Transcript 
levels of Nfkb1 were elevated in Spib
-/-
Spic
+/-
 B cells compared to Spib
-/-
 B cells. In B cell 
lines overexpressing Spi-B, Nfkb1 promoter activity was substantially elevated; however, 
Nfkb1 promoter activity was significantly reduced in B cell lines overexpressing Spi-C. It 
was demonstrated that Spi-C directly bound to the same sites as PU.1 and Spi-B at the 
Nfkb1 promoter. Therefore, Spi-C directly opposes Spi-B transcriptional regulation in B 
cells.  
These studies have identified a mechanism by which PU.1, Spi-B, and Spi-C 
regulate development and proliferative function in B cells. PU.1 and Spi-B are capable of 
each individually binding directly to the Nfkb1 promoter to activate its expression (Figure 
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4.1A). In contrast, Spi-C directly binds to the same Nfkb1 promoter region and represses 
Nfkb1 activation (Figure 4.1B). Since all three transcription factors can bind to the same 
regions, we hypothesize that Spi-C can function to compete with PU.1 and Spi-B for 
binding at the same sites within the Nfkb1 promoter. However, the mechanism of 
activation/repression through direct competition for binding can be complex.  
There are many aspects of transcriptional regulation which can be addressed in 
the future. Repression of Nfkb1 by Spi-C could be mediated through recruitment of other 
transcription factors or histone modifying proteins which affect the accessibility of the 
Nfkb1 promoter. Likewise, the activation of Nfkb1 by PU.1 and Spi-B can involve 
interactions with distal enhancer sites to recruit additional transcription factors to activate 
gene promoters or modulate chromatin accessibility. A high-throughput method of ChIP-
mass spectrometry could identify the plethora of interacting proteins recruited by PU.1, 
Spi-B, or Spi-C (Wang et al, 2013). Furthermore, using chromosome conformation 
capture (3C) assays would elucidate the interactions between distal regulatory enhancers 
or insulators (Hagege et al, 2007). Overall, determining what transcription factors or 
associated proteins are recruited by PU.1, Spi-B, and Spi-C could improve our 
understanding of transcriptional regulatory networks.  
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Figure 4.1. A model of transcriptional regulation of Nfkb1 by PU.1, Spi-B, and Spi-C. 
(A) PU.1 and Spi-B directly bind to the Nkfb1 promoter to activate transcription. (B) Spi-
C can directly bind to the same Nkfb1 promoter region to inhibit its transcription.  
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4.1 Transcriptional Nfkb1 regulation  
This thesis described transcriptional regulation of Nfkb1 by PU.1, Spi-B, and Spi-
C in B cells. Using the PUB mouse model, it was demonstrated that PU.1 and Spi-B 
directly regulated Nfkb1 transcription. Spi-C was shown to be directly responsible for 
repressing Nfkb1 transcription by interacting with the same sites in the promoter. There 
are multiple ETS binding sites within the Nfkb1 promoter, and it has now been 
demonstrated that at least the first two sites are required for Nfkb1 activation. While both 
ChIP and ChIP-seq analysis have validated direct PU.1, Spi-B, and Spi-C binding to the 
Nfkb1 promoter, there are still many unknown aspects of its regulation. Other ETS family 
transcription factors are likely involved with Nfkb1 activation in B cells. The ETS 
transcription factor Ets-1 was previously reported to be required for activating Nfkb1 in 
human Jurkat T cells at a ETS binding site further downstream of the TSS (Lambert et al, 
1997). Since Ets-1 is also expressed in B cells and is required for the generation of 
mature B cells (Eyquem et al, 2004; Garrett-Sinha, 2013), it is likely also involved with 
regulating Nfkb1 expression. Comparing enrichment of FLAG-tagged PU.1 in WEHI-279 
3XFLAG-PU.1 B cell lymphoma cells with Ets-1 binding in SH12 B cell lymphoma cell 
lines, there are regions where both transcription factors can be found (Figure 4.2A). The 
Nfkb1 promoter is likely one of the common regions where PU.1, Spi-B, and Ets-1 can 
each bind, despite the large number of unique sites bound by Ets-1 (Figure 4.2B). It is 
currently unclear which other proteins are recruited by PU.1, Spi-B, and Spi-C to the 
promoter to initiate or repress Nfkb1 transcription. Since PU.1 and Spi-B have been 
reported to interact with IRF4 (Care et al, 2014; Escalante et al, 2002), it is possible that 
PU.1 or Spi-B recruits IRF4 to regulate Nkfb1 transcription. Based on publicly available 
ChIP-seq data from splenic B cells, there is a high degree of similarity in the binding 
patterns seen at Nfkb1 between PU.1 and IRF4 in naïve splenic B cells (Figure 4.2C). 
Moreover, there are multiple overlapping sites of transcription factor binding across the 
mouse genome, when comparing ChIP-seq peaks between PU.1, Spi-B, and IRF-4 B cell 
datasets (Figure 4.2D). Therefore, it is conceivable that Nfkb1 transcription can be 
regulated through recruiting interacting transcription factors and related ETS 
transcription factors in B cells. 
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Enrichment of PU.1 and Spi-B binding did not occur most highly at the promoter 
of Nkfb1. Several intronic regions of Nfkb1 contained even larger PU.1 and Spi-B 
enrichment sites, suggesting that PU.1 or Spi-B may have higher affinity at enhancer 
regulatory elements within the gene body. Preliminary luciferase experiments suggested 
that the PU.1/Spi-B binding region in intron 6-7 of Nfkb1 was not acting as an enhancer. 
Therefore, it is unclear whether the ETS binding site within the intron 6-7 of Nkfb1 is 
essential for maximal expression. Analysis using luciferase constructs containing both 
non-mutated and mutated forms of the intron and promoter could determine the 
importance of the ETS binding site within the Nkfb1 intron. Although the intron region 
may not be an enhancer, it is possible that the site is important for regulating Nfkb1 
expression. PU.1 and Spi-B could be binding to the region with other transcription factors 
to recruit proper chromatin remodeling complexes, or could be acting on proximal genes. 
Interestingly, IκB-γ inhibits DNA binding activity of p50 (Bell et al, 1996) and  is 
encoded within the Nfkb1 gene (Heron et al, 1995). Therefore, PU.1 and Spi-B could also 
be regulating IκB-γ expression for the purpose of a feedback-loop mechanism for 
regulating NF-κB activity.  
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Figure 4.2. Potential regulation of the Nfkb1 gene by other ETS and ETS-interacting 
transcription factors. 
(A) UCSC genome browser depiction of ChIP-seq data from WEHI-279 3XFLAG-PU.1 
cells and SH12 cells showing PU.1 and Ets-1 binding at the Nfkb1 gene respectively. (B) 
Venn diagram for regions of significant ChIP binding between PU.1, Spi-B, and Ets-1 
from WEHI-279 3XFLAG-PU.1, WEHI-279 3XFLAG-Spi-B, and SH12 lymphoma cell 
lines respectively. (C) UCSC genome browser depiction of ChIP-seq data from naïve B 
cells showing PU.1 and IRF4 binding at the Nfkb1 gene respectively. (D) Venn diagram 
for regions of significant ChIP binding between PU.1, Spi-B, and Ets-1 from WEHI-279 
3XFLAG-PU.1, WEHI-279 3XFLAG-Spi-B, and naïve splenic B cells respectively. 
Overlapping binding regions in B and D were determined by subtraction of intervals. 
ChIP-seq data on Ets-1 binding in SH12 cells, PU.1 binding in naïve B cells, and IRF4 
binding in naïve B cells is listed as GSM1003774, GSM537989, and GSM978747 in 
GEO. 
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4.2 Regulation of other NF-κB family members by PU.1, Spi-B, 
and Spi-C 
It has been previously reported that PU.1 and Spi-B are involved in the 
transcriptional regulation of Rel, and it is required to maintain survival in B cells and 
allow proper development (Hu et al, 2001). Therefore, it is predicted that PU.1, Spi-B, 
and Spi-C are involved in regulating the transcription of other NF-κB family members 
aside from Nfkb1 and Rel. Re-analysis of the ChIP-seq data in WEHI-279 3XFLAG-PU.1 
and WEHI-279 3XFLAG-Spi-B cell lines confirmed that PU.1 and Spi-B bound proximal 
to the TSS of Nfkb2, Rela, Relb, and Rel (Figure 2.11). Therefore, PU.1 and Spi-B may 
be involved with the transcriptional regulation of those genes in B cells. It is 
hypothesized that Spi-C would inhibit transcriptional activation of Rel, similar to its 
effect on Nfkb1 transcription.  
Constitutive NF-κB activation is commonly seen in lymphomas (Davis et al, 
2001; Jost & Ruland, 2007). Since WEHI-279 B cells do not express Spi-C (DeKoter et 
al, 2010), down regulation of Spi-C may be one method for tumor cells maintaining high 
levels of NF-κB expression. To test if Spi-C inhibits Rel transcription, studies could be 
performed by transfecting Rel promoter-containing luciferase constructs into WEHI-279 
cell overexpressing Spi-B or Spi-C cells to determine Rel activation. Although PU.1 and 
Spi-B bind near the promoters for the NF-κB genes in WEHI-279 B cells, their 
importance in transcriptional regulation would need to be validated using expression 
constructs containing mutated ETS binding sites. Moreover, the transcriptional regulation 
of the different NF-κB members is stage specific, since different NF-κB members are 
predominantly activated depending on the cell type (Liou et al, 1994). ChIP-seq analysis 
could be performed using different types of B cell subsets to compare the differences in 
binding enrichment at various cell stages.  
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4.3 Spi-C as a repressor of PU.1 and Spi-B activity 
Interactions between IRF-4 and PU.1 or Spi-B are important for regulating 
promoters and enhancers for genes involved in B cell function (Pongubala & Atchison, 
1997; Rao et al, 1999). Spi-C was proposed as a negative control mediator due to its 
inability to interact with IRF-4 in vitro at the λB enhancer (Carlsson et al, 2003). 
Subsequent gain-of-function studies suggested that Spi-C functions as a negative 
regulator of transcription by opposing PU.1 activity. Overexpression of Spi-C in cultured 
pro-B cells resulted in decreased FcγRIIb expression and opposed transcription of the 
Fcgr2b gene mediated by PU.1 (Schweitzer et al, 2006). Furthermore, mice 
overexpressing Spi-C under control of the IgH intronic enhancer (Eµ-Spi-C) contained 
pre-B cells and FO B cells with reduced transcript levels of BLNK, Btk, and B220 
compared to WT B cells (Zhu et al, 2008). Eµ-Spi-C B cells also proliferated poorly in 
response to anti-IgM or anti-CD40 (Zhu et al, 2008). Therefore, it was suggested that 
Spi-C impairs B cell function by affecting genes associated with BCR signaling.  
The generation of a Spi-C deficient mouse (Spic
-/-
) has allowed for loss-of-
function analysis for Spi-C. However, Spic
-/-
 mice were initially reported to have no 
abnormalities in B cell development (Kohyama et al, 2009). It is possible that B cells 
from Spic
-/-
 mice could have functional differences, such as increased proliferation to 
TLR ligands or BCR signaling. By using Spib
-/-
Spic
+/-
 mice, it was demonstrated for the 
first time that reduced Spi-C expression can affect B cell proliferation and development. 
Furthermore, Spi-C expression may be normally repressed in B cells. For example, when 
the transcription factors Bach1 and Bach2 are deleted in mice, Spi-C is upregulated in B 
cells and results in altered gene expression patterns (Itoh-Nakadai et al, 2014). The 
authors concluded that expression levels of Spi-C may determine the responsiveness of B 
cells, and may be required for the differentiation and function of mature B cells (Itoh-
Nakadai et al, 2014).  
Overexpression of Spi-C in Spib
-/-
Spic
+/-
 B cells reversed the phenotype 
comparable to Spib
-/-
. LPS-mediated proliferation in Eµ-Spi-C Spib
-/-
Spic
+/-
 mice was 
impaired compared to Spib
-/-
Spic
+/-
, and there was also a significant reduction in total, 
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MZ, and FO B cells in mice overexpressing Spi-C. Therefore, the data suggests that 
relatively low levels of Spi-C expression are required for proper development and 
function in B cells. In previous studies, Eµ-Spi-C mice were crossed to PUB mice (Eµ-
Spi-C PUB) in order to determine if Spi-C could rescue the PUB phenotype. Although 
the Eµ-Spi-C PUB mice had restored frequencies of FO B cells based on CD23 
expression, it remains unclear whether B cell function is restored in these mice. During 
the start of the cumulative studies described in this thesis, some experiments were 
performed on Eµ-Spi-C PUB mice as well. Proliferation studies were performed using 
WT, PUB, and Eµ-Spi-C PUB B cells. In preliminary studies, it was found that Eµ-Spi-C 
PUB B cells proliferated more poorly than PUB B cells in response to various TLR 
ligands (Figure 4.3A-B). Furthermore, transcript expression levels of genes in the TLR 
signaling pathway, with the exception of Myd88 and Irak4, were further reduced in Eµ-
Spi-C PUB MZ B cells compared to PUB MZ B cells (Figure 4.3). At the time, it was 
unclear how overexpression of Spi-C was affecting the PUB phenotype, so those 
experiments were excluded from the manuscript described in Chapter 2. However, since 
there is now additional evidence demonstrating Spi-C’s involvement at being a repressor 
in B cells, these studies now coincide with this idea. Therefore, the data suggests that 
overexpression of Spi-C impairs the ability of B cells to function properly in response to 
TLR ligands, likely due to repression of genes within the TLR signaling pathway.   
Future experiments demonstrating competition between PU.1/Spi-B and Spi-C for 
ETS binding sites would further elucidate the role of Spi-C in gene repression. ChIP 
could be performed in Eµ-Spi-C B cells and WT B cells using anti-PU.1antibody, and 
then PU.1 binding enrichment could be determined at the Nfkb1 promoter by using 
qPCR. By comparing PU.1 enrichment in cells overexpressing Spi-C to those with 
normal Spi-C levels, it would be possible to demonstrate decreased PU.1 enrichment in 
Spi-C overexpressing cells. The same experiment would be performed with Spi-B, but 
there is currently no commercially available anti-mouse Spi-B antibody for effective 
ChIP applications. ChIP-seq has not been performed for Spi-B or Spi-C enrichment in 
naïve B cells. In Chapter 3, a Spi-C antibody was used for ChIP in WEHI-279 3XFLAG-
Spi-C cells; however, the affinity of the anti-Spi-C antibody was weaker than anti-FLAG. 
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ChIP-seq analysis performed on splenic B cells using anti-Spi-C antibody would help in 
determining potential direct targets of Spi-C in primary B cells.  
4.4 Spi-C as a transcriptional activator  
Few target genes have been demonstrated to be directly activated by Spi-C. In B 
cells, Spi-C has been reported to directly activate Fcer2a, which encodes for the IgE low 
affinity Fc receptor (DeKoter et al, 2010), Furthermore, pro-B cells ectopically 
expressing Spi-C have demonstrated direct binding of Spi-C to the IgH intronic enhancer 
to initiate transcription of the Ig heavy chain (Schweitzer et al, 2006). In macrophages, 
Spi-C was reported to directly regulate Vcam1 expression, which encodes for the cell 
adhesion molecule vascular cell adhesion molecule 1 (VCAM-1) (Kohyama et al, 2009). 
Another potential target gene of Spi-C may be Grap2, a SH2 and SH3 domain-containing 
adaptor protein, shown previously to require PU.1 and Spi-B in B cells (Garrett-Sinha et 
al, 2005). Interestingly, Eµ-Spi-C mice expressed elevated levels of Grap2 in FO B cells 
and pre-B cells (Zhu et al, 2008), suggesting that Spi-C could directly activate Grap2 
transcription. Myd88 may be a gene activated by Spi-C, since Eµ-Spi-C PUB MZ B cells 
express elevated transcript levels of Myd88 compared to PUB MZ B cells (Figure 4.3C). 
However, further analysis would need to be done to validate this hypothesis. The list of 
target Spi-C genes could be vastly expanded by performing RNA-seq analyses. RNA 
from sorted B cell subsets from Spib
-/-
Spic
+/- 
and Spib
-/- 
mice would be sequenced, 
aligned, and compared for differences in splicing, promoter use, and transcript 
abundance. Transcript levels of genes decreased in Spib
-/-
Spic
+/- 
compared to Spib
-/-
 
would suggest that Spi-C is involved in its activation. Alternatively, forced Spi-C 
expression could be conducted in the pro-B cell line 38B9 using a MIG-Spi-C retrovirus. 
RNA-seq analysis could be performed on Spi-C overexpressing 38B9 cells and compared 
to control cells to determine target genes of interest. 
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Figure 4.3. Spi-C overexpression in PUB B cells results in further impairment in TLR-
mediated proliferation and altered gene profiles.  
(A) B cells from Eµ-Spi-C PUB mice respond more poorly than PUB B cells stimulated 
with different concentrations of CL097 (TLR7 agonist). (B) B cells from Eµ-Spi-C PUB 
mice responded more poorly than PUB B cells stimulated with indicated TLR9, TLR6/2, 
TLR4, and TLR2/1 ligands. Data shows the mean ± SD for triplicate wells for A-B, and 
is a representative of two independent experiments. ***p<0.001. (C) Altered transcript 
levels of genes related to TLR signaling. RT-qPCR was performed using cDNA isolated 
from WT, PUB, and Eµ-Spi-C PUB MZ B cells. Expression levels shown are relative to 
WT levels. 
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4.5 Intrinsic vs extrinsic effects of PU.1, Spi-B, and Spi-C – 
potential uses of adoptive transfer models 
A caveat to germline knockout models of mice is that the deletion affects all cells, 
leading to both direct and indirect effects of gene loss in the target tissue. Therefore, a 
developmental or function phenotype could be due to defects in multiple cell types. For 
example, Spi-B is expressed in pDCs, and is critical for its development and function 
(Sasaki et al, 2012). Upon TLR7 or TLR9 ligand stimulation, Spib
-/-
 pDCs have impaired 
cytokine production (Sasaki et al, 2012). Therefore, it is possible that the limited 
production of cytokines by pDCs in Spib
-/-
 mice could alter development and function of 
B cells. The possibility of extrinsic effects caused by Spi-C on B cells was partially 
addressed by crossing the Eµ-Spi-C mice to Spib
-/-
Spic
+/-
 mice. Since overexpression of 
Spi-C occurs through the B cell-specific IgH intronic enhancer (Zhu et al, 2008), the 
developmental and proliferation impairment in c mice must have been a cell- intrinsic 
effect of Spi-C in B cells. However, there could still be cell-extrinsic effects on the B cell 
lineage as a result of whole-body loss of Spi-B. To fully address these limitations without 
generating a conditional knockout mouse, adoptive transfer models could be used. Fetal 
liver cells from WT, PUB, Spib
-/-
 and Spib
-/-
Spic
+/-
 mice would be isolated and injected 
into irradiated B cell deficient (µMT) mice, and cells would be allowed to reconstitute for 
four weeks. Flow cytometry analysis could be performed on the blood, spleen, and bone 
marrow to assess B cell development. Defects detected upon knockout cell reconstitution 
would suggest intrinsic effects caused by genes deleted in transferred cells.  
 
4.6 Generation of a conditional knockout model for Spi-C  
While conditional knockout models exist for PU.1 in B cells (Polli et al, 2005; 
Sokalski et al, 2011), similar models have not been generated for Spi-C. Generating a B 
cell conditional knockout mouse for Spi-C using the Cre/LoxP system would be highly 
beneficial. The conditional knockout would bypass the issues of embryonic lethality and 
confounding factors caused by all cells lacking Spi-C. Germline Spic knockout mice 
appear to cause at least partial embryonic lethality (Kohyama et al, 2009), and this 
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observation becomes more apparent when crossing the Spic null allele to mice which are 
germline Spib knockout.  
In order to utilize the Cre/LoxP system, the Spic gene would need to be flanked 
by LoxP sites for targeted deletion. One strategy would be to target exon 6 of the Spic 
gene which contains the ETS DNA binding domain, a similar approach performed for 
Spi1 gene (Polli et al, 2005). The targeting vector would contain LoxP sites flanking 
(floxed) the coding region of exon 6, and a reporter cassette containing IRES-GFP and a 
selection marker neomycin (neo) flanked by Frt sites prior to the 3’ UTR (Figure 4.4). 
Once the vector has been homologously recombined into mouse embryonic stem cells, 
clones could be selected by GFP expression and neomycin resistance. Chimeric mice 
generated would contain GFP in the Spic locus (Spi-C
GFP
), which would allow for 
measuring Spi-C levels by flow cytometry. In order to remove the GFP reporter cassette, 
chimeric mice generated could be crossed to mice expressing flp recombinanse to 
generate Spi-C
lox
 mice. A B cell-specific Cre mouse which could be used is the Mb1-Cre 
mouse, where Cre is expressed under the control of the Ig-α subunit of the BCR. The 
benefit of using the Mb1-Cre mouse rather than the CD19-Cre mouse is that the 
efficiency of targeted deletion is greater (Hobeika et al, 2006). Crossing Spi-C
lox
 mice to 
Mb1-Cre mice would delete the floxed exon 6 of Spi-C to generate Spi-C
Δ
 mice, which 
lack Spi-C expression in the B cell lineage only. In addition, mice with total Spi-C 
deletion in all cells could be generated as controls, by crossing Spi-C
lox
 mice to deleter-
Cre mice (Schwenk et al, 1995).  
It is unclear at which stages of B cell development levels of Spi-C are required for 
proper function or development. Spi-C levels have previously been reported to be lowest 
at fractions A-C in the bone marrow, and highest in immature B cells in the spleen (Zhu 
et al, 2008). The use of Spi-C
GFP
 mice would be useful in comparing the levels of Spi-C 
between different stages of B cell development through the convenience of flow 
cytometry, since GFP expression would correlate with the levels of Spi-C. Since Spi-C is 
involved with blastocyst development (Kageyama et al, 2006), Spi-C
GFP
 mice would be a 
useful system to determine Spi-C expression during embryogenesis. Aside from 
analyzing development in the bone marrow and spleen, B cells from other tissues such as 
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the peritoneal cavity and lymph nodes could be analyzed. It is hypothesized that Spi-C 
has a role in B-1 cell function. In one study, microarray analysis was performed on 
splenic and peritoneal B-1 cells to compare gene expression profiles, and it was found 
that splenic B-1a cells expressed higher Spi-C transcript expression levels compared to 
peritoneal B-1a, B-1b, or splenic B2 cells (Kretschmer et al, 2003). Interestingly, 
CD19
+
CD5
+
 B-1a cells from the peritoneal cavity of Spib
-/-
Spic
+/- 
mice express elevated 
levels of CD19 compared to WT B-1a cells (Figure 3.2C), suggesting that Cd19 
expression may be a repressor target gene of Spi-C. Therefore, levels of Spi-C expression 
may be involved with proper B-1a cell function. 
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Figure 4.4. Conditional deletion of Spi-C. 
Spi-C targeting construct containing exon 6 of Spic flanked by LoxP sites (►). The 
reporter cassette contains an internal ribosome entry site (IRES), green fluorescent 
protein (GFP) and a neomycin (Neo) selection marker flanked by Frt sites (●). GFP and 
Neo are driven by the phosphoglycerate kinase (PGK) promoter. The targeting construct 
is introduced into the Spic locus by homologous recombination to generate Spi-C
GFP
 
mice. The reporter cassette is removed by crossing Spi-C
GFP 
mice to mice expressing flp 
recombinase, generating Spi-C
lox
 mice. Exon 6 of Spic is deleted by crossing Spi-C
lox 
mice with mice expressing Cre recombinase, creating Spi-C
Δ
 mice. 
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4.7 Existing conditional knockout models for PU.1 and Spi-B 
Our laboratory has generated mice with deleted Spi1 under the control of the B 
cell-specific Cd19 locus on a Spib
-/-
 background (CD19
+/cre
Spi1
lox/lox
Spib
-/-
) (Sokalski et 
al, 2011). These mice have few CD19
+
B220
+ 
B cells within the spleen. Moreover, these 
mice develop B cell acute lymphoblastic leukemia with 100% incidence by 21 weeks of 
age (Sokalski et al, 2011). Therefore, B cell deficiency in these mice combined with 
leukemia precludes the use of this model to study mature B cell function. Another 
conditional knockout model which was generated by our lab utilizes the Mb1 gene to 
drive cre-recombinase to delete floxed Spi1 on a Spib
-/-
 background 
(Mb1
+/cre
Spi1
lox/lox
Spib
-/-
). Mb1 encodes for CD79a, a membrane glycoprotein which is 
part of the BCR. The Mb1 driven Spi1 deletion resulted in an elevated fraction C cell 
population and a developmental block at the fraction D stage in the bone marrow (Figure 
4.5A-C). Spleens of Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
mice contained no mature B220
+
IgM
+
 B cells 
in the spleen (Figure 4.5D), but contained an abnormal immature B220
+
CD93
+
 B cell 
population which was negative for both CD21 and IgM (Figure 4.5E-F). The 
B220
+
CD93
-
CD21
-
IgM
-
 B cell population in spleens of Mb1
+/cre
Spi1
lox/lox
Spib
-/-
 mice is 
similar to the leukemic population previously described in CD19
+/cre
Spi1
lox/lox
Spib
-/-
 
(Sokalski et al, 2011). Therefore, Mb1
+/cre
Spi1
lox/lox
Spib
-/-
 are likely prone to developing 
leukemia with age, as observed in CD19
+/cre
Spi1
lox/lox
Spib
-/-
 mice (Sokalski et al, 2011). 
An advantage of the Mb1
+/cre
Spi1
lox/lox
Spib
-/-
 mouse is that the developmental block is 
more defined than in the CD19 condition knockout. It would be possible to determine the 
effects of Spi-C at these early stages of development, since transcript levels of Spi-C rise 
during the transition from CD43
+
 (Fraction A-C) to CD43
-
 (Fraction D-F) stage (Zhu et 
al, 2008). Expression of Spi-C could have a role in the leukemia mouse models. Spi-C 
expression could be either increased or decreased by crossing leukemia prone mice to 
Eµ-Spi-C or Spib
-/-
Spic
+/-
 mice respectively. Since reduction of Spi-C increased 
proliferation in Spib
-/-
 mice, it is conceivable that decreased Spi-C levels in 
CD19
+/cre
Spi1
lox/lox
Spib
-/-
 mice would exacerbate the disease. In contrast, overexpression 
of Spi-C could alleviate the disease, since overexpression of Spi-C in Eµ-Spi-C PUB 
mice decreases B cell proliferation.  
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Figure 4.5. Impaired B cell development in mice deficient in PU.1 and Spi-B. 
(A) Bone marrow cells gated on B220 and CD43 for identifying “Hardy” B cell fractions 
in bone marrow. (B) Increased Fraction C population (BP-1
+
CD24
+
B220
+
CD43
+
) in 
Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
bone marrow. (C) Developmental block at Fraction D 
(B220
+
IgM
-
CD43
-
) in Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
bone marrow. (D) Absence of mature 
B220
+
IgM
+
 cells in the spleen of Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
mice. (E) An abnormal CD93
hi
 
immature B cell population exists in the Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
spleen. (F) The immature 
B cells in Mb1
+/cre
Spi1
lox/lox
Spib
-/- 
spleen are primarily CD21 and IgM negative. Analysis 
for A-F was performed by flow cytometry and are a representative of 3 independent 
experiments.  
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4.8 In Vivo Studies 
Proliferation studies performed in this thesis were ex vivo models. Primary B cells 
were isolated from the spleens of mice and cultured in media with TLR-ligands. The 
measured response in an in vitro culture system is a simplification a cell’s response. 
Since the B cells are no longer in their native environment, they are not in contact with 
other cell types within the confines of the structural organ, or with cytokines produced by 
other cells which could influence the response in B cells. Therefore, in vivo proliferation 
studies could be performed to further enhance the current results of this thesis. A 
common method to measure proliferation in vivo is based on 5-Bromo-2’-Deoxyuridine 
(BrdU) incorporation and detection by flow cytometry (Carayon & Bord, 1992). 
Proliferation analysis by BrdU incorporation would allow multiple B cell subsets to be 
simultaneously measured between different strains of mice, following inoculation with 
specific antigens such as DNP-KLH or DNP-LPS.  
Unfortunately for the described studies in chapter 2 and chapter 3, in vivo 
response studies could not be effectively performed since the mice were housed in a 
conventional facility. For future studies, the mice would need to be re-derived in a 
specific pathogen free animal facility for proper in vivo studies. WT, Spib
-/-
, and Spib
-/-
Spic
+/-
 mice immunized for DNP-KLH or DNP-LPS would be used to differentiate 
differences in TD and TI immune responses respectively. Flow cytometry and 
immunohistochemistry analysis could be performed on the spleen and lymph nodes to 
assess differences in germinal center formation. Anti-DNP-KLH or anti-DNP-LPS 
ELISAs could determine differences in antibody production using serum collected from 
mice. Immunization studies performed in Spib
-/-
Spic
+/-
 mice would determine whether 
Spi-C has an effect on germinal center formation, or antibody production. 
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4.9 Significance of these studies 
ETS transcription factors are likely involved with transcriptionally regulating 
BCR and TLR signaling genes. Since TLR and BCR signaling are both required for 
optimal antibody responses, PU.1, Spi-B, and Spi-C can potentially regulate antibody 
formation. Studying the regulatory interactions between TLR and BCR signaling will 
allow improved predictions of B cell responses during immunization approaches. 
Determining the genes essential for antibody formation could provide therapeutic 
interventions for immunodeficiencies, or improve development of effective vaccines. 
Determining how B cells respond to different antigens can lead to novel developments of 
vaccine adjuvants or synthetic vaccines designed to activate appropriate amounts of TLR 
and BCR signaling.  
Proper levels of Spi-C likely need to be regulated during B cell development. I 
hypothesize that reduced Spi-C levels can alter B cell function during development 
through the transitional B cell stages. Peripheral tolerance of B cells may be regulated by 
Spi-C through BCR signaling genes. Spi-C may negatively regulate genes involved in 
BCR signaling, which can affect the differentiation of T1 to T2 B cells. The 
developmental block at the T2 stage in Spib
-/-
 mice could result from a combination of 
Spi-B failing to activate BCR signaling genes, and Spi-C inhibiting those same genes. 
Reduced Spi-C expression could potentially alleviate defects in antibody production 
observed in Spib
-/-
 mice. It is possible that as Spic
-/- 
mice age, these mice could be prone 
to developing autoimmune or leukemic diseases due to an accumulation of T1 B cells and 
a failure of peripheral tolerance.  
 
4.10 Concluding Remarks  
The long-term goal of this research is to understand how ETS transcription factors 
regulate B cell development and control immune responses to TI and TD antigens. The 
studies presented in this thesis demonstrate the importance of the ETS transcription 
factors PU.1, Spi-B, and Spi-C in directly regulating Nfkb1 transcription, which is highly 
involved in humoral immune responses and B cell development. The network of 
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transcription factors regulating other transcription factors gives appreciable insight to the 
complexity of gene regulation. 
Studies on Spi-C are still at their infancy. Most published studies have attributed 
Spi-C towards a function in macrophages, but its expression is not limited to one 
particular cell type.  By determining that Spi-C has a negative regulatory role in B cell 
development and function, our study provides new insight on how PU.1 and Spi-B target 
genes are regulated. Nfkb1 is one of many genes likely regulated in opposing fashion 
between PU.1/Spi-B and Spi-C. Genes activated by PU.1 and Spi-B during antibody 
responses, drug treatments, and cancer growth could all be influenced by Spi-C’s 
inhibition. Hopefully, the advancement of this work yields new questions and answers in 
the fields of transcriptional regulation and B cell biology.  
149 
 
References 
 
Alberghini F, Petrocelli V, Rahmat M, Casola S (2015) An epigenetic view of B-cell 
disorders. Immunology and cell biology 93: 253-260 
 
Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell 
MA, Edelhoff S, Disteche CM, Simoneaux DK, et al. (1993) CD40 ligand gene defects 
responsible for X-linked hyper-IgM syndrome. Science 259: 990-993 
 
Back J, Allman D, Chan S, Kastner P (2005) Visualizing PU.1 activity during 
hematopoiesis. Experimental hematology 33: 395-402 
 
Baeuerle PA, Baltimore D (1988) I kappa B: a specific inhibitor of the NF-kappa B 
transcription factor. Science 242: 540-546 
 
Barber CL, Montecino-Rodriguez E, Dorshkind K (2011) Reduced production of B-1-
specified common lymphoid progenitors results in diminished potential of adult marrow 
to generate B-1 cells. Proceedings of the National Academy of Sciences of the United 
States of America 108: 13700-13704 
 
Bartel FO, Higuchi T, Spyropoulos DD (2000) Mouse models in the study of the Ets 
family of transcription factors. Oncogene 19: 6443-6454 
 
Baumgarth N (2011) The double life of a B-1 cell: self-reactivity selects for protective 
effector functions. Nature reviews Immunology 11: 34-46 
 
Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D (1995) Embryonic lethality and 
liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376: 167-
170 
 
150 
 
Bekeredjian-Ding I, Jego G (2009) Toll-like receptors--sentries in the B-cell response. 
Immunology 128: 311-323 
 
Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR (2005) The 
molecular structure of the Toll-like receptor 3 ligand-binding domain. Proceedings of the 
National Academy of Sciences of the United States of America 102: 10976-10980 
 
Bell S, Matthews JR, Jaffray E, Hay RT (1996) I(kappa)B(gamma) inhibits DNA binding 
of NF-kappaB p50 homodimers by interacting with residues that contact DNA. 
Molecular and cellular biology 16: 6477-6485 
 
Bemark M, Martensson A, Liberg D, Leanderson T (1999) Spi-C, a novel Ets protein that 
is temporally regulated during B lymphocyte development. The Journal of biological 
chemistry 274: 10259-10267 
 
Blankenberg D, Von Kuster G, Coraor N, Ananda G, Lazarus R, Mangan M, Nekrutenko 
A, Taylor J (2010) Galaxy: a web-based genome analysis tool for experimentalists. Curr 
Protoc Mol Biol Chapter 19: Unit 19 10 11-21 
 
Bone H, Williams NA (2001) Antigen-receptor cross-linking and lipopolysaccharide 
trigger distinct phosphoinositide 3-kinase-dependent pathways to NF-kappa B activation 
in primary B cells. International immunology 13: 807-816 
 
Botos I, Segal DM, Davies DR (2011) The structural biology of Toll-like receptors. 
Structure 19: 447-459 
 
Bouaziz JD, Le Buanec H, Saussine A, Bensussan A, Bagot M (2012) IL-10 producing 
regulatory B cells in mice and humans: state of the art. Current molecular medicine 12: 
519-527 
 
151 
 
Brass AL, Zhu AQ, Singh H (1999) Assembly requirements of PU.1-Pip (IRF-4) 
activator complexes: inhibiting function in vivo using fused dimers. The EMBO journal 
18: 977-991 
 
Browne EP (2012) Regulation of B-cell responses by Toll-like receptors. Immunology 
136: 370-379 
 
Buchner M, Swaminathan S, Chen Z, Muschen M (2015) Mechanisms of pre-B-cell 
receptor checkpoint control and its oncogenic subversion in acute lymphoblastic 
leukemia. Immunological reviews 263: 192-209 
 
Burger JA, Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic 
leukemia. Trends in immunology 34: 592-601 
 
Caamano JH, Rizzo CA, Durham SK, Barton DS, Raventos-Suarez C, Snapper CM, 
Bravo R (1998) Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic 
microarchitecture and B cell-mediated immune responses. The Journal of experimental 
medicine 187: 185-196 
 
Carayon P, Bord A (1992) Identification of DNA-replicating lymphocyte subsets using a 
new method to label the bromo-deoxyuridine incorporated into the DNA. Journal of 
immunological methods 147: 225-230 
 
Care MA, Cocco M, Laye JP, Barnes N, Huang Y, Wang M, Barrans S, Du M, Jack A, 
Westhead DR, Doody GM, Tooze RM (2014) SPIB and BATF provide alternate 
determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease 
heterogeneity. Nucleic acids research 42: 7591-7610 
 
Cariappa A, Liou HC, Horwitz BH, Pillai S (2000) Nuclear factor kappa B is required for 
the development of marginal zone B lymphocytes. The Journal of experimental medicine 
192: 1175-1182 
152 
 
 
Carlsson R, Hjalmarsson A, Liberg D, Persson C, Leanderson T (2002) Genomic 
structure of mouse SPI-C and genomic structure and expression pattern of human SPI-C. 
Gene 299: 271-278 
 
Carlsson R, Persson C, Leanderson T (2003) SPI-C, a PU-box binding ETS protein 
expressed temporarily during B-cell development and in macrophages, contains an acidic 
transactivation domain located to the N-terminus. Molecular immunology 39: 1035-1043 
 
Carlsson R, Thorell K, Liberg D, Leanderson T (2006) SPI-C and STAT6 can cooperate 
to stimulate IgE germline transcription. Biochemical and biophysical research 
communications 344: 1155-1160 
 
Carotta S, Wu L, Nutt SL (2010) Surprising new roles for PU.1 in the adaptive immune 
response. Immunological reviews 238: 63-75 
 
Castellanos MC, Munoz C, Montoya MC, Lara-Pezzi E, Lopez-Cabrera M, de Landazuri 
MO (1997) Expression of the leukocyte early activation antigen CD69 is regulated by the 
transcription factor AP-1. Journal of immunology 159: 5463-5473 
 
Cesta MF (2006) Normal structure, function, and histology of the spleen. Toxicologic 
pathology 34: 455-465 
 
Chan O, Shlomchik MJ (1998) A new role for B cells in systemic autoimmunity: B cells 
promote spontaneous T cell activation in MRL-lpr/lpr mice. Journal of immunology 160: 
51-59 
 
Chen FE, Huang DB, Chen YQ, Ghosh G (1998) Crystal structure of p50/p65 
heterodimer of transcription factor NF-kappaB bound to DNA. Nature 391: 410-413 
 
153 
 
Chung JB, Silverman M, Monroe JG (2003) Transitional B cells: step by step towards 
immune competence. Trends in immunology 24: 343-349 
 
Ciau-Uitz A, Wang L, Patient R, Liu F (2013) ETS transcription factors in hematopoietic 
stem cell development. Blood cells, molecules & diseases 51: 248-255 
 
Claudio E, Brown K, Park S, Wang H, Siebenlist U (2002) BAFF-induced NEMO-
independent processing of NF-kappa B2 in maturing B cells. Nature immunology 3: 958-
965 
 
Cogswell PC, Scheinman RI, Baldwin AS, Jr. (1993) Promoter of the human NF-kappa B 
p50/p105 gene. Regulation by NF-kappa B subunits and by c-REL. Journal of 
immunology 150: 2794-2804 
 
Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, 
Howard V, Campana D (2009) Primary B cell immunodeficiencies: comparisons and 
contrasts. Annual review of immunology 27: 199-227 
 
Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J (1998) Mutations in btk in 
patients with presumed X-linked agammaglobulinemia. American journal of human 
genetics 62: 1034-1043 
 
Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical 
and immunological features of 248 patients. Clinical immunology 92: 34-48 
 
Dahl R, Ramirez-Bergeron DL, Rao S, Simon MC (2002) Spi-B can functionally replace 
PU.1 in myeloid but not lymphoid development. The EMBO journal 21: 2220-2230 
 
Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H (2005) Expression of toll-like 
receptors on B lymphocytes. Cellular immunology 236: 140-145 
 
154 
 
Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor 
kappaB activity is required for survival of activated B cell-like diffuse large B cell 
lymphoma cells. The Journal of experimental medicine 194: 1861-1874 
 
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy 
L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas 
CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson 
NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, 
Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM 
(2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 
Nature 463: 88-92 
 
DeKoter RP, Geadah M, Khoosal S, Xu LS, Thillainadesan G, Torchia J, Chin SS, 
Garrett-Sinha LA (2010) Regulation of follicular B cell differentiation by the related E26 
transformation-specific transcription factors PU.1, Spi-B, and Spi-C. Journal of 
immunology 185: 7374-7384 
 
DeKoter RP, Singh H (2000) Regulation of B lymphocyte and macrophage development 
by graded expression of PU.1. Science 288: 1439-1441 
 
Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg 
RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL (2005) Negative 
regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. 
Nature immunology 6: 571-578 
 
Doi TS, Marino MW, Takahashi T, Yoshida T, Sakakura T, Old LJ, Obata Y (1999) 
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. 
Proceedings of the National Academy of Sciences of the United States of America 96: 
2994-2999 
 
155 
 
Donahue AC, Fruman DA (2003) Proliferation and survival of activated B cells requires 
sustained antigen receptor engagement and phosphoinositide 3-kinase activation. Journal 
of immunology 170: 5851-5860 
 
Ehlich A, Schaal S, Gu H, Kitamura D, Muller W, Rajewsky K (1993) Immunoglobulin 
heavy and light chain genes rearrange independently at early stages of B cell 
development. Cell 72: 695-704 
 
Escalante CR, Brass AL, Pongubala JM, Shatova E, Shen L, Singh H, Aggarwal AK 
(2002) Crystal structure of PU.1/IRF-4/DNA ternary complex. Molecular cell 10: 1097-
1105 
 
Eyquem S, Chemin K, Fasseu M, Chopin M, Sigaux F, Cumano A, Bories JC (2004) The 
development of early and mature B cells is impaired in mice deficient for the Ets-1 
transcription factor. European journal of immunology 34: 3187-3196 
 
Ferguson AR, Corley RB (2005) Accumulation of marginal zone B cells and accelerated 
loss of follicular dendritic cells in NF-kappaB p50-deficient mice. BMC immunology 6: 8 
 
Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, Grinberg A, Tran 
T, Scharton-Kersten T, Anver M, Love P, Brown K, Siebenlist U (1998) Mice deficient 
in nuclear factor (NF)-kappa B/p52 present with defects in humoral responses, germinal 
center reactions, and splenic microarchitecture. The Journal of experimental medicine 
187: 147-159 
 
Fugier-Vivier I, de Bouteiller O, Guret C, Fossiez F, Banchereau J, Mattei MG, Ait-
Yahia S, Garcia E, Lebecque S, Liu YJ (1997) Molecular cloning of human RP105. 
European journal of immunology 27: 1824-1827 
 
Fuleihan RL (1998) The X-linked hyperimmunoglobulin M syndrome. Seminars in 
hematology 35: 321-331 
156 
 
 
Garrett-Sinha LA (2013) Review of Ets1 structure, function, and roles in immunity. 
Cellular and molecular life sciences : CMLS 70: 3375-3390 
 
Garrett-Sinha LA, Hou P, Wang D, Grabiner B, Araujo E, Rao S, Yun TJ, Clark EA, 
Simon MC, Clark MR (2005) Spi-1 and Spi-B control the expression of the Grap2 gene 
in B cells. Gene 353: 134-146 
 
Garrett-Sinha LA, Su GH, Rao S, Kabak S, Hao Z, Clark MR, Simon MC (1999) PU.1 
and Spi-B are required for normal B cell receptor-mediated signal transduction. Immunity 
10: 399-408 
 
Gay D, Saunders T, Camper S, Weigert M (1993) Receptor editing: an approach by 
autoreactive B cells to escape tolerance. The Journal of experimental medicine 177: 999-
1008 
 
Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, Defrance T (2007) TLR 
agonists selectively promote terminal plasma cell differentiation of B cell subsets 
specialized in thymus-independent responses. Journal of immunology 178: 7779-7786 
 
Gerondakis S, Grumont RJ, Banerjee A (2007) Regulating B-cell activation and survival 
in response to TLR signals. Immunology and cell biology 85: 471-475 
 
Giardine B, Riemer C, Hardison RC, Burhans R, Elnitski L, Shah P, Zhang Y, 
Blankenberg D, Albert I, Taylor J, Miller W, Kent WJ, Nekrutenko A (2005) Galaxy: a 
platform for interactive large-scale genome analysis. Genome Res 15: 1451-1455 
 
Goecks J, Nekrutenko A, Taylor J (2010) Galaxy: a comprehensive approach for 
supporting accessible, reproducible, and transparent computational research in the life 
sciences. Genome Biol 11: R86 
 
157 
 
Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, Eibel H, 
Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH (2003) Homozygous loss of 
ICOS is associated with adult-onset common variable immunodeficiency. Nature 
immunology 4: 261-268 
 
Grumont RJ, Rourke IJ, O'Reilly LA, Strasser A, Miyake K, Sha W, Gerondakis S (1998) 
B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) 
transcription factors to regulate cell cycle progression and apoptosis in quiescent and 
mitogen-activated cells. The Journal of experimental medicine 187: 663-674 
 
Guo F, Weih D, Meier E, Weih F (2007) Constitutive alternative NF-kappaB signaling 
promotes marginal zone B-cell development but disrupts the marginal sinus and induces 
HEV-like structures in the spleen. Blood 110: 2381-2389 
 
Gururajan M, Jacob J, Pulendran B (2007) Toll-like receptor expression and 
responsiveness of distinct murine splenic and mucosal B-cell subsets. PloS one 2: e863 
 
Hagege H, Klous P, Braem C, Splinter E, Dekker J, Cathala G, de Laat W, Forne T 
(2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). 
Nature protocols 2: 1722-1733 
 
Haldar M, Kohyama M, So AY, Kc W, Wu X, Briseno CG, Satpathy AT, Kretzer NM, 
Arase H, Rajasekaran NS, Wang L, Egawa T, Igarashi K, Baltimore D, Murphy TL, 
Murphy KM (2014) Heme-mediated SPI-C induction promotes monocyte differentiation 
into iron-recycling macrophages. Cell 156: 1223-1234 
 
Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K (1991) Resolution and 
characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. The 
Journal of experimental medicine 173: 1213-1225 
 
158 
 
Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain 
SL, Lund FE (2000) Reciprocal regulation of polarized cytokine production by effector B 
and T cells. Nature immunology 1: 475-482 
 
Hashimoto C, Hudson KL, Anderson KV (1988) The Toll gene of Drosophila, required 
for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 
52: 269-279 
 
Hashimoto S, Nishizumi H, Hayashi R, Tsuboi A, Nagawa F, Takemori T, Sakano H 
(1999) Prf, a novel Ets family protein that binds to the PU.1 binding motif, is specifically 
expressed in restricted stages of B cell development. International immunology 11: 1423-
1429 
 
Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132: 344-
362 
 
Hayden MS, Ghosh S (2012) NF-kappaB, the first quarter-century: remarkable progress 
and outstanding questions. Genes Dev 26: 203-234 
 
Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh 
H, Glass CK (2010) Simple combinations of lineage-determining transcription factors 
prime cis-regulatory elements required for macrophage and B cell identities. Molecular 
cell 38: 576-589 
 
Heron E, Deloukas P, van Loon AP (1995) The complete exon-intron structure of the 
156-kb human gene NFKB1, which encodes the p105 and p50 proteins of transcription 
factors NF-kappa B and I kappa B-gamma: implications for NF-kappa B-mediated signal 
transduction. Genomics 30: 493-505 
 
Himmelmann A, Thevenin C, Harrison K, Kehrl JH (1996) Analysis of the Bruton's 
tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites. Blood 87: 1036-1044 
159 
 
 
Hobeika E, Thiemann S, Storch B, Jumaa H, Nielsen PJ, Pelanda R, Reth M (2006) 
Testing gene function early in the B cell lineage in mb1-cre mice. Proceedings of the 
National Academy of Sciences of the United States of America 103: 13789-13794 
 
Homig-Holzel C, Hojer C, Rastelli J, Casola S, Strobl LJ, Muller W, Quintanilla-
Martinez L, Gewies A, Ruland J, Rajewsky K, Zimber-Strobl U (2008) Constitutive 
CD40 signaling in B cells selectively activates the noncanonical NF-kappaB pathway and 
promotes lymphomagenesis. The Journal of experimental medicine 205: 1317-1329 
 
Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, 
Hartmann G (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular 
subsets of human peripheral blood mononuclear cells and sensitivity to CpG 
oligodeoxynucleotides. Journal of immunology 168: 4531-4537 
 
Houston IB, Kamath MB, Schweitzer BL, Chlon TM, DeKoter RP (2007) Reduction in 
PU.1 activity results in a block to B-cell development, abnormal myeloid proliferation, 
and neonatal lethality. Experimental hematology 35: 1056-1068 
 
Hu CJ, Rao S, Ramirez-Bergeron DL, Garrett-Sinha LA, Gerondakis S, Clark MR, 
Simon MC (2001) PU.1/Spi-B regulation of c-rel is essential for mature B cell survival. 
Immunity 15: 545-555 
 
Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L (2014) Toll-like 
receptors in the pathogenesis of human B cell malignancies. Journal of hematology & 
oncology 7: 57 
 
Itoh-Nakadai A, Hikota R, Muto A, Kometani K, Watanabe-Matsui M, Sato Y, 
Kobayashi M, Nakamura A, Miura Y, Yano Y, Tashiro S, Sun J, Ikawa T, Ochiai K, 
Kurosaki T, Igarashi K (2014) The transcription repressors Bach2 and Bach1 promote B 
cell development by repressing the myeloid program. Nature immunology 15: 1171-1180 
160 
 
 
Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, 
consequences, and therapeutic implications. Blood 109: 2700-2707 
 
Kageyama S-i, Liu H, Nagata M, Aoki F (2006) The role of ETS transcription factors in 
transcription and development of mouse preimplantation embryos. Biochemical and 
biophysical research communications 344: 675-679 
 
Kanaya T, Hase K, Takahashi D, Fukuda S, Hoshino K, Sasaki I, Hemmi H, Knoop KA, 
Kumar N, Sato M, Katsuno T, Yokosuka O, Toyooka K, Nakai K, Sakamoto A, Kitahara 
Y, Jinnohara T, McSorley SJ, Kaisho T, Williams IR, Ohno H (2012) The Ets 
transcription factor Spi-B is essential for the differentiation of intestinal microfold cells. 
Nature immunology 13: 729-736 
 
Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, 
Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, 
Garcia-Sastre A, Compans R, Pulendran B (2011) Programming the magnitude and 
persistence of antibody responses with innate immunity. Nature 470: 543-547 
 
Kawai T, Akira S (2006) TLR signaling. Cell death and differentiation 13: 816-825 
 
Kawai T, Akira S (2007) TLR signaling. Seminars in immunology 19: 24-32 
 
Kikuchi K, Kondo M (2006) Developmental switch of mouse hematopoietic stem cells 
from fetal to adult type occurs in bone marrow after birth. Proceedings of the National 
Academy of Sciences of the United States of America 103: 17852-17857 
 
Kohyama M, Ise W, Edelson BT, Wilker PR, Hildner K, Mejia C, Frazier WA, Murphy 
TL, Murphy KM (2009) Role for Spi-C in the development of red pulp macrophages and 
splenic iron homeostasis. Nature 457: 318-321 
 
161 
 
Kontgen F, Grumont RJ, Strasser A, Metcalf D, Li R, Tarlinton D, Gerondakis S (1995) 
Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, 
humoral immunity, and interleukin-2 expression. Genes & development 9: 1965-1977 
 
Kretschmer K, Jungebloud A, Stopkowicz J, Stoermann B, Hoffmann R, Weiss S (2003) 
Antibody repertoire and gene expression profile: implications for different developmental 
and functional traits of splenic and peritoneal B-1 lymphocytes. Journal of immunology 
171: 1192-1201 
 
Kreuzaler M, Rauch M, Salzer U, Birmelin J, Rizzi M, Grimbacher B, Plebani A, 
Lougaris V, Quinti I, Thon V, Litzman J, Schlesier M, Warnatz K, Thiel J, Rolink AG, 
Eibel H (2012) Soluble BAFF levels inversely correlate with peripheral B cell numbers 
and the expression of BAFF receptors. Journal of immunology 188: 497-503 
 
Lambert PF, Ludford-Menting MJ, Deacon NJ, Kola I, Doherty RR (1997) The nfkb1 
promoter is controlled by proteins of the Ets family. Molecular biology of the cell 8: 313-
323 
 
Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient 
alignment of short DNA sequences to the human genome. Genome Biol 10: R25 
 
Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nature reviews 
Immunology 2: 725-734 
 
Li SK, Abbas AK, Solomon LA, M. GG, DeKoter RP (2015) Nfkb1 Activation by the 
ETS Transcription Factors PU.1 and Spi-B Promotes Toll-Like Receptor-Mediated 
Splenic B cell Proliferation. Molecular and cellular biology 35: 1619-1632 
 
Li YS, Wasserman R, Hayakawa K, Hardy RR (1996) Identification of the earliest B 
lineage stage in mouse bone marrow. Immunity 5: 527-535 
 
162 
 
Liou HC, Sha WC, Scott ML, Baltimore D (1994) Sequential induction of NF-kappa 
B/Rel family proteins during B-cell terminal differentiation. Molecular and cellular 
biology 14: 5349-5359 
 
Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H, Cao X (2011) Intracellular MHC 
class II molecules promote TLR-triggered innate immune responses by maintaining 
activation of the kinase Btk. Nature immunology 12: 416-424 
 
Lopez-Cabrera M, Munoz E, Blazquez MV, Ursa MA, Santis AG, Sanchez-Madrid F 
(1995) Transcriptional regulation of the gene encoding the human C-type lectin leukocyte 
receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-
responsive elements. The Journal of biological chemistry 270: 21545-21551 
 
Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A (1998) Survival of long-lived 
plasma cells is independent of antigen. International immunology 10: 1703-1711 
 
Martin F, Kearney JF (2000) B-cell subsets and the mature preimmune repertoire. 
Marginal zone and B1 B cells as part of a "natural immune memory". Immunological 
reviews 175: 70-79 
 
Maston GA, Evans SK, Green MR (2006) Transcriptional regulatory elements in the 
human genome. Annual review of genomics and human genetics 7: 29-59 
 
McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, Klemsz 
M, Feeney AJ, Wu GE, Paige CJ, Maki RA (1996) Targeted disruption of the PU.1 gene 
results in multiple hematopoietic abnormalities. The EMBO journal 15: 5647-5658 
 
McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, 
Bejerano G (2010) GREAT improves functional interpretation of cis-regulatory regions. 
Nature biotechnology 28: 495-501 
 
163 
 
Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. (1997) A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397 
 
Minegishi Y, Coustan-Smith E, Rapalus L, Ersoy F, Campana D, Conley ME (1999a) 
Mutations in Igalpha (CD79a) result in a complete block in B-cell development. The 
Journal of clinical investigation 104: 1115-1121 
 
Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME (1998) 
Mutations in the human lambda5/14.1 gene result in B cell deficiency and 
agammaglobulinemia. The Journal of experimental medicine 187: 71-77 
 
Minegishi Y, Rohrer J, Coustan-Smith E, Lederman HM, Pappu R, Campana D, Chan 
AC, Conley ME (1999b) An essential role for BLNK in human B cell development. 
Science 286: 1954-1957 
 
Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M (1995) RP105, a novel B cell 
surface molecule implicated in B cell activation, is a member of the leucine-rich repeat 
protein family. Journal of immunology 154: 3333-3340 
 
Montecino-Rodriguez E, Dorshkind K (2012) B-1 B cell development in the fetus and 
adult. Immunity 36: 13-21 
 
Moreau-Gachelin F, Tavitian A, Tambourin P (1988) Spi-1 is a putative oncogene in 
virally induced murine erythroleukaemias. Nature 331: 277-280 
 
Morel L (2004) Mouse models of human autoimmune diseases: essential tools that 
require the proper controls. PLoS biology 2: E241 
 
Morita S, Kojima T, Kitamura T (2000) Plat-E: an efficient and stable system for 
transient packaging of retroviruses. Gene Ther 7: 1063-1066 
 
164 
 
Muller S, Sideras P, Smith CI, Xanthopoulos KG (1996) Cell specific expression of 
human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and 
Spi-1/PU.1-family members. Oncogene 13: 1955-1964 
 
Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T (2000) Class 
switch recombination and hypermutation require activation-induced cytidine deaminase 
(AID), a potential RNA editing enzyme. Cell 102: 553-563 
 
Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, 
Kimoto M, Miyake K (2002a) Essential role of MD-2 in LPS responsiveness and TLR4 
distribution. Nature immunology 3: 667-672 
 
Nagai Y, Shimazu R, Ogata H, Akashi S, Sudo K, Yamasaki H, Hayashi S, Iwakura Y, 
Kimoto M, Miyake K (2002b) Requirement for MD-1 in cell surface expression of 
RP105/CD180 and B-cell responsiveness to lipopolysaccharide. Blood 99: 1699-1705 
 
Nagai Y, Yanagibashi T, Watanabe Y, Ikutani M, Kariyone A, Ohta S, Hirai Y, Kimoto 
M, Miyake K, Takatsu K (2012) The RP105/MD-1 complex is indispensable for 
TLR4/MD-2-dependent proliferation and IgM-secreting plasma cell differentiation of 
marginal zone B cells. International immunology 24: 389-400 
 
Nagasawa T (2006) Microenvironmental niches in the bone marrow required for B-cell 
development. Nature reviews Immunology 6: 107-116 
 
Nakashima M, Kinoshita M, Nakashima H, Habu Y, Miyazaki H, Shono S, Hiroi S, 
Shinomiya N, Nakanishi K, Seki S (2012) Pivotal advance: characterization of mouse 
liver phagocytic B cells in innate immunity. Journal of leukocyte biology 91: 537-546 
 
Nemazee D, Buerki K (1989) Clonal deletion of autoreactive B lymphocytes in bone 
marrow chimeras. Proceedings of the National Academy of Sciences of the United States 
of America 86: 8039-8043 
165 
 
 
Ni M, MacFarlane AWt, Toft M, Lowell CA, Campbell KS, Hamerman JA (2012) B-cell 
adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through 
activation of PI3K. Proceedings of the National Academy of Sciences of the United States 
of America 109: 267-272 
 
Nossal GJ, Pike BL (1980) Clonal anergy: persistence in tolerant mice of antigen-binding 
B lymphocytes incapable of responding to antigen or mitogen. Proceedings of the 
National Academy of Sciences of the United States of America 77: 1602-1606 
 
Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L (2005) Dynamic regulation of PU.1 
expression in multipotent hematopoietic progenitors. The Journal of experimental 
medicine 201: 221-231 
 
Obukhanych TV, Nussenzweig MC (2006) T-independent type II immune responses 
generate memory B cells. The Journal of experimental medicine 203: 305-310 
 
Ogata H, Su I, Miyake K, Nagai Y, Akashi S, Mecklenbrauker I, Rajewsky K, Kimoto 
M, Tarakhovsky A (2000) The toll-like receptor protein RP105 regulates 
lipopolysaccharide signaling in B cells. The Journal of experimental medicine 192: 23-29 
 
Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF (1997) Marginal zone B cells 
exhibit unique activation, proliferative and immunoglobulin secretory responses. 
European journal of immunology 27: 2366-2374 
 
Oliver AM, Martin F, Kearney JF (1999) IgMhighCD21high lymphocytes enriched in the 
splenic marginal zone generate effector cells more rapidly than the bulk of follicular B 
cells. Journal of immunology 162: 7198-7207 
 
Ong CT, Corces VG (2011) Enhancer function: new insights into the regulation of tissue-
specific gene expression. Nature reviews Genetics 12: 283-293 
166 
 
 
Packham G, Krysov S, Allen A, Savelyeva N, Steele AJ, Forconi F, Stevenson FK (2014) 
The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation 
or anergy. Haematologica 99: 1138-1148 
 
Parra D, Rieger AM, Li J, Zhang YA, Randall LM, Hunter CA, Barreda DR, Sunyer JO 
(2012) Pivotal advance: peritoneal cavity B-1 B cells have phagocytic and microbicidal 
capacities and present phagocytosed antigen to CD4+ T cells. Journal of leukocyte 
biology 91: 525-536 
 
Pasare C, Medzhitov R (2005) Control of B-cell responses by Toll-like receptors. Nature 
438: 364-368 
 
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, Pendergast AM, Bronson 
R, Aster JC, Scott ML, Baltimore D (1998) Efficient and rapid induction of a chronic 
myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-
transduced bone marrow. Blood 92: 3780-3792 
 
Perlot T, Li G, Alt FW (2008) Antisense transcripts from immunoglobulin heavy-chain 
locus V(D)J and switch regions. Proceedings of the National Academy of Sciences of the 
United States of America 105: 3843-3848 
 
Peters LL, Ciciotte SL, Su GH, Simon MC (1997) The gene encoding the transcription 
factor Spi-B maps to mouse chromosome 7. Mammalian genome : official journal of the 
International Mammalian Genome Society 8: 452-453 
 
Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for 
group-wise comparison and statistical analysis of relative expression results in real-time 
PCR. Nucleic acids research 30: e36 
 
167 
 
Pillai S, Cariappa A (2009) The follicular versus marginal zone B lymphocyte cell fate 
decision. Nature reviews Immunology 9: 767-777 
 
Pillai S, Cariappa A, Moran ST (2005) Marginal zone B cells. Annual review of 
immunology 23: 161-196 
 
Pio F, Kodandapani R, Ni CZ, Shepard W, Klemsz M, McKercher SR, Maki RA, Ely KR 
(1996) New insights on DNA recognition by ets proteins from the crystal structure of the 
PU.1 ETS domain-DNA complex. The Journal of biological chemistry 271: 23329-23337 
 
Plotkin SA (2009) Vaccines: the fourth century. Clinical and vaccine immunology : CVI 
16: 1709-1719 
 
Pohl T, Gugasyan R, Grumont RJ, Strasser A, Metcalf D, Tarlinton D, Sha W, Baltimore 
D, Gerondakis S (2002) The combined absence of NF-kappa B1 and c-Rel reveals that 
overlapping roles for these transcription factors in the B cell lineage are restricted to the 
activation and function of mature cells. Proceedings of the National Academy of Sciences 
of the United States of America 99: 4514-4519 
 
Polli M, Dakic A, Light A, Wu L, Tarlinton DM, Nutt SL (2005) The development of 
functional B lymphocytes in conditional PU.1 knock-out mice. Blood 106: 2083-2090 
 
Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva 
M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) 
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. 
Science 282: 2085-2088 
 
Pone EJ, Zan H, Zhang J, Al-Qahtani A, Xu Z, Casali P (2010) Toll-like receptors and B-
cell receptors synergize to induce immunoglobulin class-switch DNA recombination: 
relevance to microbial antibody responses. Critical reviews in immunology 30: 1-29 
 
168 
 
Pongubala JM, Atchison ML (1997) PU.1 can participate in an active enhancer complex 
without its transcriptional activation domain. Proceedings of the National Academy of 
Sciences of the United States of America 94: 127-132 
 
Prendes M, Zheng Y, Beg AA (2003) Regulation of developing B cell survival by RelA-
containing NF-kappa B complexes. Journal of immunology 171: 3963-3969 
 
Racine R, Winslow GM (2009) IgM in microbial infections: taken for granted? 
Immunology letters 125: 79-85 
 
Rao S, Matsumura A, Yoon J, Simon MC (1999) SPI-B activates transcription via a 
unique proline, serine, and threonine domain and exhibits DNA binding affinity 
differences from PU.1. The Journal of biological chemistry 274: 11115-11124 
 
Ray-Gallet D, Mao C, Tavitian A, Moreau-Gachelin F (1995) DNA binding specificities 
of Spi-1/PU.1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding 
site in the c-fes/c-fps promoter. Oncogene 11: 303-313 
 
Ray D, Bosselut R, Ghysdael J, Mattei MG, Tavitian A, Moreau-Gachelin F (1992) 
Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-
1/PU.1. Molecular and cellular biology 12: 4297-4304 
 
Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, 
Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse 
N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A (2000) 
Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive 
form of the Hyper-IgM syndrome (HIGM2). Cell 102: 565-575 
 
Roger T, Miconnet I, Schiesser AL, Kai H, Miyake K, Calandra T (2005) Critical role for 
Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 
(Tlr4) gene expression. The Biochemical journal 387: 355-365 
169 
 
 
Rogers S, Wells R, Rechsteiner M (1986) Amino acid sequences common to rapidly 
degraded proteins: the PEST hypothesis. Science 234: 364-368 
 
Rolink AG, Andersson J, Melchers F (1998) Characterization of immature B cells by a 
novel monoclonal antibody, by turnover and by mitogen reactivity. European journal of 
immunology 28: 3738-3748 
 
Rothenberg EV (2014) Transcriptional control of early T and B cell developmental 
choices. Annual review of immunology 32: 283-321 
 
Ruprecht CR, Lanzavecchia A (2006) Toll-like receptor stimulation as a third signal 
required for activation of human naive B cells. European journal of immunology 36: 810-
816 
 
Sanjabi S, Williams KJ, Saccani S, Zhou L, Hoffmann A, Ghosh G, Gerondakis S, Natoli 
G, Smale ST (2005) A c-Rel subdomain responsible for enhanced DNA-binding affinity 
and selective gene activation. Genes Dev 19: 2138-2151 
 
Sasaki I, Hoshino K, Sugiyama T, Yamazaki C, Yano T, Iizuka A, Hemmi H, Tanaka T, 
Saito M, Sugiyama M, Fukuda Y, Ohta T, Sato K, Ainai A, Suzuki T, Hasegawa H, 
Toyama-Sorimachi N, Kohara H, Nagasawa T, Kaisho T (2012) Spi-B is critical for 
plasmacytoid dendritic cell function and development. Blood 120: 4733-4743 
 
Sato S, Kaneto S, Shibata N, Takahashi Y, Okura H, Yuki Y, Kunisawa J, Kiyono H 
(2013) Transcription factor Spi-B-dependent and -independent pathways for the 
development of Peyer's patch M cells. Mucosal immunology 6: 838-846 
 
Schroder K, Lichtinger M, Irvine KM, Brion K, Trieu A, Ross IL, Ravasi T, Stacey KJ, 
Rehli M, Hume DA, Sweet MJ (2007) PU.1 and ICSBP control constitutive and IFN-
170 
 
gamma-regulated Tlr9 gene expression in mouse macrophages. Journal of leukocyte 
biology 81: 1577-1590 
 
Schweitzer BL, Huang KJ, Kamath MB, Emelyanov AV, Birshtein BK, DeKoter RP 
(2006) Spi-C has opposing effects to PU.1 on gene expression in progenitor B cells. 
Journal of immunology 177: 2195-2207 
 
Schwenk F, Baron U, Rajewsky K (1995) A cre-transgenic mouse strain for the 
ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. 
Nucleic acids research 23: 5080-5081 
 
Scott EW, Fisher RC, Olson MC, Kehrli EW, Simon MC, Singh H (1997) PU.1 functions 
in a cell-autonomous manner to control the differentiation of multipotential lymphoid-
myeloid progenitors. Immunity 6: 437-447 
 
Scott EW, Simon MC, Anastasi J, Singh H (1994) Requirement of transcription factor 
PU.1 in the development of multiple hematopoietic lineages. Science 265: 1573-1577 
 
Sen R, Baltimore D (1986a) Inducibility of kappa immunoglobulin enhancer-binding 
protein Nf-kappa B by a posttranslational mechanism. Cell 47: 921-928 
 
Sen R, Baltimore D (1986b) Multiple nuclear factors interact with the immunoglobulin 
enhancer sequences. Cell 46: 705-716 
 
Sha WC, Liou HC, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 
subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80: 321-330 
 
Sharrocks AD (2001) The ETS-domain transcription factor family. Nature reviews 
Molecular cell biology 2: 827-837 
 
171 
 
Siegrist CA (2008) Vaccine Immunology. In Vaccines, 5th edn, 2, pp 17-36. 
Philadelphia, PA: Saunders Elsevier 
 
Snapper CM, Rosas FR, Zelazowski P, Moorman MA, Kehry MR, Bravo R, Weih F 
(1996a) B cells lacking RelB are defective in proliferative responses, but undergo normal 
B cell maturation to Ig secretion and Ig class switching. The Journal of experimental 
medicine 184: 1537-1541 
 
Snapper CM, Yamada H, Smoot D, Sneed R, Lees A, Mond JJ (1993) Comparative in 
vitro analysis of proliferation, Ig secretion, and Ig class switching by murine marginal 
zone and follicular B cells. Journal of immunology 150: 2737-2745 
 
Snapper CM, Zelazowski P, Rosas FR, Kehry MR, Tian M, Baltimore D, Sha WC 
(1996b) B cells from p50/NF-kappa B knockout mice have selective defects in 
proliferation, differentiation, germ-line CH transcription, and Ig class switching. Journal 
of immunology 156: 183-191 
 
Sokalski KM, Li SK, Welch I, Cadieux-Pitre HA, Gruca MR, DeKoter RP (2011) 
Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation and induces 
pre-B cell acute lymphoblastic leukemia. Blood 118: 2801-2808 
 
Souvannavong V, Saidji N, Chaby R (2007) Lipopolysaccharide from Salmonella 
enterica activates NF-kappaB through both classical and alternative pathways in primary 
B Lymphocytes. Infection and immunity 75: 4998-5003 
 
Spitz F, Furlong EE (2012) Transcription factors: from enhancer binding to 
developmental control. Nature reviews Genetics 13: 613-626 
 
Su GH, Chen HM, Muthusamy N, Garrett-Sinha LA, Baunoch D, Tenen DG, Simon MC 
(1997) Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-
B. The EMBO journal 16: 7118-7129 
172 
 
 
Su GH, Ip HS, Cobb BS, Lu MM, Chen HM, Simon MC (1996) The Ets protein Spi-B is 
expressed exclusively in B cells and T cells during development. The Journal of 
experimental medicine 184: 203-214 
 
Sun SC (2011) Non-canonical NF-kappaB signaling pathway. Cell research 21: 71-85 
 
Tiegs SL, Russell DM, Nemazee D (1993) Receptor editing in self-reactive bone marrow 
B cells. The Journal of experimental medicine 177: 1009-1020 
 
Turkistany SA, DeKoter RP (2011) The transcription factor PU.1 is a critical regulator of 
cellular communication in the immune system. Archivum immunologiae et therapiae 
experimentalis 59: 431-440 
 
van Zelm MC, Reisli I, van der Burg M, Castano D, van Noesel CJ, van Tol MJ, 
Woellner C, Grimbacher B, Patino PJ, van Dongen JJ, Franco JL (2006) An antibody-
deficiency syndrome due to mutations in the CD19 gene. The New England journal of 
medicine 354: 1901-1912 
 
Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, Hammarstrom L, 
Kinnon C, Levinsky R, Bobrow M, et al. (1993) The gene involved in X-linked 
agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 
361: 226-233 
 
Visintin A, Iliev DB, Monks BG, Halmen KA, Golenbock DT (2006) Md-2. 
Immunobiology 211: 437-447 
 
Vitale G, Mion F, Pucillo C (2010) Regulatory B cells: evidence, developmental origin 
and population diversity. Molecular immunology 48: 1-8 
 
173 
 
Wang CI, Alekseyenko AA, LeRoy G, Elia AE, Gorchakov AA, Britton LM, Elledge SJ, 
Kharchenko PV, Garcia BA, Kuroda MI (2013) Chromatin proteins captured by ChIP-
mass spectrometry are linked to dosage compensation in Drosophila. Nature structural & 
molecular biology 20: 202-209 
 
Wasylyk B, Hahn SL, Giovane A (1993) The Ets family of transcription factors. 
European journal of biochemistry / FEBS 211: 7-18 
 
Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, 
Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Gutenberger 
S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debre P, Jacobs R, Jones J, 
Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, 
Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K 
(2008) The EUROclass trial: defining subgroups in common variable immunodeficiency. 
Blood 111: 77-85 
 
Weih DS, Yilmaz ZB, Weih F (2001) Essential role of RelB in germinal center and 
marginal zone formation and proper expression of homing chemokines. Journal of 
immunology 167: 1909-1919 
 
Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, Ryseck RP, Lira SA, Bravo R 
(1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted 
disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 331-340 
 
Weih F, Durham SK, Barton DS, Sha WC, Baltimore D, Bravo R (1996) Both multiorgan 
inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. 
Journal of immunology 157: 3974-3979 
 
Weil R, Israel A (2004) T-cell-receptor- and B-cell-receptor-mediated activation of NF-
kappaB in lymphocytes. Current opinion in immunology 16: 374-381 
 
174 
 
West AP, Koblansky AA, Ghosh S (2006) Recognition and signaling by toll-like 
receptors. Annual review of cell and developmental biology 22: 409-437 
 
Wong FS, Wen L, Tang M, Ramanathan M, Visintin I, Daugherty J, Hannum LG, 
Janeway CA, Jr., Shlomchik MJ (2004) Investigation of the role of B-cells in type 1 
diabetes in the NOD mouse. Diabetes 53: 2581-2587 
 
Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a 
therapeutic target in CLL. Blood 120: 1175-1184 
 
Xu LS, Sokalski KM, Hotke K, Christie DA, Zarnett O, Piskorz J, Thillainadesan G, 
Torchia J, DeKoter RP (2012) Regulation of B cell linker protein transcription by PU.1 
and Spi-B in murine B cell acute lymphoblastic leukemia. Journal of immunology 189: 
3347-3354 
 
Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF (2008) A regulatory 
B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent 
inflammatory responses. Immunity 28: 639-650 
 
Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, 
Kitchingman GR, Campana D, Rohrer J, Conley ME (1996) Mutations in the mu heavy-
chain gene in patients with agammaglobulinemia. The New England journal of medicine 
335: 1486-1493 
 
Yoon H, Boss JM (2010) PU.1 binds to a distal regulatory element that is necessary for B 
cell-specific expression of CIITA. Journal of immunology 184: 5018-5028 
 
Yoshimoto M, Montecino-Rodriguez E, Ferkowicz MJ, Porayette P, Shelley WC, 
Conway SJ, Dorshkind K, Yoder MC (2011) Embryonic day 9 yolk sac and intra-
embryonic hemogenic endothelium independently generate a B-1 and marginal zone 
175 
 
progenitor lacking B-2 potential. Proceedings of the National Academy of Sciences of the 
United States of America 108: 1468-1473 
 
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers 
RM, Brown M, Li W, Liu XS (2008) Model-based analysis of ChIP-Seq (MACS). 
Genome Biol 9: R137 
 
Zhu X, Schweitzer BL, Romer EJ, Sulentic CE, DeKoter RP (2008) Transgenic 
expression of Spi-C impairs B-cell development and function by affecting genes 
associated with BCR signaling. European journal of immunology 38: 2587-2599 
176 
 
Appendices 
 
Appendix A. Statement of Permission for the Use of Animals for Experimental Research.  
 
All animal experimentation was conducted in compliance with the animal use protocol 
2009-10 held by Dr. Rodney DeKoter, principal investigator at the Schulich School of 
Medicine and Dentistry and the department of Microbiology and Immunology at the 
University of Western Ontario in London, Ontario, Canada.  
 
 
177 
 
Appendix B. Permission request for reproducing published manuscript represented in 
chapter 2. 
 
178 
 
Appendix C. Permissions of copyright transfer for reproducing published manuscript 
represented in chapter 3. 
179 
 
Curriculum Vitae - Stephen K. H. Li 
ACADEMIC HISTORY 
Doctor of Philosophy (Ph.D.) in Microbiology and Immunology  (2015) 
 Microbiology and Immunology, Specialization in Developmental Biology 
 Department of Microbiology and Immunology, Western University 
 Collaborative Graduate Program in Developmental Biology, Western University 
 Supervisor: Dr. Rodney P. DeKoter 
Honors Bachelor of Medical Sciences, Specialization in Microbiology and Immunology  (2010) 
 Distinction and Western Scholars 
 Department of Microbiology and Immunology, University of Western Ontario  
HONORS AND AWARDS 
 Ontario Graduate Scholarship, Western University ($15,000)  (2014) 
 
 American Association of Immunologists (AAI) Trainee Poster Award,  (2014) 
2014 AAI annual meeting, Pittsburgh, Pennsylvania, USA ($300) 
 The Canadian Society for Immunology Travel Award,  (2014) 
27
th
 Annual CSI Conference, Quebec City, Quebec ($500)  
 
 Queen Elizabeth II Graduate Scholarship in Science and Technology,  (2014) 
Western University ($15,000) 
 Microbiology and Immunology Graduate Student Travel Award,  (2011-2014) 
Western University ($1000/year) 
 The Canadian Society for Immunology Poster Award  (2011) 
24
th
 Annual CSI Conference, Lake Louise, Alberta ($100) 
 Industrial NSERC Undergraduate Student Research Award,  (2009) 
Pharma Research Toronto – Hoffman-La Roche Ltd, Toronto, Ontario ($4500) 
 Industrial NSERC Undergraduate Student Research Award,  (2008) 
Arius Research Inc, Toronto, Ontario ($4500) 
 Dean’s Honor list, Western University  (2007-2010) 
 
 Western Scholarship of Distinction, Western University ($1500)  (2007) 
INDUSTRIAL RESEARCH EXPERIENCE 
Pharma Research Toronto – Hoffman-La Roche Ltd, Toronto, Ontario,  (05/2009-08/2009) 
In Vivo division  
Arius Research Inc, Toronto, Ontario,  (05/2009-08/2009) 
Assay support division  
 
180 
 
TEACHING EXPERIENCE 
Department of Microbiology and Immunology, Western University, (2012-2015)  
Teaching Assistant - MicroImm 3600G 
PUBLICATIONS 
1. Stephen K. H. Li, Ali K. Abbas, Lauren A. Solomon, Gaëlle M.N. Groux, and Rodney 
P. DeKoter. 2015. Nfkb1 Activation by the ETS Transcription Factors PU.1 and Spi-B 
Promotes Toll-Like Receptor-Mediated Splenic B cell Proliferation. Molecular and 
Cellular Biology. 35(9):1619-1632.  
2. Stephen K. H. Li, Lauren A. Solomon, Patricia C. Fulkerson, and Rodney P. DeKoter. 
2015. Identification of a negative regulatory role for Spi-C in the murine B cell lineage. 
Journal of Immunology. 194:3798-3807. 
3. Lauren A. Solomon, Stephen K. H. Li, Jan Piskorz, Li S. Xu and Rodney P. 
DeKoter. 2014. Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse 
B lymphoma cell line. BMC Genomics. 16:76. doi:10.1186/s12864-015-1303-0. 
4. Darah A. Christie, Li S. Xu, Shereen A. Turkistany, Lauren A. Solomon, Stephen K. H. 
Li, Edmund Yim, Ian Welch, Gillian I. Bell, David A. Hess and Rodney P. DeKoter. 
2015. PU.1 opposes IL-7-dependent proliferation of developing B cells with 
involvement of the direct target gene Bruton Tyrosine Kinase. Journal of Immunology. 
194(2):595-605. 
5. Kristen M. Sokalski, Stephen K. H. Li, Ian Welch, Heather-Anne T. Cadieux-Pitre, 
Marek R. Gruca, and Rodney P. DeKoter.  2011. Deletion of genes encoding PU.1 
and Spi-B in B cells impairs differentiation and induces pre-B cell acute 
lymphoblastic leukemia. Blood. 118:2801-2808. 
 
CONFERENCE MEETINGS – ORAL PRESENTATIONS 
 
 Li, S. K. H., Solomon, L.A., Fulkerson, P.C., and DeKoter, R. P.  2014. Identification 
of a negative regulatory role for Spi-C in the murine B cell lineage. Keystone 
Symposia - The Golden Anniversary of B cell Discovery, Banff, Alberta. 
(2015) 
 Li, S. K. H., Abbas, A. K., and DeKoter, R. P. Toll-like Receptor-Mediated Splenic B 
cell Proliferation Requires Activation of Nfkb1 by the Related ETS Transcription 
Factors PU.1 and Spi-B. 5th Annual Developmental Biology Research Day, London, 
Ontario.  
(2013) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor (TLR) Signalling by 
Transcription Factors PU.1 and Spi-B in Splenic B cells. 24
th
 Annual Canadian 
Society for Immunology Conference, Lake Louise, Alberta. 
(2011) 
 
CONFERENCE MEETINGS – POSTER PRESENTATIONS 
 
 Li, S. K. H., Solomon, L.A., Fulkerson, P.C., and DeKoter, R. P.  2014. Identification 
of a negative regulatory role for Spi-C in the murine B cell lineage. Keystone 
Symposia - The Golden Anniversary of B cell Discovery, Banff, Alberta. 
(2015) 
 Li, S. K. H. and DeKoter, R. P. Novel Role of the ETS Transcription Factor Spi-C in 
B Cell Development and Function. 6th Annual Developmental Biology Research 
Day, London, Ontario. 
(2014) 
 Li, S. K. H. and DeKoter, R. P. Novel Role of the ETS Transcription Factor Spi-C in 
B Cell Development and Function. The American Asociation of Immunologists 
(AAI) Annual Meeting, Pittsburgh, Pennsylvania.    
(2014) 
 Li, S. K. H. and DeKoter, R. P. Novel Role of the ETS Transcription Factor Spi-C in 
B Cell Development and Function. 27
th
 Annual Canadian Society for Immunology 
Conference, Québec City, Québec. 
(2014) 
181 
 
 Li, S. K. H. and DeKoter, R. P. Novel Role of the ETS Transcription Factor Spi-C in 
B Cell Development. 8
th
 annual meeting of the Infection and Immunity Research 
Forum, London, Ontario. 
(2013) 
 Li, S. K. H., Abbas, A. K., and DeKoter, R. P. Toll-like Receptor-Mediated Splenic 
B cell Proliferation Requires Activation of Nfkb1 by the Related ETS Transcription 
Factors PU.1 and Spi-B. 2013 London Health Research Day, London, Ontario.  
(2013) 
 Li, S. K. H. and DeKoter, R. P. Toll-like Receptor-Mediated Splenic B cell 
Proliferation Requires Activation of Nfkb1 by the Related ETS Transcription Factors 
PU.1 and Spi-B. Keystone Symposia – B cell Development and Function, Keystone, 
Colorado, USA.  
(2013) 
 Li, S. K. H. and DeKoter, R. P. Toll-like Receptor-Mediated Splenic B cell 
Proliferation Requires Activation of Nfkb1 by the Related ETS Transcription Factors 
PU.1 and Spi-B. 7
th
 Annual meeting of the Infection and Immunity Research Forum, 
London, Ontario.  
(2012) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor Mediated Splenic B 
cell Proliferation by the Related ETS Transcription Factors PU.1 and Spi-B. 25
th
 
Annual Canadian Society for Immunology Conference, St. John’s, Newfoundland.  
(2012) 
 Li, S. K. H. and DeKoter, R. P.  Regulation of Toll-like Receptor Mediated Splenic B 
cell Proliferation by the Related ETS Transcription Factors PU.1 and Spi-B. 2012 
London Health Research Day, London, Ontario.  
(2012) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor Mediated Splenic B 
cell Proliferation by the Related ETS Transcription Factors PU.1 and Spi-B. 6
th
 
Annual Meeting of the Infection and Immunity Research Forum, London, Ontario.  
(2011) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor (TLR) Signalling by 
Transcription Factors PU.1 and Spi-B in Splenic B cells. 24
th
 Annual Canadian 
Society for Immunology Conference, Lake Louise, Alberta. (Recipient of $100 CSI 
Poster award) 
(2011) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor (TLR) Signalling by 
Transcription Factors PU.1 and Spi-B in Splenic B cells. 2011 Margaret Moffat 
Research Day, London, Ontario.  
(2011) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor (TLR) Signalling by 
PU.1 and Spi-B Transcription Factors in Splenic B cells. 2011 Great Lakes 
Mammalian Development Meeting, Toronto, Ontario.  
(2011) 
 Li, S. K. H. and DeKoter, R. P. Regulation of Toll-like Receptor (TLR) Signalling by 
PU.1 and Spi-B Transcription Factors in Splenic B cells. 5th Annual Meeting of the 
Infection and Immunity Research Forum, London, Ontario.  
(2010) 
 
